

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

<b>GSK Medicine:</b> HIV vaccine 732462
<b>Study Number:</b> 111679 (TH-HIV-008)
<b>Title:</b> Efficacy and safety of HIV Vaccine 732462 in ART*-naïve HIV-1 infected persons. HIV Vaccine 732462 (HIV): GlaxoSmithKline (GSK) Biologicals' candidate Human Immunodeficiency Virus (HIV) F4co <sup>£</sup> (p24-RT-Nef-p17) vaccine, adjuvanted. <i>*ART stands for Antiretroviral therapy</i> <i>£F4co is a single fusion antigen including Gag, Pol and Nef antigens.</i>
<b>Rationale:</b> The purpose of this study was to evaluate the efficacy and safety of the HIV vaccine, when administered intramuscularly according to either a 2-dose (0, 4 weeks) or a 3-dose (0, 4, 28 weeks) schedule in ART-naïve HIV-1 infected persons aged 18-55 years. The duration of the study was of approximately 52 weeks for all subjects.
<b>Phase:</b> IIB
<b>Study Period:</b> 8 November 2010 to 5 November 2012.
<b>Study Design:</b> Randomized, observer-blind, placebo controlled, multi-center study with 3 groups (1:1:1)
<b>Centres:</b> 40 centers, 15 in the United States, 7 in Spain, 8 in Germany and 10 in France.
<b>Indication:</b> Human immunodeficiency virus (HIV) in HIV-infected subjects at least 18 years of age
<b>Treatment:</b> Study groups were as follows: <ul style="list-style-type: none"> <li>– HIV Group: Subjects received 2 doses of the HIV vaccine at Weeks 0 and 4. This group included the following subgroups: <ul style="list-style-type: none"> <li>○ 3-Doses HIV Group: Subjects received 3 doses of the HIV vaccine at Weeks 0, 4 and 28.</li> <li>○ 2-Doses HIV Group: Subjects received 2 doses of the HIV vaccine at Weeks 0 and 4 and one dose of placebo at Week 28.</li> </ul> </li> <li>– Placebo Group: Subjects received 3 doses of placebo at Weeks 0, 4 and 28.</li> </ul> The HIV vaccine and the placebo (saline solution) were administered intramuscularly in the deltoid of the non-dominant arm.
<b>Objectives:</b> <ul style="list-style-type: none"> <li>• To show a difference in change from baseline* of HIV-1 viral load (VL) at Week 48 between persons who received 2 doses of the HIV vaccine and persons who received placebo alone or between persons who received 3 doses of the HIV vaccine and persons who received placebo alone. <ul style="list-style-type: none"> <li>- A difference (in favor of the vaccine) was concluded if the upper limit (UL) for the two-sided 97.5% confidence interval (CI) for the difference in change between the two arms (vaccine – placebo) was below 0 for at least one vaccine schedule (2 or 3 doses of HIV vaccine)</li> </ul> </li> <li>• To evaluate the safety of the HIV vaccine</li> </ul> <i>*Baseline for VL analysis was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0.</i>
<b>Primary Outcome/Efficacy Variable:</b> <ul style="list-style-type: none"> <li>• HIV-1 VL change <ul style="list-style-type: none"> <li>- HIV-1 VL change from baseline at Week 48</li> </ul> </li> <li>• Solicited local and general symptoms <ul style="list-style-type: none"> <li>- Occurrence of solicited local and general symptoms (any, grade ≥ 3, related, grade ≥ 3 related, requiring medical attention) during a 7-day (Day 0 to Day 6) follow-up period after each vaccination</li> </ul> </li> <li>• Unsolicited adverse events <ul style="list-style-type: none"> <li>- Occurrence of unsolicited adverse events (AEs) (any, grade ≥ 3, related, grade ≥ 3 related, requiring medical attention) during a 28-day (Day 0 to Day 27) follow-up period after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.</li> </ul> </li> <li>• Serious adverse events and potentially immune mediated diseases (pIMDs) <ul style="list-style-type: none"> <li>- Occurrence of all serious adverse events (SAEs) throughout the study period</li> <li>- Occurrence of all pIMDs throughout the study period</li> </ul> </li> <li>• Biochemistry and hematology <ul style="list-style-type: none"> <li>- Occurrence of abnormal biochemical and hematological values (any and grade ≥ 3) throughout the study period.</li> </ul> </li> </ul>
<b>Secondary Outcome/Efficacy Variable(s):</b> <ul style="list-style-type: none"> <li>• HIV-1 VL</li> </ul>

- HIV-1 VL change from baseline throughout the study period
- HIV-1 VL levels throughout the study period
- Proportion of subjects with  $> 1 \log_{10}$  decrease in VL at Week 48
- CD4 cell count
  - Change from baseline<sup>(1)</sup> of absolute CD4 cell counts throughout the study period
  - Absolute CD4 count throughout the study period
- Initiation of ART
  - Time either to initiation of ART or occurrence of any of the HIV-related clinical events<sup>(2)</sup> throughout the study period
- Immunogenicity with respect to components of the investigational vaccine
  - Magnitude, breadth and cytokine co-expression profile of HIV-1 specific cluster of differentiation-40-ligand (CD40L)+ CD4+ or CD8+ T-cell responses assessed by Intracellular Cytokine Staining (ICS) measuring Interleukin-2 (IL-2) and/or interferon- $\gamma$  (IFN- $\gamma$ ) and/or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) throughout the study period after stimulation with HIV-1 Clade B peptide pools matched to the vaccine antigens<sup>(3)</sup>
  - Seropositivity rates and anti-p17, p24, Nef, RT and F4co antibody concentrations as measured by enzyme-linked immunosorbent assay (ELISA)

<sup>(1)</sup> Baseline for CD4 cell count analysis was defined as the mean of values measured in blood samples taken at Screening and at Week 0.

<sup>(2)</sup> HIV-related clinical events were defined as either 1) clinical disease progression, or 2) confirmed VL  $> 100,000$  copies/mL, or 3) confirmed CD4 cell count  $< 350$  cells/mm<sup>3</sup>.

<sup>(3)</sup> Please refer to the Statistical Methods section below for definitions of cell-mediated immunogenicity (CMI) response breadth, intensity and cytokine co-expression profile. Vaccine antigens were the HIV vaccine-specific antigens, i. e. the Anti-Nef, Anti-p17, Anti-p24, Anti-RT, and Anti-F4co antigens.

#### **Statistical Methods:**

Analyses were performed on the Total Vaccinated cohort, on the Modified Total Vaccinated cohort and on the According-to-Protocol (ATP) cohort for immunogenicity:

- The Total vaccinated cohort included all subjects with at least one vaccine administration documented.
- The Modified Total Vaccinated cohort included all subjects with at least one vaccine administration documented who complied with the protocol-defined inclusion/exclusion criteria and with sufficient data to perform the efficacy analysis (at least one VL measurement post Dose 2). Subjects with CD4/VL recorded when under ART were excluded from this cohort.
- The ATP cohort for immunogenicity included all evaluable subjects (who met all eligibility criteria, complied with the procedures and intervals for inclusion as defined in the protocol, with no elimination criteria during the study) for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.

#### Analysis of Efficacy

The analysis was performed on the Modified Total Vaccinated cohort.

For the VL ( $\log_{10}$ -transformed), a mixed model for repeated measurement was used for the analysis. The model included the baseline VL ( $\log_{10}$ -transformed), the baseline CD4 count (crude value), the gender and the country as covariate and used an unstructured variance-covariance matrix and time and time\*group as fixed categorical effects. The demonstration that the change in VL reached at Week 48 in at least one of the HIV groups was different from the corresponding change in the Placebo Group (and in favor of the vaccine) was based on the following criterion: the UL for the 2-sided 97.5% CI for the difference in change between the 2 HIV groups minus the Placebo Group was below 0 for at least one vaccine schedule (2 or 3 doses of HIV vaccine).

VL (crude value and  $\log_{10}$ -transformed) was summarized (mean, standard error, median, Q1 and Q3) for each treatment group and at each time point this measure was available. In addition, proportion of subjects with plasma VL decrease  $> 1 \log_{10}$  at Week 48 was provided (point estimate and exact 95% CI) for each treatment group. Change (ratio between crude values and difference for  $\log_{10}$ -transformed) in VL from baseline (each value minus or over baseline value) was summarized (mean, standard error, median, Q1, Q3) for each treatment group and at each time point this measure was available. CD4 counts and change in CD4 counts were summarized using crude values (mean, median, standard error) for each treatment group and at each time point this measure was available.

ART initiation and occurrence of any of the HIV-related clinical events expressed in days from Dose 1 administration were summarized for each treatment group.

#### Analysis of Immunogenicity

The analysis was performed on the ATP cohort for immunogenicity.

### *CMI Immunogenicity*

CMI ICS responses were tabulated for each treatment group at Year 1 for intensity (or magnitude), breadth and cytokine co-expression profile.

- Magnitude was defined as the frequency of F4co, p17, p24, Nef and RT-specific CD40L+ CD4+ T-cells expressing at least IL-2 or at least one cytokine.
- Breadth was assessed only for the HIV specific CD4+ T cells and was measured by evaluating response to at least 1, 2, 3 antigens and to all 4 antigens.
- The cytokine co-expression profile was defined by the frequency of F4co, P17, P24, Nef and RT specific CD4+ (or respectively CD8+) T-cells expressing CD40L and/or IL-2 and/or TNF- $\alpha$  and /or IFN- $\gamma$ .

### *Humoral Immunogenicity*

The seropositivity rates of subjects whose concentration (measured by ELISA) for antibodies against the Nef, p17, p24, RT, and F4co antigens above cut-off were tabulated per group cohorts with exact 95% CI. A seropositive subject was a subject whose antibody concentration was equal or above cut-off value for the corresponding antibody: 187 mEL.U/mL (Anti-p17 antibodies), 119 mEL.U/mL (Anti-p24 antibodies), 494 mEL.U/mL (Anti-Nef antibodies), 125 mEL.U/mL (Anti-RT antibodies), and 42 mEL.U/mL (Anti-F4co antibodies). Geometric Mean Concentrations (GMCs) were also tabulated for the same antibodies with 95% CI.

### Analysis of Safety

The analysis was performed on the Total Vaccinated cohort.

The percentages of subjects reporting each solicited local and general symptom during the 7-day (Days 0-6) follow-up period after each vaccination and across doses were tabulated with exact 95% CI for each of the groups. The same tabulation was done for symptoms of Grade 3 intensity and above, for symptoms requiring medical attention and for any general symptoms and general symptoms of Grade 3 intensity and above, that were assessed by the investigators to be related to study vaccination.

The percentages of subjects reporting unsolicited AEs within 28 days (Days 0-27) following vaccination were tabulated according to the Medical Dictionary for Regulatory Activities (MedDRA) preferred term after each vaccination, and overall. The same tabulation was done for unsolicited AEs of Grade 3 intensity and above, for any unsolicited AEs and AEs of Grade 3 intensity and above assessed by the investigators to be related to study vaccination, and for unsolicited AEs requiring medical attention..

The percentages of SAEs and fatal SAEs for the entire study period were tabulated, according to the MedDRA classification.

The percentage of subjects reporting pIMDs for the entire study period was also tabulated, according to the MedDRA preferred terms.

The frequency distribution of each Division of AIDS (DAIDS) category was tabulated for each hemato-biochemistry laboratory parameter per treatment group at each scheduled time point.

**Study Population:** Male and female subjects between and including 18–55 years of age at the time of first vaccination, diagnosed as HIV-1 infected and under the care of an HIV physician for a minimum of 6 months were enrolled in this study. Subjects initially presented with a clinical diagnosis of primary HIV-1 infection were to have been diagnosed and under care for at least 12 months. To be included, subjects were to be ART-naïve, i. e. never to have received ART after HIV diagnosis, with commencement of ART not expected within the following 12 months, with VL level of 2,000-80,000 copies/mL and CD4 count > 500 cells per mm<sup>3</sup> at Screening. Female subjects were to be of non-childbearing potential or if of childbearing potential had to practice adequate contraception for 30 days prior to vaccination, had a negative pregnancy test and continued such precautions for the entire duration of the study. Subjects were excluded from study participation if they were diagnosed as with HIV-2 infection or dual infection with HIV-1/HIV-2, had an acquired immunodeficiency syndrome (AIDS) defining clinical illness (Centers for Disease Control and Prevention [CDC] Category C event), had been previously vaccinated against or received immunotherapy against HIV, had acute or chronic infective hepatitis or clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination and/or medical history at screening. Subjects with Grade 3 or 4 laboratory abnormality, as defined by Division of AIDS (DAIDS) grading table, at Screening, history of medically confirmed autoimmune disease or malignancy were also excluded. Written informed consent was obtained from subjects prior to any study procedure.

<b>Number of Subjects:</b>	<b>3-Doses HIV Group</b>	<b>2-Doses HIV Group</b>	<b>Placebo Group</b>
Planned, N	63	63	63
Randomised, N (Total Vaccinated cohort)	62	64	64
Completed, n (%)	57 (91.9)	63 (98.4)	58 (90.6)
Total Number Subjects Withdrawn, N (%)	5 (8.1)	1 (1.6)	6 (9.4)
Withdrawn due to Adverse Events n (%)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawn due to Lack of Efficacy n (%)	Not applicable	Not applicable	Not applicable
Withdrawn for other reasons n (%)	5 (8.1)	1 (1.6)	6 (9.4)

Demographics	3-Doses HIV Group	2-Doses HIV Group	Placebo Group
N (Total Vaccinated cohort)	62	64	64
Sex, n (%)			
Females	9 (14.5)	10 (15.6)	10 (15.6)
Males	53 (85.5)	54 (84.4)	54 (84.4)
Mean Age, years (SD)	34.9 (7.58)	37.0 (8.24)	35.9 (8.41)
Median	34.5	37.0	33.0
Minimum, Maximum	18; 51	22; 53	24; 55
Race: White-Caucasian/European heritage, n (%)	43 (69.4)	51 (79.7)	42 (65.6)
Race: African heritage/African American, n (%)	11 (17.7)	10 (15.6)	15 (23.4)
Race: White-Arabic/North African heritage	4 (6.5)	3 (4.7)	3 (4.7)

**Primary Efficacy Results:** Comparison between each vaccine schedule (2 or 3 doses of HIV vaccine) and placebo in terms of change from baseline of HIV-1 viral load at Week 48, based on a repeated-measures mixed model (Modified Total Vaccinated cohort)

										Ratio (HIV Group over Placebo Group)		
			95% CI					95% CI			97.5% CI	
HIV Group	N	GM	LL	UL	Placebo Group	N	GM	LL	UL	GMR	LL	UL
3-Doses HIV	61	1.09	0.849	1.398	Placebo	60	1.36	1.079	1.713	0.801	0.553	1.162
2-Doses HIV	64	1.609	1.255	2.064	Placebo	60	1.36	1.079	1.713	1.184	0.816	1.717

N = number of subjects used in the model;

GM = geometric mean based on least squares means from the repeated-measures mixed model;

GMR = estimate for the geometric mean ratio from the repeated-measures mixed model;

CI = confidence interval, LL = lower limit, UL = upper limit

**Primary Efficacy Results:** Comparison between each vaccine schedule (2 or 3 doses of HIV vaccine) and placebo in terms of change from baseline of Log-transformed HIV-1 viral load at Week 48, based on a repeated-measures mixed model (Modified Total Vaccinated cohort)

										Difference (HIV Group – Placebo Group)		
			95% CI					95% CI			97.5% CI	
HIV Group	N	Mean	LL	UL	Placebo Group	N	Mean	LL	UL	Mean Diff	LL	UL*
3-Doses HIV	61	0.037	-0.071	0.146	Placebo	60	0.133	0.033	0.234	-0.096	-0.257	0.065
2-Doses HIV	64	0.207	0.099	0.315	Placebo	60	0.133	0.033	0.234	0.073	-0.088	0.235

N = number of subjects used in the model;

Mean = geometric mean based on least squares means from the repeated-measures mixed model;

Diff = estimate of the difference from the repeated-measures mixed model;

CI = confidence interval, LL = lower limit, UL = upper limit

*\*Criterion of comparison: UL for the 2-sided 97.5% CI for the difference in change between vaccine and placebo < 0 for at least one vaccine schedule (2 or 3 doses of HIV vaccine)*

**Primary Efficacy Results:** Descriptive statistics of changes in HIV-1 viral load from baseline (ratio of each value over baseline value), using crude values (Modified Total Vaccinated cohort)

Group	Activity	N	GM	SD	Min	Q1	Median	Q3	Max
HIV	PI(W1)	78	1.0	0.18	0.4	0.8	1.0	1.2	3.1
	PI(W4)	124	1.1	0.28	0.2	0.8	1.1	1.5	14.9
	PII(W6)	118	1.1	0.26	0.2	0.7	1.2	1.6	12.7
	PII(W16)	121	1.1	0.31	0.2	0.7	1.0	1.6	7.6
	PII(W28)	116	1.2	0.35	0.2	0.7	1.0	1.8	20.4
3-Doses HIV	PIII(W30)	53	1.1	0.24	0.3	0.7	1.0	1.4	4.7
	PIII(W38)	49	0.9	0.28	0.3	0.6	1.0	1.4	4.1
	PIII(W48)	46	1.0	0.35	0.1	0.5	1.0	1.8	5.1
2-Doses HIV	PIII(W30)	58	1.2	0.38	0.3	0.6	1.1	1.8	15.1
	PIII(W38)	57	1.2	0.32	0.2	0.8	1.3	2.1	6.4
	PIII(W48)	55	1.5	0.38	0.3	0.9	1.3	2.7	10
Placebo	PI(W1)	40	0.9	0.18	0.3	0.7	1.0	1.1	1.8

	PI(W4)	58	1.1	0.32	0.3	0.7	1.0	1.5	16.4
	PII(W6)	60	1.2	0.37	0.4	0.7	1.1	1.8	69.9
	PII(W16)	56	1.1	0.28	0.3	0.7	1.0	1.6	7.3
	PII(W28)	54	1.2	0.36	0.2	0.7	1.1	1.8	11.5
	PIII(W30)	54	1.2	0.34	0.2	0.8	1.1	1.7	11.1
	PIII(W38)	52	1.2	0.43	0.1	0.8	1.2	1.9	24.7
	PIII(W48)	50	1.3	0.34	0.2	0.7	1.1	2.5	7

N = number of subjects with available results

SD = Standard deviation of values;

Q1,Q3 = First and third quartiles;

Min, Max = Minimum, Maximum

Px (Wy) = Post-Dose x at Week y

**Primary Efficacy Results:** Descriptive statistics of changes in HIV-1 viral load from baseline (difference of each value minus baseline value), using log10-transformed values (Modified Total Vaccinated cohort)

Group	Activity	N	Mean	SD	Min	Q1	Median	Q3	Max
HIV	PI(W1)	78	0.0	0.18	-0.4	-0.1	0.0	0.1	0.5
	PI(W4)	124	0.0	0.28	-0.6	-0.1	0.0	0.2	1.2
	PII(W6)	118	0.1	0.26	-0.6	-0.1	0.1	0.2	1.1
	PII(W16)	121	0.0	0.31	-0.6	-0.2	0.0	0.2	0.9
	PII(W28)	116	0.1	0.35	-0.7	-0.2	0.0	0.3	1.3
3-Doses HIV	PIII(W30)	53	0.0	0.24	-0.5	-0.1	0.0	0.2	0.7
	PIII(W38)	49	0.0	0.28	-0.6	-0.2	0.0	0.1	0.6
	PIII(W48)	46	0.0	0.35	-0.9	-0.3	0.0	0.2	0.7
2-Doses HIV	PIII(W30)	58	0.1	0.38	-0.5	-0.2	0.0	0.3	1.2
	PIII(W38)	57	0.1	0.32	-0.8	-0.1	0.1	0.3	0.8
	PIII(W48)	55	0.2	0.38	-0.5	-0.1	0.1	0.4	1.0
Placebo	PI(W1)	40	-0.1	0.18	-0.6	-0.2	0.0	0	0.3
	PI(W4)	58	0.1	0.32	-0.5	-0.1	0.0	0.2	1.2
	PII(W6)	60	0.1	0.37	-0.4	-0.2	0.0	0.2	1.8
	PII(W16)	56	0.0	0.28	-0.5	-0.2	0.0	0.2	0.9
	PII(W28)	54	0.1	0.36	-0.6	-0.1	0.1	0.2	1.1
	PIII(W30)	54	0.1	0.34	-0.7	-0.1	0.0	0.2	1.0
	PIII(W38)	52	0.1	0.43	-1.0	-0.1	0.1	0.3	1.4
	PIII(W48)	50	0.1	0.34	-0.7	-0.2	0.1	0.4	0.8

N = number of subjects with available results;

SD = Standard deviation of log10-transformed values;

Q1,Q3 = First and third quartiles;

Min, Max = Minimum, Maximum

Px (Wy) = Post-Dose x at Week y

**Primary Efficacy Results:** Incidence of solicited local symptoms (any, Grade  $\geq 3$ , requiring medical attention) reported following injection Dose 1 and Dose 2 during the 7-day (Days 0-6) post-vaccination period (Total Vaccinated cohort)

		HIV Group					Placebo Group				
					95 % CI					95 % CI	
Symptom	Intensity	N	n	%	LL	UL	N	n	%	LL	UL
<b>Dose 1</b>											
Pain	Any	125	112	89.6	82.9	94.3	63	12	19.0	10.2	30.9
	Grade $\geq 3$	125	9	7.2	3.3	13.2	63	0	0.0	0.0	5.7
	Medical advice	125	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Redness	$\geq 50$ mm	125	16	12.8	7.5	20.0	63	0	0.0	0.0	5.7
	Grade $\geq 3$	125	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	125	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Swelling	$\geq 50$ mm	125	7	5.6	2.3	11.2	63	0	0.0	0.0	5.7
	Grade $\geq 3$	125	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	125	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
<b>Dose 2</b>											
Pain	Any	120	98	81.7	73.6	88.1	61	5	8.2	2.7	18.1

	Grade ≥ 3	120	11	9.2	4.7	15.8	61	0	0.0	0.0	5.9
	Medical advice	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
Redness	≥ 50 mm	120	15	12.5	7.2	19.8	61	0	0.0	0.0	5.9
	Grade ≥ 3	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
Swelling	≥ 50 mm	120	6	5.0	1.9	10.6	61	0	0.0	0.0	5.9
	Grade ≥ 3	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9

N = number of subjects with at least one documented dose;

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = Exact 95% confidence interval; LL = lower limit, UL = upper limits

Any = occurrence of any local symptom regardless of intensity grade

Grade 3 pain = cried when limb was moved/spontaneously painful

Grades 3 and 4 for Redness and Swelling:

- Grade 3 Redness or Swelling = Redness or swelling associated with ulceration or secondary infection or phlebitis or sterile abscess or drainage.
- Grade 4 Redness or Swelling = Redness or swelling associated with Necrosis (involving dermis and deeper tissue)

**Primary Efficacy Results:** Incidence of solicited local symptoms (any, grade ≥ 3, requiring medical attention) reported following injection Dose 3, and across doses during the 7-day (Days 0-6) post-vaccination period (Total Vaccinated cohort)

		3-Doses HIV Group					2-Doses HIV Group					Placebo Group				
		95 % CI					95 % CI					95 % CI				
Symptom	Intensity	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
<b>Dose 3</b>																
Pain	Any	55	42	76.4	63.0	86.8	58	9	15.5	7.3	27.4	54	3	5.6	1.2	15.4
	Grade ≥ 3	55	6	10.9	4.1	22.2	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	55	0	0.0	0.0	6.5	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Redness	≥ 50 mm	55	10	18.2	9.1	30.9	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Grade ≥ 3	55	0	0.0	0.0	6.5	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	55	0	0.0	0.0	6.5	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Swelling	≥ 50 mm	55	3	5.5	1.1	15.1	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Grade ≥ 3	55	0	0.0	0.0	6.5	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	55	0	0.0	0.0	6.5	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
<b>Across doses</b>																
Pain	Any	62	58	93.5	84.3	98.2	64	57	89.1	78.8	95.5	64	14	21.9	12.5	34.0
	Grade ≥ 3	62	15	24.2	14.2	36.7	64	6	9.4	3.5	19.3	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
Redness	≥ 50 mm	62	17	27.4	16.9	40.2	64	14	21.9	12.5	34.0	64	0	0.0	0.0	5.6
	Grade ≥ 3	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
Swelling	≥ 50 mm	62	4	6.5	1.8	15.7	64	8	12.5	5.6	23.2	64	0	0.0	0.0	5.6
	Grade ≥ 3	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6

N = number of subjects with at least one documented dose;

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = Exact 95% confidence interval; LL = lower limit, UL = upper limits

Any = occurrence of any local symptom regardless of intensity grade

Grade 3 pain = cried when limb was moved/spontaneously painful

Grades 3 and 4 for Redness and Swelling:

- Grade 3 Redness or Swelling = Redness or swelling associated with ulceration or secondary infection or phlebitis or sterile abscess or drainage.
- Grade 4 Redness or Swelling = Redness or swelling associated with Necrosis (involving dermis and deeper tissue)

**Primary Efficacy Results:** Incidence of solicited general symptoms (any, grade ≥ 3, related, grade ≥ 3 related, requiring medical attention) reported following injection Dose 1 and Dose 2 during the 7-day (Days 0 post-vaccination period (Total Vaccinated cohort)

		HIV Group					Placebo Group				
--	--	-----------	--	--	--	--	---------------	--	--	--	--

					95 % CI					95 % CI	
Symptom	Intensity/Relationship	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1											
Abdominal pain	Any	124	14	11.3	6.3	18.2	63	3	4.8	1.0	13.3
	Grade ≥ 3	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Related	124	2	1.6	0.2	5.7	63	0	0.0	0.0	5.7
	Grade ≥ 3 Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
Anorexia	Any	124	7	5.6	2.3	11.3	63	2	3.2	0.4	11.0
	Grade ≥ 3	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Related	124	4	3.2	0.9	8.1	63	0	0.0	0.0	5.7
	Grade ≥ 3 Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Diarrhoea	Any	124	16	12.9	7.6	20.1	63	5	7.9	2.6	17.6
	Grade ≥ 3	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Related	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Grade ≥ 3 Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
Fatigue	Any	124	56	45.2	36.2	54.3	63	16	25.4	15.3	37.9
	Grade ≥ 3	124	3	2.4	0.5	6.9	63	1	1.6	0.0	8.5
	Related	124	24	19.4	12.8	27.4	63	7	11.1	4.6	21.6
	Grade ≥ 3 Related	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Headache	Any	124	40	32.3	24.1	41.2	63	14	22.2	12.7	34.5
	Grade ≥ 3	124	4	3.2	0.9	8.1	63	1	1.6	0.0	8.5
	Related	124	16	12.9	7.6	20.1	63	8	12.7	5.6	23.5
	Grade ≥ 3 &Related	124	4	3.2	0.9	8.1	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	1	1.6	0.0	8.5
Myalgia	Any	124	44	35.5	27.1	44.6	63	9	14.3	6.7	25.4
	Grade ≥ 3	124	2	1.6	0.2	5.7	63	0	0.0	0.0	5.7
	Related	124	26	21.0	14.2	29.2	63	4	6.3	1.8	15.5
	Grade ≥ 3 Related	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Nausea	Any	124	17	13.7	8.2	21.0	63	5	7.9	2.6	17.6
	Grade ≥ 3	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Related	124	4	3.2	0.9	8.1	63	2	3.2	0.4	11.0
	Grade ≥ 3 Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Sweating	Any	124	16	12.9	7.6	20.1	63	6	9.5	3.6	19.6
	Grade ≥ 3	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Related	124	3	2.4	0.5	6.9	63	1	1.6	0.0	8.5
	Grade ≥ 3 Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Temperature (Orally)	Any	124	8	6.5	2.8	12.3	63	2	3.2	0.4	11.0
	≥ 39.4 °C	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Related	124	3	2.4	0.5	6.9	63	0	0.0	0.0	5.7
	≥ 39.4°C Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
Vomiting	Any	124	2	1.6	0.2	5.7	63	1	1.6	0.0	8.5
	Grade ≥ 3	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Related	124	1	0.8	0.0	4.4	63	0	0.0	0.0	5.7
	Grade ≥ 3 Related	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
	Medical advice	124	0	0.0	0.0	2.9	63	0	0.0	0.0	5.7
Dose 2											
Abdominal pain	Any	120	9	7.5	3.5	13.8	61	1	1.6	0.0	8.8
	Grade ≥ 3	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9

	Related	120	3	2.5	0.5	7.1	61	0	0.0	0.0	5.9
	Grade $\geq$ 3 Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9
Anorexia	Any	120	7	5.8	2.4	11.6	61	2	3.3	0.4	11.3
	Grade $\geq$ 3	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9
	Related	120	3	2.5	0.5	7.1	61	0	0.0	0.0	5.9
	Grade $\geq$ 3 Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9
Diarrhoea	Any	120	13	10.8	5.9	17.8	61	7	11.5	4.7	22.2
	Grade $\geq$ 3	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Related	120	2	1.7	0.2	5.9	61	1	1.6	0.0	8.8
	Grade $\geq$ 3 Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
Fatigue	Any	120	56	46.7	37.5	56.0	61	10	16.4	8.2	28.1
	Grade $\geq$ 3	120	6	5.0	1.9	10.6	61	2	3.3	0.4	11.3
	Related	120	25	20.8	14.0	29.2	61	4	6.6	1.8	15.9
	Grade $\geq$ 3 Related	120	4	3.3	0.9	8.3	61	1	1.6	0.0	8.8
	Medical advice	120	2	1.7	0.2	5.9	61	0	0.0	0.0	5.9
Headache	Any	120	34	28.3	20.5	37.3	61	8	13.1	5.8	24.2
	Grade $\geq$ 3	120	5	4.2	1.4	9.5	61	1	1.6	0.0	8.8
	Related	120	15	12.5	7.2	19.8	61	3	4.9	1.0	13.7
	Grade $\geq$ 3 Related	120	3	2.5	0.5	7.1	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9
Myalgia	Any	120	42	35.0	26.5	44.2	61	6	9.8	3.7	20.2
	Grade $\geq$ 3	120	6	5.0	1.9	10.6	61	1	1.6	0.0	8.8
	Related	120	26	21.7	14.7	30.1	61	1	1.6	0.0	8.8
	Grade $\geq$ 3 Related	120	6	5.0	1.9	10.6	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	1	1.6	0.0	8.8
Nausea	Any	120	11	9.2	4.7	15.8	61	0	0.0	0.0	5.9
	Grade $\geq$ 3	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Related	120	4	3.3	0.9	8.3	61	0	0.0	0.0	5.9
	Grade $\geq$ 3 Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9
Sweating	Any	120	17	14.2	8.5	21.7	61	3	4.9	1.0	13.7
	Grade $\geq$ 3	120	2	1.7	0.2	5.9	61	0	0.0	0.0	5.9
	Related	120	8	6.7	2.9	12.7	61	0	0.0	0.0	5.9
	Grade $\geq$ 3 Related	120	2	1.7	0.2	5.9	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	0	0.0	0.0	5.9
Temperature (Orally)	Any	120	11	9.2	4.7	15.8	61	3	4.9	1.0	13.7
	$\geq 39.4$ °C	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Related	120	7	5.8	2.4	11.6	61	0	0.0	0.0	5.9
	$\geq 39.4$ °C Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	1	0.8	0.0	4.6	61	1	1.6	0.0	8.8
Vomiting	Any	120	2	1.7	0.2	5.9	61	1	1.6	0.0	8.8
	Grade $\geq$ 3	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Grade $\geq$ 3 Related	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9
	Medical advice	120	0	0.0	0.0	3.0	61	0	0.0	0.0	5.9

N = number of subjects with at least one documented dose;

n/% = number/percentage of subjects reporting the symptom at least once;

95% CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

Grades 3 and 4 for Abdominal pain, Fatigue, Myalgia and Sweating:

- Grade 3 Abdominal pain, Fatigue, Myalgia and Sweating = Symptoms causing inability to perform usual social and functional activities
- Grade 4 Abdominal pain, Fatigue, Myalgia and Sweating = Symptoms causing inability to perform usual social and functional activities



Grades 3 and 4 for Anorexia:															
- Grade 3 Anorexia = Loss of appetite associated with significant weight loss															
- Grade 4 Anorexia = Aggressive intervention indicated (e.g. tube feeding or total parenteral nutrition)															
Grades 3 and 4 for Diarrhoea:															
- Grade 3 Diarrhoea = Bloody diarrhoea or increase of $\geq 7$ stools per 24-hour period or IV fluid replacement															
- Grade 4 Diarrhoea = Life threatening consequences (e.g., hypotensive shock)															
Grades 3 and 4 for Headache:															
- Grade 3 Headache = Headache causing inability to perform usual social and functional activities															
- Grade 4 Headache = Headache causing inability to perform basic self-care functions or Hospitalization indicated (other than an emergency room visit) or Headache with significant impairment of alertness or other neurologic function.															
Grades 3 and 4 for Nausea:															
- Grade 3 Nausea = Persistent nausea resulting in minimal oral intake for > 48 hours or Aggressive rehydration indicated (e.g., IV fluids)															
- Grade 4 Nausea = Life threatening consequences (e.g., hypotensive shock)															
Grades 3 and 4 for Vomiting:															
- Grade 3 Vomiting = Persistent vomiting resulting in orthostatic hypotension or Aggressive rehydration indicated (e.g., IV fluids)															
- Grade 4 Vomiting = Life threatening consequences (e.g., hypotensive shock)															

**Primary Efficacy Results:** Incidence of solicited general symptoms (any, Grade  $\geq 3$ , related, Grade  $\geq 3$  Related, requiring medical attention) reported following injection Dose 3, and across doses during the 7-day (Days 0-6) post-vaccination period (Total Vaccinated cohort)

Symptom		3-Doses HIV Group					2-Doses HIV Group					Placebo Group				
					95 % CI					95 % CI					95 % CI	
		N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
<b>Dose 3</b>																
Abdominal pain	Any	56	4	7.1	2.0	17.3	58	4	6.9	1.9	16.7	54	2	3.7	0.5	12.7
	Grade $\geq 3$	56	0	0.0	0.0	6.4	58	2	3.4	0.4	11.9	54	0	0.0	0.0	6.6
	Related	56	1	1.8	0.0	9.6	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
	Grade $\geq 3$ Related	56	0	0.0	0.0	6.4	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
	Medical advice	56	1	1.8	0.0	9.6	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
Anorexia	Any	56	7	12.5	5.2	24.1	58	3	5.2	1.1	14.4	54	3	5.6	1.2	15.4
	Grade $\geq 3$	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Related	56	3	5.4	1.1	14.9	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Grade $\geq 3$ Related	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Diarrhoea	Any	56	8	14.3	6.4	26.2	58	12	20.7	11.2	33.4	54	5	9.3	3.1	20.3
	Grade $\geq 3$	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	1	1.9	0.0	9.9
	Related	56	4	7.1	2.0	17.3	58	3	5.2	1.1	14.4	54	1	1.9	0.0	9.9
	Grade $\geq 3$ Related	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Fatigue	Any	56	25	44.6	31.3	58.5	58	11	19.0	9.9	31.4	54	8	14.8	6.6	27.1
	Grade $\geq 3$	56	3	5.4	1.1	14.9	58	2	3.4	0.4	11.9	54	1	1.9	0.0	9.9
	Related	56	15	26.8	15.8	40.3	58	3	5.2	1.1	14.4	54	2	3.7	0.5	12.7
	Grade $\geq 3$ Related	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Headache	Any	56	16	28.6	17.3	42.2	58	17	29.3	18.1	42.7	54	7	13.0	5.4	24.9
	Grade $\geq 3$	56	1	1.8	0.0	9.6	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
	Related	56	8	14.3	6.4	26.2	58	5	8.6	2.9	19.0	54	1	1.9	0.0	9.9
	Grade $\geq 3$ Related	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	2	3.6	0.4	12.3	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
Myalgia	Any	56	19	33.9	21.8	47.8	58	9	15.5	7.3	27.4	54	4	7.4	2.1	17.9
	Grade $\geq 3$	56	2	3.6	0.4	12.3	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
	Related	56	13	23.2	13.0	36.4	58	3	5.2	1.1	14.4	54	1	1.9	0.0	9.9
	Grade $\geq 3$ Related	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
Nausea	Any	56	7	12.5	5.2	24.1	58	2	3.4	0.4	11.9	54	3	5.6	1.2	15.4

	Grade ≥ 3	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Related	56	3	5.4	1.1	14.9	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Grade ≥ 3 Related	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Sweating	Any	56	7	12.5	5.2	24.1	58	8	13.8	6.1	25.4	54	2	3.7	0.5	12.7
	Grade ≥ 3	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Related	56	4	7.1	2.0	17.3	58	1	1.7	0.0	9.2	54	0	0.0	0.0	6.6
	Grade ≥ 3 Related	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Temperature (Orally)	Any	56	5	8.9	3.0	19.6	58	3	5.2	1.1	14.4	54	1	1.9	0.0	9.9
	≥ 39.4°C	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Related	56	4	7.1	2.0	17.3	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	≥ 39.4°C Related	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Vomiting	Any	56	2	3.6	0.4	12.3	58	0	0.0	0.0	6.2	54	1	1.9	0.0	9.9
	Grade ≥ 3	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Related	56	1	1.8	0.0	9.6	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Grade ≥ 3 Related	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
	Medical advice	56	0	0.0	0.0	6.4	58	0	0.0	0.0	6.2	54	0	0.0	0.0	6.6
Across doses																
Abdominal pain	Any	62	13	21.0	11.7	33.2	64	10	15.6	7.8	26.9	64	4	6.3	1.7	15.2
	Grade ≥ 3	62	1	1.6	0.0	8.7	64	2	3.1	0.4	10.8	64	0	0.0	0.0	5.6
	Related	62	3	4.8	1.0	13.5	64	3	4.7	1.0	13.1	64	0	0.0	0.0	5.6
	Grade ≥ 3 Related	62	0	0.0	0.0	5.8	64	1	1.6	0.0	8.4	64	0	0.0	0.0	5.6
	Medical advice	62	3	4.8	1.0	13.5	64	1	1.6	0.0	8.4	64	0	0.0	0.0	5.6
Anorexia	Any	62	11	17.7	9.2	29.5	64	10	15.6	7.8	26.9	64	7	10.9	4.5	21.2
	Grade ≥ 3	62	1	1.6	0.0	8.7	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Related	62	5	8.1	2.7	17.8	64	4	6.3	1.7	15.2	64	0	0.0	0.0	5.6
	Grade ≥ 3 Related	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	1	1.6	0.0	8.4	64	0	0.0	0.0	5.6
Diarrhoea	Any	62	17	27.4	16.9	40.2	64	19	29.7	18.9	42.4	64	14	21.9	12.5	34.0
	Grade ≥ 3	62	1	1.6	0.0	8.7	64	0	0.0	0.0	5.6	64	1	1.6	0.0	8.4
	Related	62	5	8.1	2.7	17.8	64	4	6.3	1.7	15.2	64	2	3.1	0.4	10.8
	Grade ≥ 3 Related	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	2	3.2	0.4	11.2	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
Fatigue	Any	62	43	69.4	56.3	80.4	64	38	59.4	46.4	71.5	64	20	31.3	20.2	44.1
	Grade ≥ 3	62	8	12.9	5.7	23.9	64	4	6.3	1.7	15.2	64	3	4.7	1.0	13.1
	Related	62	24	38.7	26.6	51.9	64	24	37.5	25.7	50.5	64	9	14.1	6.6	25.0
	Grade ≥ 3 Related	62	3	4.8	1.0	13.5	64	2	3.1	0.4	10.8	64	1	1.6	0.0	8.4
	Medical advice	62	1	1.6	0.0	8.7	64	1	1.6	0.0	8.4	64	0	0.0	0.0	5.6
Headache	Any	62	32	51.6	38.6	64.5	64	33	51.6	38.7	64.2	64	21	32.8	21.6	45.7
	Grade ≥ 3	62	4	6.5	1.8	15.7	64	4	6.3	1.7	15.2	64	1	1.6	0.0	8.4
	Related	62	15	24.2	14.2	36.7	64	17	26.6	16.3	39.1	64	11	17.2	8.9	28.7
	Grade ≥ 3 Related	62	3	4.8	1.0	13.5	64	2	3.1	0.4	10.8	64	0	0.0	0.0	5.6
	Medical advice	62	2	3.2	0.4	11.2	64	2	3.1	0.4	10.8	64	1	1.6	0.0	8.4
Myalgia	Any	62	33	53.2	40.1	66.0	64	32	50.0	37.2	62.8	64	12	18.8	10.1	30.5
	Grade ≥ 3	62	4	6.5	1.8	15.7	64	5	7.8	2.6	17.3	64	1	1.6	0.0	8.4
	Related	62	22	35.5	23.7	48.7	64	21	32.8	21.6	45.7	64	4	6.3	1.7	15.2
	Grade ≥ 3 Related	62	2	3.2	0.4	11.2	64	4	6.3	1.7	15.2	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	2	3.1	0.4	10.8	64	1	1.6	0.0	8.4
Nausea	Any	62	17	27.4	16.9	40.2	64	14	21.9	12.5	34.0	64	8	12.5	5.6	23.2
	Grade ≥ 3	62	1	1.6	0.0	8.7	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Related	62	7	11.3	4.7	21.9	64	4	6.3	1.7	15.2	64	2	3.1	0.4	10.8
	Grade ≥ 3 Related	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	1	1.6	0.0	8.7	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
Sweating	Any	62	11	17.7	9.2	29.5	64	20	31.3	20.2	44.1	64	10	15.6	7.8	26.9

	Grade ≥ 3	62	1	1.6	0.0	8.7	64	2	3.1	0.4	10.8	64	0	0.0	0.0	5.6
	Related	62	6	9.7	3.6	19.9	64	7	10.9	4.5	21.2	64	1	1.6	0.0	8.4
	Grade ≥ 3 Related	62	1	1.6	0.0	8.7	64	1	1.6	0.0	8.4	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	1	1.6	0.0	8.4	64	0	0.0	0.0	5.6
Temperature (Orally)	Any	62	14	22.6	12.9	35.0	64	9	14.1	6.6	25.0	64	6	9.4	3.5	19.3
	≥ 39.4°C	62	2	3.2	0.4	11.2	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Related	62	9	14.5	6.9	25.8	64	4	6.3	1.7	15.2	64	0	0.0	0.0	5.6
	≥39.4 °C Related	62	1	1.6	0.0	8.7	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	1	1.6	0.0	8.7	64	1	1.6	0.0	8.4	64	1	1.6	0.0	8.4
Vomiting	Any	62	3	4.8	1.0	13.5	64	2	3.1	0.4	10.8	64	3	4.7	1.0	13.1
	Grade ≥ 3	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Related	62	2	3.2	0.4	11.2	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Grade ≥ 3 Related	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6
	Medical advice	62	0	0.0	0.0	5.8	64	0	0.0	0.0	5.6	64	0	0.0	0.0	5.6

N = number of subjects with at least one documented dose;

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

Grades 3 and 4 for Abdominal pain, Fatigue, Myalgia and Sweating

- Grade 3 Abdominal pain, Fatigue, Myalgia and Sweating = Symptoms causing inability to perform usual social and functional activities
- Grade 4 Abdominal pain, Fatigue, Myalgia and Sweating = Symptoms causing inability to perform usual social and functional activities

Grades 3 and 4 for Anorexia:

- Grade 3 Anorexia = Loss of appetite associated with significant weight loss
- Grade 4 Anorexia = Aggressive intervention indicated (e.g. tube feeding or total parenteral nutrition)

Grades 3 and 4 for Diarrhoea:

- Grade 3 Diarrhoea = Bloody diarrhoea or increase of ≥ 7 stools per 24-hour period or IV fluid replacement
- Grade 4 Diarrhoea = Life threatening consequences (e.g., hypotensive shock)

Grades 3 and 4 for Headache:

- Grade 3 Headache = Headache causing inability to perform usual social and functional activities
- Grade 4 Headache = Headache causing inability to perform basic self-care functions or Hospitalization indicated (other than an emergency room visit) or Headache with significant impairment of alertness or other neurologic function.

Grades 3 and 4 for Nausea:

- Grade 3 Nausea = Persistent nausea resulting in minimal oral intake for > 48 hours or Aggressive rehydration indicated (e.g., IV fluids)
- Grade 4 Nausea = Life threatening consequences (e.g., hypotensive shock)

Grades 3 and 4 for Vomiting:

- Grade 3 Vomiting = Persistent vomiting resulting in orthostatic hypotension or Aggressive rehydration indicated (e.g., IV fluids)
- Grade 4 Vomiting = Life threatening consequences (e.g., hypotensive shock)

**Primary Efficacy Results:** Number (%) of subjects with pIMDs during the entire study period (Total Vaccinated cohort)

pIMDs	3-Doses HIV Group N = 62	2-Doses HIV Group N = 64	Placebo Group N = 64
Subjects with any pIMD(s), n (%)	0 (0.0)	1 (1.6)	0 (0.0)
Psoriasis	-	1 (1.6)	-
- = event absent.			

**Primary Efficacy Results:** Percentage of subjects with DAIDS graded hemato-biochemistry parameters at each time points (Total Vaccinated cohort)

			DAIDS Grade Categories									
			0		1		2		3		4	
Component code	Timing	Groups	n	%	n	%	n	%	n	%	n	%
Alanine aminotransferase	SCR	HIV	115	91.3	9	7.1	2	1.6	0	0.0	0	0.0
		Placebo	63	98.4	1	1.6	0	0.0	0	0.0	0	0.0
	PRE	HIV	117	92.9	6	4.8	3	2.4	0	0.0	0	0.0
		Placebo	62	96.9	2	3.1	0	0.0	0	0.0	0	0.0

		PI(W4)	HIV	114	90.5	10	7.9	2	1.6	0	0.0	0	0.0
			Placebo	62	98.4	0	0.0	1	1.6	0	0.0	0	0.0
		PII(W6)	HIV	117	93.6	5	4.0	3	2.4	0	0.0	0	0.0
			Placebo	60	96.8	2	3.2	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	113	91.1	10	8.1	1	0.8	0	0.0	0	0.0
			Placebo	60	98.4	0	0.0	1	1.6	0	0.0	0	0.0
		PII(W28)	HIV	112	92.6	5	4.1	3	2.5	0	0.0	1	0.8
			Placebo	57	95.0	2	3.3	1	1.7	0	0.0	0	0.0
		PIII(W30)	Placebo	53	91.4	5	8.6	0	0.0	0	0.0	0	0.0
			3-Doses HIV	54	94.7	2	3.5	1	1.8	0	0.0	0	0.0
			2-Doses HIV	57	95.0	1	1.7	1	1.7	0	0.0	1	1.7
		PIII(W38)	Placebo	53	91.4	4	6.9	0	0.0	1	1.7	0	0.0
			3-Doses HIV	52	91.2	3	5.3	2	3.5	0	0.0	0	0.0
			2-Doses HIV	61	96.8	1	1.6	1	1.6	0	0.0	0	0.0
		PIII(W48)	Placebo	52	89.7	3	5.2	2	3.4	1	1.7	0	0.0
			3-Doses HIV	55	96.5	1	1.8	1	1.8	0	0.0	0	0.0
			2-Doses HIV	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0
Albumin		SCR	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PRE	HIV	125	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PI(W4)	HIV	125	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W6)	HIV	124	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	123	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W30)	Placebo	57	98.3	1	1.7	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	57	98.3	0	0.0	1	1.7	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Alkaline phosphatase		SCR	HIV	125	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PRE	HIV	125	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PI(W4)	HIV	124	98.4	2	1.6	0	0.0	0	0.0	0	0.0
			Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W6)	HIV	123	98.4	2	1.6	0	0.0	0	0.0	0	0.0
			Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	122	98.4	2	1.6	0	0.0	0	0.0	0	0.0
			Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	55	96.5	2	3.5	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0

	PIII(W48)	Placebo	57	98.3	1	1.7	0	0.0	0	0.0	0	0.0
		3-Doses HIV	55	96.5	2	3.5	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Aspartate aminotransferase	SCR	HIV	120	95.2	6	4.8	0	0.0	0	0.0	0	0.0
		Placebo	63	98.4	1	1.6	0	0.0	0	0.0	0	0.0
	PRE	HIV	121	96.0	3	2.4	2	1.6	0	0.0	0	0.0
		Placebo	61	95.3	3	4.7	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	119	94.4	5	4.0	2	1.6	0	0.0	0	0.0
		Placebo	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	118	94.4	6	4.8	1	0.8	0	0.0	0	0.0
		Placebo	61	98.4	1	1.6	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	117	94.4	6	4.8	1	0.8	0	0.0	0	0.0
		Placebo	59	96.7	2	3.3	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	115	95.0	4	3.3	1	0.8	0	0.0	1	0.8
		Placebo	57	95.0	3	5.0	0	0.0	0	0.0	0	0.0
	PIII(W30)	Placebo	55	94.8	3	5.2	0	0.0	0	0.0	0	0.0
		3-Doses HIV	54	94.7	3	5.3	0	0.0	0	0.0	0	0.0
		2-Doses HIV	58	96.7	1	1.7	0	0.0	1	1.7	0	0.0
	PIII(W38)	Placebo	55	94.8	2	3.4	1	1.7	0	0.0	0	0.0
		3-Doses HIV	52	91.2	4	7.0	1	1.8	0	0.0	0	0.0
		2-Doses HIV	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0
	PIII(W48)	Placebo	54	93.1	2	3.4	2	3.4	0	0.0	0	0.0
		3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Bilirubin (total)	SCR	HIV	123	97.6	2	1.6	1	0.8	0	0.0	0	0.0
		Placebo	63	98.4	0	0.0	1	1.6	0	0.0	0	0.0
	PRE	HIV	125	99.2	1	0.8	0	0.0	0	0.0	0	0.0
		Placebo	63	98.4	0	0.0	1	1.6	0	0.0	0	0.0
	PI(W4)	HIV	125	99.2	1	0.8	0	0.0	0	0.0	0	0.0
		Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	121	96.8	4	3.2	0	0.0	0	0.0	0	0.0
		Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	59	96.7	1	1.6	1	1.6	0	0.0	0	0.0
	PII(W28)	HIV	119	98.3	1	0.8	1	0.8	0	0.0	0	0.0
		Placebo	59	98.3	0	0.0	1	1.7	0	0.0	0	0.0
	PIII(W30)	Placebo	55	94.8	3	5.2	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	59	98.3	1	1.7	0	0.0	0	0.0	0	0.0
	PIII(W38)	Placebo	56	96.6	1	1.7	1	1.7	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	61	96.8	1	1.6	1	1.6	0	0.0	0	0.0
	PIII(W48)	Placebo	56	96.6	1	1.7	1	1.7	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Creatinine	SCR	HIV	124	98.4	2	1.6	0	0.0	0	0.0	0	0.0
		Placebo	62	96.9	1	1.6	1	1.6	0	0.0	0	0.0
	PRE	HIV	125	99.2	0	0.0	1	0.8	0	0.0	0	0.0
		Placebo	61	95.3	3	4.7	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	121	96.0	5	4.0	0	0.0	0	0.0	0	0.0
		Placebo	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	119	95.2	6	4.8	0	0.0	0	0.0	0	0.0
		Placebo	60	96.8	2	3.2	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	119	96.0	5	4.0	0	0.0	0	0.0	0	0.0
		Placebo	60	98.4	1	1.6	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	119	98.3	2	1.7	0	0.0	0	0.0	0	0.0

		PIII(W30)	Placebo	59	98.3	0	0.0	1	1.7	0	0.0	0	0.0
			Placebo	57	98.3	1	1.7	0	0.0	0	0.0	0	0.0
			3-Doses HIV	55	96.5	2	3.5	0	0.0	0	0.0	0	0.0
			2-Doses HIV	59	98.3	1	1.7	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	56	96.6	2	3.4	0	0.0	0	0.0	0	0.0
			3-Doses HIV	54	94.7	3	5.3	0	0.0	0	0.0	0	0.0
			2-Doses HIV	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0
		PIII(W48)	Placebo	55	94.8	3	5.2	0	0.0	0	0.0	0	0.0
			3-Doses HIV	54	94.7	3	5.3	0	0.0	0	0.0	0	0.0
			2-Doses HIV	62	98.4	1	1.6	0	0.0	0	0.0	0	0.0
	Eosinophils	SCR	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PRE	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PI(W4)	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W6)	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	Eosinophils/100 leukocytes	SCR	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PRE	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PI(W4)	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W6)	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
		PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	Bicarbonate	SCR	HIV	118	93.7	8	6.3	0	0.0	0	0.0	0	0.0
			Placebo	59	92.2	5	7.8	0	0.0	0	0.0	0	0.0
		PRE	HIV	100	79.4	26	20.6	0	0.0	0	0.0	0	0.0
			Placebo	47	73.4	17	26.6	0	0.0	0	0.0	0	0.0

		PI(W4)	HIV	99	78.6	27	21.4	0	0.0	0	0.0	0	0.0
			Placebo	48	76.2	15	23.8	0	0.0	0	0.0	0	0.0
		PII(W6)	HIV	92	73.6	33	26.4	0	0.0	0	0.0	0	0.0
			Placebo	39	62.9	23	37.1	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	93	75.0	31	25.0	0	0.0	0	0.0	0	0.0
			Placebo	47	77.0	14	23.0	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	92	76.0	29	24.0	0	0.0	0	0.0	0	0.0
			Placebo	45	75.0	15	25.0	0	0.0	0	0.0	0	0.0
		PIII(W30)	Placebo	43	74.1	15	25.9	0	0.0	0	0.0	0	0.0
			3-Doses HIV	45	78.9	12	21.1	0	0.0	0	0.0	0	0.0
			2-Doses HIV	45	75.0	15	25.0	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	46	79.3	11	19.0	1	1.7	0	0.0	0	0.0
			3-Doses HIV	47	82.5	10	17.5	0	0.0	0	0.0	0	0.0
			2-Doses HIV	51	81.0	12	19.0	0	0.0	0	0.0	0	0.0
		PIII(W48)	Placebo	49	84.5	9	15.5	0	0.0	0	0.0	0	0.0
			3-Doses HIV	43	75.4	14	24.6	0	0.0	0	0.0	0	0.0
			2-Doses HIV	51	81.0	12	19.0	0	0.0	0	0.0	0	0.0
Hemoglobin	SCR	HIV	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PRE	HIV	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	HIV	122	98.4	2	1.6	0	0.0	0	0.0	0	0.0
			Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	HIV	120	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	59	98.3	1	1.7	0	0.0	0	0.0	0	0.0
	PIII(W30)	Placebo	Placebo	57	98.3	0	0.0	0	0.0	1	1.7	0	0.0
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W38)	Placebo	Placebo	57	98.3	0	0.0	0	0.0	0	0.0	1	1.7
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W48)	Placebo	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Potassium	SCR	HIV	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PRE	HIV	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	HIV	124	98.4	2	1.6	0	0.0	0	0.0	0	0.0
			Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	HIV	124	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	60	96.8	2	3.2	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	HIV	123	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	HIV	120	99.2	1	0.8	0	0.0	0	0.0	0	0.0
			Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W30)	Placebo	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W38)	Placebo	Placebo	57	98.3	1	1.7	0	0.0	0	0.0	0	0.0
			3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
			2-Doses HIV	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0

	PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0
Lymphocytes	SCR	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PRE	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Lymphocytes/100 leukocytes	SCR	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PRE	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0
		Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
	PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0
Sodium	SCR	HIV	115	91.3	11	8.7	0	0.0	0	0.0	0	0.0
		Placebo	63	98.4	1	1.6	0	0.0	0	0.0	0	0.0
	PRE	HIV	114	90.5	11	8.7	1	0.8	0	0.0	0	0.0
		Placebo	59	92.2	5	7.8	0	0.0	0	0.0	0	0.0
	PI(W4)	HIV	119	94.4	7	5.6	0	0.0	0	0.0	0	0.0
		Placebo	60	95.2	3	4.8	0	0.0	0	0.0	0	0.0
	PII(W6)	HIV	117	93.6	7	5.6	1	0.8	0	0.0	0	0.0
		Placebo	58	93.5	4	6.5	0	0.0	0	0.0	0	0.0
	PII(W16)	HIV	121	97.6	3	2.4	0	0.0	0	0.0	0	0.0
		Placebo	58	95.1	3	4.9	0	0.0	0	0.0	0	0.0
	PII(W28)	HIV	115	95.0	6	5.0	0	0.0	0	0.0	0	0.0



	PIII(W30)	Placebo	57	95.0	3	5.0	0	0.0	0	0.0	0	0.0	
		Placebo	51	87.9	7	12.1	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	55	96.5	2	3.5	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	59	98.3	1	1.7	0	0.0	0	0.0	0	0.0	
	PIII(W38)	Placebo	54	93.1	4	6.9	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	54	94.7	3	5.3	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	61	96.8	2	3.2	0	0.0	0	0.0	0	0.0	
	PIII(W48)	Placebo	55	94.8	3	5.2	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	58	92.1	5	7.9	0	0.0	0	0.0	0	0.0	
	Neutrophils	SCR	HIV	119	96.0	3	2.4	2	1.6	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
PRE		HIV	123	97.6	2	1.6	1	0.8	0	0.0	0	0.0	
		Placebo	62	96.9	0	0.0	2	3.1	0	0.0	0	0.0	
PI(W4)		HIV	122	96.8	4	3.2	0	0.0	0	0.0	0	0.0	
		Placebo	62	98.4	1	1.6	0	0.0	0	0.0	0	0.0	
PII(W6)		HIV	121	96.8	3	2.4	1	0.8	0	0.0	0	0.0	
		Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0	
PII(W16)		HIV	121	97.6	2	1.6	1	0.8	0	0.0	0	0.0	
		Placebo	60	98.4	1	1.6	0	0.0	0	0.0	0	0.0	
PII(W28)		HIV	115	95.0	3	2.5	3	2.5	0	0.0	0	0.0	
		Placebo	58	96.7	2	3.3	0	0.0	0	0.0	0	0.0	
PIII(W30)		Placebo	55	94.8	3	5.2	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	53	93.0	4	7.0	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	58	96.7	2	3.3	0	0.0	0	0.0	0	0.0	
PIII(W38)		Placebo	56	96.6	2	3.4	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	54	94.7	2	3.5	1	1.8	0	0.0	0	0.0	
		2-Doses HIV	59	93.7	3	4.8	1	1.6	0	0.0	0	0.0	
PIII(W48)		Placebo	57	98.3	0	0.0	1	1.7	0	0.0	0	0.0	
		3-Doses HIV	53	93.0	4	7.0	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	60	95.2	3	4.8	0	0.0	0	0.0	0	0.0	
Neutrophils/100 leukocytes		SCR	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0
			Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0
		PRE	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0
	Placebo		64	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PI(W4)	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0	
		Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PII(W6)	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0	
		Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0	
		Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0	
		Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0	
	PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0	
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0	
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0	
	Platelet count	SCR	HIV	122	98.4	2	1.6	0	0.0	0	0.0	0	0.0
			Placebo	63	98.4	0	0.0	1	1.6	0	0.0	0	0.0
		PRE	HIV	121	96.0	5	4.0	0	0.0	0	0.0	0	0.0
Placebo			63	98.4	0	0.0	1	1.6	0	0.0	0	0.0	

		PI(W4)	HIV	123	97.6	2	1.6	1	0.8	0	0.0	0	0.0
			Placebo	62	98.4	0	0.0	1	1.6	0	0.0	0	0.0
		PII(W6)	HIV	122	97.6	3	2.4	0	0.0	0	0.0	0	0.0
			Placebo	61	98.4	0	0.0	0	0.0	1	1.6	0	0.0
		PII(W16)	HIV	119	96.0	4	3.2	1	0.8	0	0.0	0	0.0
			Placebo	60	98.4	1	1.6	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	118	97.5	2	1.7	1	0.8	0	0.0	0	0.0
			Placebo	59	98.3	0	0.0	1	1.7	0	0.0	0	0.0
		PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	59	98.3	0	0.0	1	1.7	0	0.0	0	0.0
		PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	55	96.5	2	3.5	0	0.0	0	0.0	0	0.0
			2-Doses HIV	59	93.7	3	4.8	1	1.6	0	0.0	0	0.0
		PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
			3-Doses HIV	56	98.2	0	0.0	1	1.8	0	0.0	0	0.0
			2-Doses HIV	62	98.4	0	0.0	1	1.6	0	0.0	0	0.0
	Prothrombin time. International normalized ratio	SCR	HIV	116	92.1	10	7.9	0	0.0	0	0.0	0	0.0
			Placebo	59	93.7	4	6.3	0	0.0	0	0.0	0	0.0
		PRE	HIV	118	93.7	7	5.6	1	0.8	0	0.0	0	0.0
			Placebo	55	85.9	9	14.1	0	0.0	0	0.0	0	0.0
		PI(W4)	HIV	115	91.3	11	8.7	0	0.0	0	0.0	0	0.0
			Placebo	54	85.7	9	14.3	0	0.0	0	0.0	0	0.0
		PII(W6)	HIV	118	94.4	7	5.6	0	0.0	0	0.0	0	0.0
			Placebo	51	82.3	11	17.7	0	0.0	0	0.0	0	0.0
		PII(W16)	HIV	111	89.5	13	10.5	0	0.0	0	0.0	0	0.0
			Placebo	55	90.2	6	9.8	0	0.0	0	0.0	0	0.0
		PII(W28)	HIV	110	90.9	11	9.1	0	0.0	0	0.0	0	0.0
			Placebo	54	90.0	6	10.0	0	0.0	0	0.0	0	0.0
		PIII(W30)	Placebo	53	91.4	5	8.6	0	0.0	0	0.0	0	0.0
			3-Doses HIV	51	89.5	6	10.5	0	0.0	0	0.0	0	0.0
			2-Doses HIV	56	93.3	4	6.7	0	0.0	0	0.0	0	0.0
		PIII(W38)	Placebo	51	87.9	7	12.1	0	0.0	0	0.0	0	0.0
			3-Doses HIV	52	91.2	5	8.8	0	0.0	0	0.0	0	0.0
			2-Doses HIV	55	87.3	7	11.1	0	0.0	1	1.6	0	0.0
		PIII(W48)	Placebo	48	82.8	8	13.8	0	0.0	2	3.4	0	0.0
			3-Doses HIV	55	96.5	2	3.5	0	0.0	0	0.0	0	0.0
			2-Doses HIV	58	92.1	5	7.9	0	0.0	0	0.0	0	0.0
White Blood Cell count	SCR	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		Placebo	64	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
	PRE	HIV	125	99.2	0	0.0	1	0.8	0	0.0	0	0.0	0.0
		Placebo	63	98.4	0	0.0	1	1.6	0	0.0	0	0.0	0.0
	PI(W4)	HIV	126	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		Placebo	63	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
	PII(W6)	HIV	125	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		Placebo	62	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
	PII(W16)	HIV	124	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		Placebo	61	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
	PII(W28)	HIV	121	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		Placebo	60	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
	PIII(W30)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		2-Doses HIV	60	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
	PIII(W38)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0
		3-Doses HIV	56	98.2	1	1.8	0	0.0	0	0.0	0	0.0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0	0.0

	PIII(W48)	Placebo	58	100	0	0.0	0	0.0	0	0.0	0	0.0
		3-Doses HIV	57	100	0	0.0	0	0.0	0	0.0	0	0.0
		2-Doses HIV	63	100	0	0.0	0	0.0	0	0.0	0	0.0

DAIDS = Division of AIDS table for grading the severity of adult and podiatric adverse events (Version 1.0 December, 2004 Clarification August 2009)

n = number of subject number in a given category;

% = n / Number of subject number with available results x 100

SCR = Screening

PRE = Pre-Vaccination

Px(Wy)= Post-Dose x at Week y

**Primary Efficacy Results:** For unsolicited AEs and SAES results, please refer to the Safety results section at the end of the summary.

**Secondary Outcome Results:** Descriptive statistics of HIV-1 viral load, using crude values (Modified Total Vaccinated cohort)

Group	Activity	N	GM	SD	Min	Q1	Median	Q3	Max
HIV	SCR	125	13535.4	0.42	2261	6823	13797	28493	78085
	PRE	122	12431.8	0.49	326	5800	12982	29086	318715
	PI(W1)	78	12202.8	0.42	1396	5486	14939	24432	68196
	PI(W4)	124	14362	0.46	880	6151	14242.5	32192.5	228184
	PII(W6)	118	15198.2	0.44	1076	6676	17019	32848	132414
	PII(W16)	121	14205.9	0.46	1299	6040	15045	28436	351446
	PII(W28)	116	14820.1	0.46	2278	6970.5	12552.5	32604.5	184511
3-Doses HIV	PIII(W30)	53	14277	0.44	2272	7365	14703	25970	134997
	PIII(W38)	49	12149.2	0.43	1127	6977	12248	23435	130798
	PIII(W48)	46	12732.3	0.41	2830	5910	11004.5	25624	86119
2-Doses HIV	PIII(W30)	58	15098	0.51	1549	6977	13902	29316	314660
	PIII(W38)	57	14378.7	0.48	640	8367	14739	28182	156581
	PIII(W48)	55	17507.1	0.56	1746	6741	18415	38871	514302
Placebo	SCR	60	12950.1	0.4	2548	6441.5	12882.5	27468.5	78281
	PRE	58	12061.7	0.49	449	6882	12688.5	26514	166458
	PI(W1)	40	11334.8	0.43	1783	6142	11936	21405.5	67175
	PI(W4)	58	14003.4	0.51	1958	7010	11627.5	25070	897291
	PII(W6)	60	15645.2	0.54	1613	6488.5	15117.5	35630	1061357
	PII(W16)	56	13576.1	0.49	1465	5698.5	14605	33234	117315
	PII(W28)	54	13934	0.5	1119	5910	13208	28274	457965
	PIII(W30)	54	14602.3	0.47	2460	5996	12855.5	32574	416033
	PIII(W38)	52	14260.9	0.52	2015	5068	12264.5	27001	427668
	PIII(W48)	50	15470.3	0.55	1511	6000	15266.5	39189	384789

N = number of subjects with available results;

SD = Standard deviation of crude values;

Q1,Q3 = First and third quartiles;

Min, Max = Minimum, Maximum

SCR = Screening

PRE = Pre-vaccination at Week 0

Px(Wy) = Post Dose x at Week y

**Secondary Outcome Results:** Descriptive statistics of HIV-1 viral load, using log10-transformed values (Modified Total Vaccinated cohort)

Group	Activity	N	Mean	SD	Min	Q1	Median	Q3	Max
HIV	SCR	125	4.131	0.42	3.354	3.834	4.14	4.455	4.893
	PRE	122	4.095	0.49	2.513	3.763	4.113	4.464	5.503
	PI(W1)	78	4.086	0.42	3.145	3.739	4.174	4.388	4.834
	PI(W4)	124	4.157	0.46	2.944	3.789	4.153	4.508	5.358
	PII(W6)	118	4.182	0.44	3.032	3.825	4.231	4.517	5.122
	PII(W16)	121	4.152	0.46	3.114	3.781	4.177	4.454	5.546
	PII(W28)	116	4.171	0.46	3.358	3.843	4.099	4.513	5.266
3-Doses HIV	PIII(W30)	53	4.155	0.44	3.356	3.867	4.167	4.414	5.13
	PIII(W38)	49	4.085	0.43	3.052	3.844	4.088	4.37	5.117



	PIII(W48)	50	601.9	186.81	371	463	580.5	677	1310
N = number of subjects with available results; SD = Standard deviation; Q1,Q3 = First and third quartiles; Min, Max = Minimum, Maximum SCR = Screening PRE = Pre-vaccination at Week 0 Px(Wy) = Post Dose x at Week y									
<b>Secondary Outcome Results:</b> Descriptive statistics of changes in CD4 counts from baseline, using crude values (Modified Total Vaccinated cohort)									
Group	Activity	N	Mean	SD	Min	Q1	Median	Q3	Max
HIV	PI(W1)	78	4.633	16.53	-33.975	-6.47	3.972	16.294	41.284
	PI(W4)	124	-0.201	17.97	-44.941	-9.096	-0.465	6.227	73.333
	PII(W6)	121	2.066	19.97	-41.878	-10.425	0.761	8.929	73.449
	PII(W16)	121	-0.52	20.82	-81.466	-13.218	-2.037	12.941	59.453
	PII(W28)	116	-5.782	19.13	-49.072	-21.154	-8.698	6.625	52.304
3-Doses HIV	PIII(W30)	53	-5.641	19.17	-38.406	-21.03	-6.187	5.23	56.409
	PIII(W38)	49	-4.224	22.97	-49.329	-22.031	-5.92	9.973	50.676
	PIII(W48)	46	-9.859	18.66	-47.359	-19.165	-13.274	-1.257	51.76
2-Doses HIV	PIII(W30)	58	-2.417	20.31	-39.007	-16.597	-4.374	8.279	51.673
	PIII(W38)	57	-4.626	20.01	-37.5	-17.538	-5.673	4.983	84.249
	PIII(W48)	55	-3.915	19.56	-41.315	-19.162	-3.768	8.899	36.273
Placebo	PI(W1)	42	0.589	17.98	-33.333	-13.076	0.025	8.074	45.261
	PI(W4)	60	-1.212	18.58	-48.541	-13.023	-1.869	11.89	53.625
	PII(W6)	60	-1.713	19.68	-50.563	-14.353	-3.032	9.742	58.776
	PII(W16)	56	-2.568	19.68	-53.214	-17.514	-2.87	14.18	33.695
	PII(W28)	54	-4.421	16.06	-39.987	-14.844	-6.18	6.403	35.552
	PIII(W30)	54	-4.403	19.88	-61.383	-14.193	-4.719	6.591	53.012
	PIII(W38)	52	-5.936	16.85	-39.639	-16.303	-7.734	4.075	36.274
	PIII(W48)	50	-13.82	18.67	-56.961	-25.704	-14.862	-2.314	30.739
N = number of subjects with available results; SD = Standard deviation; Q1,Q3 = First and third quartiles; Min, Max = Minimum, Maximum Px(Wy) = Post Dose x at Week y									
<b>Secondary Outcome Results:</b> Summary descriptive statistics for the time to initiation of ART, or to occurrence of any of the HIV-related clinical events, expressed in days from dose 1 administration (Modified Total Vaccinated cohort)									
			3-Doses HIV Group N = 61		2-Doses HIV Group N = 64		Placebo Group N = 60		
Characteristics	Parameters or Categories	Value or n	%	Value or n	%	Value or n	%		
ART initiation	n	5	8.2	4	6.3	5	8.3		
	Mean	261.40	-	253.50	-	179.80	-		
	Minimum	216.00	-	223.00	-	56.00	-		
	Maximum	337.00	-	277.00	-	287.00	-		
HIV-related clinical events	n	6	9.8	7	10.9	6	10.0		
	Mean	171.33	-	185.57	-	100.83	-		
	Minimum	49.00	-	28.00	-	0.00	-		
	Maximum	350.00	-	342.00	-	197.00	-		
Only actual ART initiations were reported under the category “ART initiation”. HIV related clinical events either 1) clinical disease progression, or 2) confirmed VL > 100,000 copies/mL, or 3) confirmed CD4 cell count < 350 cells/mm <sup>3</sup> N = number of subjects with available results n = number of subjects in a given category Value = value of the considered parameter % = n / Number of subject number with available results x 100									
<b>Secondary Outcome Results:</b> Descriptive statistics for the number of F4co-Computed* and each antigen specific CD40L+CD4+ T cells expressing at least IL-2 per million CD4+ T cells (ATP cohort for immunogenicity)									

Antigen	Group	Timing	N	GM	Mean	SD	Median
F4co-Computed	3-Doses HIV	PRE	38	450.67	524.71	291.63	430.0
		PII(W6)	32	2118.04	3323.16	3624.19	2559.5
		PII(W28)	31	873.25	1409.65	2050.82	818.0
		PIII(W30)	34	2486.39	4074.21	4901.12	2495.5
		PIII(W48)	35	1016.29	1822.97	2764.09	937.0
	2-Doses HIV	PRE	37	393.58	496.97	302.75	469.0
		PII(W6)	36	1582.15	2605.67	3087.10	1686.0
		PII(W28)	40	621.73	1001.28	1032.57	677.5
		PIII(W30)	35	651.11	997.03	1014.68	681.0
		PIII(W48)	36	573.73	918.89	973.49	534.5
	HIV	PRE	75	421.54	511.03	295.48	435.0
		PII(W6)	68	1814.95	2943.31	3344.53	2014.5
		PII(W28)	71	721.14	1179.58	1561.46	751.0
	Placebo	PRE	35	384.73	502.09	352.63	364.0
		PII(W6)	32	452.32	577.06	342.27	557.5
		PII(W28)	35	328.25	429.77	306.81	345.0
		PIII(W30)	34	438.32	538.15	311.88	521.0
		PIII(W48)	31	364.30	453.68	308.12	365.0
Nef	3-Doses HIV	PRE	38	39.83	67.95	69.31	43.0
		PII(W6)	32	341.73	713.38	882.96	521.0
		PII(W28)	31	121.09	312.58	516.85	157.0
		PIII(W30)	35	625.90	1081.94	1292.93	672.0
		PIII(W48)	36	161.38	455.33	688.69	166.0
	2-Doses HIV	PRE	37	35.18	66.27	78.32	42.0
		PII(W6)	36	216.42	568.31	946.77	219.0
		PII(W28)	40	79.23	215.40	358.87	97.5
		PIII(W30)	35	76.07	193.94	294.74	104.0
		PIII(W48)	37	64.43	202.97	353.01	96.0
	HIV	PRE	75	37.46	67.12	73.40	43.0
		PII(W6)	68	268.32	636.57	913.40	259.0
		PII(W28)	71	95.35	257.83	434.27	122.0
	Placebo	PRE	35	25.96	61.31	67.92	46.0
		PII(W6)	32	29.93	51.91	43.34	45.5
		PII(W28)	35	25.27	43.29	44.55	29.0
		PIII(W30)	34	27.78	62.50	74.18	42.0
		PIII(W48)	32	20.06	47.19	52.25	26.0
p17	3-Doses HIV	PRE	38	79.35	104.08	65.17	111.5
		PII(W6)	33	201.68	395.67	602.76	226.0
		PII(W28)	31	104.87	212.45	401.69	132.0
		PIII(W30)	34	192.43	419.68	740.74	173.5
		PIII(W48)	35	114.75	204.97	332.65	100.0
	2-Doses HIV	PRE	37	60.73	117.05	102.59	92.0
		PII(W6)	36	200.72	395.92	645.67	226.0
		PII(W28)	40	76.78	173.20	266.56	109.5
		PIII(W30)	36	109.34	197.67	250.58	115.0
		PIII(W48)	37	81.98	175.16	224.51	120.0
	HIV	PRE	75	69.54	110.48	85.36	97.0
		PII(W6)	69	201.18	395.80	620.93	226.0
		PII(W28)	71	87.97	190.34	330.34	118.0
	Placebo	PRE	35	80.85	122.57	96.71	105.0
		PII(W6)	32	93.76	126.66	76.39	130.5
		PII(W28)	35	57.02	91.71	74.39	68.0
		PIII(W30)	34	71.48	110.00	75.46	106.5
		PIII(W48)	32	49.30	99.16	103.16	78.5
p24	3-Doses HIV	PRE	38	136.57	181.89	140.27	140.5

		PII(W6)	33	215.10	457.00	828.19	271.0
		PII(W28)	31	162.16	313.90	565.35	184.0
		PIII(W30)	35	293.68	727.51	1376.00	256.0
		PIII(W48)	35	179.22	350.34	605.58	197.0
	2-Doses HIV	PRE	37	92.30	151.05	132.75	121.0
		PII(W6)	36	218.40	382.78	511.29	222.0
		PII(W28)	40	110.71	204.73	185.25	159.0
		PIII(W30)	36	155.19	238.78	212.05	183.5
	HIV	PIII(W48)	37	129.25	233.30	244.37	129.0
		PRE	75	112.57	166.68	136.57	127.0
		PII(W6)	69	216.82	418.28	677.29	253.0
		PII(W28)	71	130.78	252.39	398.84	178.0
	Placebo	PRE	35	119.32	173.83	144.76	129.0
		PII(W6)	32	134.85	198.97	161.62	127.0
		PII(W28)	35	88.52	159.57	151.61	120.0
		PIII(W30)	34	111.66	164.53	126.25	155.0
PIII(W48)		32	107.32	165.28	146.87	119.5	
RT	3-Doses HIV	PRE	38	136.69	170.79	112.73	158.0
		PII(W6)	32	1065.59	1746.94	1744.93	1160.0
		PII(W28)	31	308.07	570.71	763.75	297.0
		PIII(W30)	35	979.92	1980.77	2038.80	1155.0
		PIII(W48)	36	334.85	788.08	1296.03	365.5
	2-Doses HIV	PRE	37	116.42	162.59	140.37	126.0
		PII(W6)	36	736.41	1258.67	1259.71	837.0
		PII(W28)	40	225.07	407.95	395.58	279.5
		PIII(W30)	36	199.45	390.08	406.68	245.5
		PIII(W48)	38	138.17	297.58	308.91	170.0
	HIV	PRE	75	126.28	166.75	126.32	132.0
		PII(W6)	68	876.26	1488.44	1515.92	1070.5
		PII(W28)	71	258.13	479.01	586.33	297.0
	Placebo	PRE	35	75.93	144.37	133.61	116.0
		PII(W6)	33	128.81	207.24	161.05	174.0
		PII(W28)	35	84.20	135.20	119.35	101.0
		PIII(W30)	34	148.47	201.12	143.87	180.5
		PIII(W48)	31	82.20	137.19	121.03	120.0
<i>*F4co-Computed = Frequency of CD4+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T cells to each of the 4 antigens (Nef, p17, p24, RT)</i>							
N = number of subjects with available results							
GM = Geometric Mean							
SD = Standard Deviation							
PRE = Pre Dose1							
PII(W6) = Post-Dose 2 (6 weeks post Dose 1)							
PII(W28) = Post-Dose 2 (28 weeks post Dose 1)							
PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)							
PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)							
<b>Secondary Outcome Results:</b> Descriptive statistics for the number of F4co-Computed* and each antigen specific CD40L+CD4+ T cells expressing at least one cytokine per million CD4+ T cells (ATP cohort for immunogenicity)							
<b>Antigen</b>	<b>Group</b>	<b>Timing</b>	<b>N</b>	<b>GM</b>	<b>Mean</b>	<b>SD</b>	<b>Median</b>
F4co-Computed	3-Doses HIV	PRE	38	1087.50	1257.63	662.14	1135.5
		PII(W6)	32	3364.14	4670.81	4473.62	3675.0
		PII(W28)	31	1575.74	2047.65	2160.89	1587.0
		PIII(W30)	34	3970.16	5623.21	6071.68	4039.0
		PIII(W48)	35	1767.88	2596.03	3380.15	1947.0
	2-Doses HIV	PRE	37	974.80	1237.46	941.97	997.0
		PII(W6)	36	2561.42	3645.39	3559.36	2506.5
		PII(W28)	40	1190.72	1661.30	1273.95	1253.0

			PIII(W30)	35	1342.03	1777.40	1379.44	1108.0
			PIII(W48)	36	1217.49	1685.75	1518.34	1039.5
		HIV	PRE	75	1030.36	1247.68	806.83	1022.0
			PII(W6)	68	2912.03	4127.94	4017.95	2864.0
			PII(W28)	71	1345.66	1829.99	1715.41	1433.0
		Placebo	PRE	35	1071.82	1453.71	1420.70	953.0
			PII(W6)	32	1224.86	1607.84	1406.23	1243.0
			PII(W28)	35	1004.96	1517.71	1718.46	786.0
			PIII(W30)	34	1208.53	1626.47	1532.64	1157.0
			PIII(W48)	31	1094.70	1408.52	1035.70	1251.0
Nef	3-Doses HIV		PRE	38	94.94	133.29	107.82	87.0
			PII(W6)	32	533.78	941.19	1090.44	599.0
			PII(W28)	31	213.31	391.00	533.65	227.0
			PIII(W30)	35	926.93	1406.83	1602.94	763.0
			PIII(W48)	36	282.76	570.58	825.69	258.5
	2-Doses HIV		PRE	37	94.70	147.14	136.53	87.0
			PII(W6)	36	374.48	729.08	1042.11	392.0
			PII(W28)	40	164.24	284.90	368.73	179.5
			PIII(W30)	35	146.62	275.00	310.29	204.0
			PIII(W48)	37	147.14	293.81	391.08	146.0
	HIV		PRE	75	94.82	140.12	122.18	87.0
			PII(W6)	68	442.46	828.90	1062.47	434.0
			PII(W28)	71	184.10	331.23	447.89	208.0
	Placebo		PRE	35	91.02	197.63	420.25	108.0
			PII(W6)	32	87.91	198.16	357.14	115.0
			PII(W28)	35	83.04	222.74	555.94	73.0
			PIII(W30)	34	99.74	256.47	461.93	113.0
			PIII(W48)	32	91.66	150.41	186.75	87.0
p17	3-Doses HIV		PRE	38	227.80	287.74	191.25	249.5
			PII(W6)	33	438.22	652.27	701.66	517.0
			PII(W28)	31	257.00	357.35	417.74	284.0
			PIII(W30)	34	465.94	684.97	854.31	413.0
			PIII(W48)	35	248.46	354.31	402.29	261.0
	2-Doses HIV		PRE	37	192.95	312.46	301.46	164.0
			PII(W6)	36	359.88	601.00	796.85	379.5
			PII(W28)	40	210.78	364.63	359.59	243.5
			PIII(W30)	36	260.04	421.14	417.59	242.0
			PIII(W48)	37	203.08	353.97	368.48	244.0
	HIV		PRE	75	209.88	299.93	250.31	228.0
			PII(W6)	69	395.43	625.52	747.78	393.0
			PII(W28)	71	229.84	361.45	383.20	281.0
	Placebo		PRE	35	241.25	360.57	382.51	263.0
			PII(W6)	32	292.50	388.59	317.92	267.0
			PII(W28)	35	202.42	325.26	304.54	228.0
			PIII(W30)	34	265.95	360.00	315.98	303.0
			PIII(W48)	32	213.86	317.06	267.60	245.5
p24	3-Doses HIV		PRE	38	428.99	527.21	331.62	459.0
			PII(W6)	33	534.34	863.36	1186.00	596.0
			PII(W28)	31	441.22	616.48	677.46	439.0
			PIII(W30)	35	707.72	1232.09	1907.11	596.0
			PIII(W48)	35	499.94	710.69	899.91	486.0
	2-Doses HIV		PRE	37	314.08	494.46	526.75	339.0
			PII(W6)	36	540.76	754.44	659.61	452.0
			PII(W28)	40	344.57	499.05	401.20	381.5
			PIII(W30)	36	413.21	604.28	518.97	424.5
			PIII(W48)	37	405.45	619.22	689.30	371.0



RT	HIV	PRE	75	367.83	511.05	436.16	379.0
		PII(W6)	69	537.68	806.54	942.80	486.0
		PII(W28)	71	383.85	550.32	538.34	408.0
	Placebo	PRE	35	424.20	608.51	593.18	379.0
		PII(W6)	32	485.14	704.31	710.44	505.5
		PII(W28)	35	382.80	690.23	843.42	277.0
		PIII(W30)	34	435.99	656.76	692.41	401.5
		PIII(W48)	32	398.83	608.00	609.97	404.5
	3-Doses HIV	PRE	38	258.74	309.39	189.15	268.5
		PII(W6)	32	1492.02	2203.81	1990.05	1588.5
		PII(W28)	31	455.93	682.81	779.18	378.0
		PIII(W30)	35	1464.57	2439.29	2394.59	1629.0
		PIII(W48)	36	483.04	938.19	1458.72	451.5
	2-Doses HIV	PRE	37	217.91	283.41	207.67	238.0
		PII(W6)	36	977.99	1560.86	1427.05	1074.0
		PII(W28)	40	315.65	512.73	432.95	379.0
		PIII(W30)	36	313.69	503.53	452.88	327.5
		PIII(W48)	38	258.44	410.50	351.45	299.0
	HIV	PRE	75	237.72	296.57	197.58	247.0
		PII(W6)	68	1193.05	1863.43	1732.26	1346.0
		PII(W28)	71	370.62	586.99	609.79	378.0
	Placebo	PRE	35	188.46	287.00	247.38	204.0
		PII(W6)	33	253.94	322.94	229.13	296.0
		PII(W28)	35	212.32	279.49	243.46	204.0
		PIII(W30)	34	268.74	353.24	267.64	256.0
		PIII(W48)	31	211.68	305.48	231.15	222.0

*\*F4co-Computed = Frequency of CD4+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T cells to each of the 4 antigens (Nef, p17, p24, RT)*

N = number of subjects with available results

GM = Geometric Mean

SD = Standard Deviation

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Descriptive statistics for the number of F4co-Computed\* and each antigen specific CD40L-CD4+ T cells expressing at least one cytokine per million CD4+T cells (ATP cohort for immunogenicity)

Antigen	Group	Timing	N	GM	Mean	SD	Median
F4co-Computed	3-Doses HIV	PRE	38	1050.78	1695.71	2804.31	874.0
		PII(W6)	32	1243.10	1566.31	1122.18	1189.0
		PII(W28)	31	1022.08	1526.94	2160.64	892.0
		PIII(W30)	34	1482.53	1948.29	1777.03	1376.0
		PIII(W48)	35	1089.19	1367.09	947.35	1193.0
	2-Doses HIV	PRE	37	1094.95	1375.73	1209.08	973.0
		PII(W6)	36	1343.72	1816.06	1649.89	1086.5
		PII(W28)	40	967.08	1226.35	1045.26	1115.5
		PIII(W30)	35	1110.36	1454.54	1158.11	1198.0
		PIII(W48)	36	977.34	1463.75	1710.01	1006.5
	HIV	PRE	75	1072.34	1537.85	2160.83	945.0
		PII(W6)	68	1295.39	1698.53	1421.42	1090.0
		PII(W28)	71	990.72	1357.59	1622.34	986.0
	Placebo	PRE	35	1424.89	2093.17	2160.54	1433.0
		PII(W6)	32	1391.93	2059.00	2217.92	1227.0
		PII(W28)	35	1222.11	1737.46	1543.45	1118.0
		PIII(W30)	34	1387.44	2051.88	2258.58	1416.0

		PIII(W48)	31	1341.80	1819.00	1543.60	1419.0
Nef	3-Doses HIV	PRE	38	180.35	673.37	2583.41	148.0
		PII(W6)	32	223.76	311.94	249.09	302.0
		PII(W28)	31	191.98	588.90	1561.21	169.0
		PIII(W30)	35	270.13	413.77	428.22	245.0
		PIII(W48)	36	182.46	266.64	215.67	215.0
	2-Doses HIV	PRE	37	216.32	323.38	277.30	239.0
		PII(W6)	36	311.22	563.75	740.64	301.5
		PII(W28)	40	189.93	316.73	274.40	261.5
		PIII(W30)	35	272.65	419.77	414.97	273.0
		PIII(W48)	37	166.08	341.51	560.02	174.0
	HIV	PRE	75	197.28	500.71	1845.39	195.0
		PII(W6)	68	266.47	445.25	575.58	301.5
		PII(W28)	71	190.83	435.56	1051.20	241.0
	Placebo	PRE	35	225.54	430.31	591.85	263.0
		PII(W6)	32	184.43	383.06	576.16	211.5
		PII(W28)	35	188.37	347.11	584.77	197.0
		PIII(W30)	34	210.31	479.88	852.09	250.0
		PIII(W48)	32	195.78	405.00	404.38	267.5
p17	3-Doses HIV	PRE	38	186.79	263.08	241.73	204.5
		PII(W6)	33	179.23	271.09	213.32	229.0
		PII(W28)	31	173.70	241.55	204.33	164.0
		PIII(W30)	34	244.81	326.12	296.42	279.5
		PIII(W48)	35	164.40	227.23	170.64	210.0
	2-Doses HIV	PRE	37	164.79	285.05	290.89	184.0
		PII(W6)	36	209.32	377.31	568.22	231.5
		PII(W28)	40	204.47	276.70	209.00	238.0
		PIII(W30)	36	173.01	259.42	239.43	166.0
		PIII(W48)	37	171.80	322.08	444.90	177.0
	HIV	PRE	75	175.59	273.92	265.53	188.0
		PII(W6)	69	194.35	326.51	436.41	230.0
		PII(W28)	71	190.42	261.35	206.25	210.0
	Placebo	PRE	35	228.12	388.31	403.69	230.0
		PII(W6)	32	262.55	400.28	410.23	293.5
		PII(W28)	35	171.90	305.60	320.21	203.0
		PIII(W30)	34	205.70	397.65	459.24	229.0
		PIII(W48)	32	211.10	358.75	367.60	224.5
p24	3-Doses HIV	PRE	38	310.66	457.71	424.13	297.5
		PII(W6)	33	281.46	385.30	306.86	287.0
		PII(W28)	31	268.41	384.35	360.46	296.0
		PIII(W30)	35	412.36	621.86	770.38	389.0
		PIII(W48)	35	332.73	496.17	512.17	341.0
	2-Doses HIV	PRE	37	317.49	514.86	697.98	287.0
		PII(W6)	36	342.14	495.86	520.12	344.5
		PII(W28)	40	250.12	440.40	616.58	340.0
		PIII(W30)	36	318.26	500.33	626.91	298.0
		PIII(W48)	37	319.74	612.59	913.92	369.0
	HIV	PRE	75	314.01	485.91	572.52	294.0
		PII(W6)	69	311.64	442.99	432.03	288.0
		PII(W28)	71	257.95	415.93	517.96	313.0
	Placebo	PRE	35	442.91	915.66	1573.12	377.0
		PII(W6)	32	515.63	1012.38	1596.04	428.5
		PII(W28)	35	415.85	761.29	904.17	487.0
		PIII(W30)	34	486.39	898.35	1250.65	492.5
		PIII(W48)	32	459.71	728.78	708.38	396.5
RT	3-Doses HIV	PRE	38	177.69	301.55	393.26	175.5

		PII(W6)	32	326.64	599.34	800.87	369.0
		PII(W28)	31	194.64	312.13	324.03	210.0
		PIII(W30)	35	372.33	623.54	696.10	369.0
		PIII(W48)	36	226.59	364.11	424.77	270.5
	2-Doses HIV	PRE	37	149.43	252.43	235.45	194.0
		PII(W6)	36	264.81	379.14	320.51	258.5
		PII(W28)	40	107.38	192.53	183.35	118.0
		PIII(W30)	36	168.91	272.08	259.46	162.0
	HIV	PIII(W48)	38	151.70	253.00	250.92	132.5
		PRE	75	163.13	277.32	323.90	194.0
		PII(W6)	68	292.30	482.76	602.23	304.0
		PII(W28)	71	139.22	244.75	259.41	148.0
	Placebo	PRE	35	184.47	358.89	480.52	235.0
		PII(W6)	33	147.06	288.52	371.03	144.0
		PII(W28)	35	169.37	323.46	576.53	138.0
		PIII(W30)	34	170.60	276.00	326.58	162.0
		PIII(W48)	31	173.05	300.81	467.89	158.0

*\*F4co-Computed = Frequency of CD4+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T cells to each of the 4 antigens (Nef, p17, p24, RT)*

N = number of subjects with available results

GM = Geometric Mean

SD = Standard Deviation

PRE = Pre Dose1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Descriptive statistics for the number of F4co-Computed\* and each antigen specific CD4+ T cells expressing at least one cytokine per million CD4+ T cells (ATP cohort for immunogenicity)

Antigen	Group	Timing	N	GM	Mean	SD	Median
F4co-Computed	3-Doses HIV	PRE	38	2265.21	2953.34	3186.15	2360.5
		PII(W6)	32	4941.16	6237.13	5108.61	5024.5
		PII(W28)	31	2849.79	3574.58	3181.93	2885.0
		PIII(W30)	34	5769.05	7571.50	7520.69	5376.5
		PIII(W48)	35	3100.14	3963.11	3833.58	3266.0
	2-Doses HIV	PRE	37	2178.18	2613.19	1769.08	1998.0
		PII(W6)	36	4207.52	5461.44	4495.20	4146.5
		PII(W28)	40	2402.78	2887.65	1822.99	2374.0
		PIII(W30)	35	2604.22	3231.94	2208.73	2538.0
	HIV	PIII(W48)	36	2403.35	3149.50	2610.48	2544.5
		PRE	75	2221.85	2785.53	2574.41	2068.0
		PII(W6)	68	4538.11	5826.47	4773.17	4432.0
		PII(W28)	71	2588.61	3187.58	2511.66	2459.0
	Placebo	PRE	35	2618.65	3546.89	3374.82	2420.0
		PII(W6)	32	2745.10	3666.84	3350.90	2711.5
		PII(W28)	35	2386.86	3255.17	3017.58	2052.0
		PIII(W30)	34	2718.48	3678.35	3582.61	2593.0
		PIII(W48)	31	2569.04	3227.52	2335.86	2398.0
Nef	3-Doses HIV	PRE	38	313.06	806.66	2613.12	284.5
		PII(W6)	32	857.51	1253.13	1238.06	983.5
		PII(W28)	31	523.91	979.90	1640.76	494.0
		PIII(W30)	35	1291.28	1820.60	1890.97	1220.0
		PIII(W48)	36	557.96	837.22	918.48	568.0
	2-Doses HIV	PRE	37	364.02	470.51	334.07	390.0
		PII(W6)	36	807.29	1292.83	1429.51	805.0
		PII(W28)	40	456.43	601.63	450.62	444.0

p17	HIV	PIII(W30)	35	510.23	694.77	546.01	512.0
		PIII(W48)	37	399.95	635.32	690.10	356.0
		PRE	75	337.24	640.83	1870.06	337.0
		PII(W6)	68	830.55	1274.15	1333.08	813.0
		PII(W28)	71	484.75	766.79	1141.31	455.0
		PRE	35	385.47	627.94	946.55	386.0
		PII(W6)	32	305.74	581.22	900.62	323.5
		PII(W28)	35	300.24	569.86	1126.83	283.0
		PIII(W30)	34	402.15	736.35	1273.47	357.0
		PIII(W48)	32	348.17	555.41	516.87	377.5
	3-Doses HIV	PRE	38	451.58	550.82	339.71	463.0
		PII(W6)	33	718.07	923.36	760.67	797.0
		PII(W28)	31	492.62	598.90	467.59	494.0
		PIII(W30)	34	770.47	1011.09	956.78	798.0
		PIII(W48)	35	460.33	581.54	469.57	525.0
	2-Doses HIV	PRE	37	423.72	597.51	449.57	434.0
		PII(W6)	36	647.16	978.31	1262.68	561.5
		PII(W28)	40	487.87	641.33	458.86	527.5
		PIII(W30)	36	503.50	680.56	555.69	473.0
		PIII(W48)	37	463.46	676.05	582.94	580.0
p24	HIV	PRE	75	437.62	573.85	395.70	457.0
		PII(W6)	69	680.16	952.03	1045.79	682.0
		PII(W28)	71	489.94	622.80	459.85	494.0
	Placebo	PRE	35	537.49	748.89	742.84	578.0
		PII(W6)	32	603.35	788.88	678.68	562.0
		PII(W28)	35	458.36	630.86	530.90	433.0
		PIII(W30)	34	546.24	757.65	707.95	536.0
		PIII(W48)	32	494.61	675.81	592.41	498.5
	3-Doses HIV	PRE	38	808.81	984.92	609.19	794.5
		PII(W6)	33	872.82	1248.67	1417.22	902.0
		PII(W28)	31	789.40	1000.84	828.47	784.0
		PIII(W30)	35	1195.09	1853.94	2610.22	988.0
		PIII(W48)	35	904.96	1206.86	1237.50	856.0
	2-Doses HIV	PRE	37	715.69	1009.32	989.32	699.0
		PII(W6)	36	971.68	1250.31	951.09	1033.0
		PII(W28)	40	683.18	939.45	879.54	670.5
		PIII(W30)	36	815.45	1104.61	1081.16	708.0
		PIII(W48)	37	833.39	1231.81	1465.79	831.0
RT	HIV	PRE	75	761.45	996.96	813.55	759.0
		PII(W6)	69	923.07	1249.52	1187.76	977.0
		PII(W28)	71	727.67	966.25	852.11	726.0
	Placebo	PRE	35	956.85	1524.17	1842.81	733.0
		PII(W6)	32	1111.65	1716.69	1963.63	943.0
		PII(W28)	35	924.52	1451.51	1511.19	883.0
		PIII(W30)	34	1010.56	1555.12	1659.33	944.5
		PIII(W48)	32	933.17	1336.78	1209.67	891.0
	3-Doses HIV	PRE	38	485.10	610.95	470.28	494.5
		PII(W6)	32	2075.06	2803.16	2470.30	1916.5
		PII(W28)	31	745.20	994.94	927.09	599.0
		PIII(W30)	35	2099.54	3062.83	2910.84	2138.0
		PIII(W48)	36	840.16	1302.31	1562.53	797.5
	2-Doses HIV	PRE	37	456.89	535.84	327.80	442.0
		PII(W6)	36	1364.05	1940.00	1622.76	1426.5
		PII(W28)	40	526.27	705.25	475.64	667.5
		PIII(W30)	36	579.50	775.61	580.87	540.0
		PIII(W48)	38	523.34	663.50	444.04	573.0

	HIV	PRE	75	470.98	573.89	405.32	455.0
		PII(W6)	68	1661.77	2346.19	2094.64	1680.0
		PII(W28)	71	612.58	831.73	717.87	634.0
	Placebo	PRE	35	482.59	645.89	610.85	474.0
		PII(W6)	33	464.94	611.45	533.04	416.0
		PII(W28)	35	434.98	602.94	642.87	384.0
		PIII(W30)	34	488.98	629.24	520.02	477.0
		PIII(W48)	31	449.91	606.29	573.45	470.0

*\*F4co-Computed = Frequency of CD4+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T cells to each of the 4 antigens (Nef, p17, p24, RT)*

N = number of subjects with available results  
GM= Geometric Mean  
SD = Standard Deviation  
PRE = Pre Dose 1  
PII(W6) = Post-Dose 2 (6 weeks post Dose 1)  
PII(W28) = Post-Dose 2 (28 weeks post Dose 1)  
PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)  
PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Descriptive statistics for the number of F4co-Computed\* and each antigen specific CD8+ T cells expressing at least one cytokine per million CD8+ T cells (ATP cohort for immunogenicity)

Antigen	Group	Timing	N	GM	Mean	SD	Median
F4co-Computed	3-Doses HIV	PRE	38	14602.32	20190.92	16436.97	15895.5
		PII(W6)	32	13737.55	18333.66	12256.57	16727.0
		PII(W28)	31	16003.40	22858.10	21037.82	17526.0
		PIII(W30)	34	13703.98	18186.74	12874.63	15659.5
		PIII(W48)	35	14787.07	19456.29	15314.84	16143.0
	2-Doses HIV	PRE	37	19291.08	25086.30	17149.01	19633.0
		PII(W6)	36	19977.15	25961.69	19507.49	19340.0
		PII(W28)	40	17762.39	24382.03	21158.64	17186.5
		PIII(W30)	35	18725.64	23640.03	15874.21	19210.0
		PIII(W48)	36	18645.29	25447.89	19511.74	21063.0
	HIV	PRE	75	16752.63	22605.97	16859.06	17609.0
		PII(W6)	68	16749.60	22372.03	16822.89	17839.5
		PII(W28)	71	16971.77	23716.65	20968.71	17344.0
	Placebo	PRE	35	25058.71	33074.46	28941.01	25819.0
		PII(W6)	32	28294.37	37728.81	32906.28	29786.5
		PII(W28)	35	23642.83	30320.89	24987.71	25798.0
		PIII(W30)	34	26010.41	33847.09	30706.68	29064.0
		PIII(W48)	31	23276.26	29931.23	24973.70	25564.0
Nef	3-Doses HIV	PRE	38	2386.91	4043.47	3481.39	3187.0
		PII(W6)	32	2105.36	3940.06	3490.39	3141.0
		PII(W28)	31	2370.03	4031.00	3800.99	2641.0
		PIII(W30)	35	2185.22	4148.09	4990.16	2790.0
		PIII(W48)	36	2357.57	4559.25	6995.14	2444.5
	2-Doses HIV	PRE	37	2721.08	5309.46	5609.30	2453.0
		PII(W6)	36	3130.62	5197.92	4766.49	3497.5
		PII(W28)	40	2951.69	5172.30	4996.27	3655.0
		PIII(W30)	35	3121.92	5056.09	4449.19	3387.0
		PIII(W48)	37	2530.27	5074.70	5101.37	2478.0
	HIV	PRE	75	2546.30	4668.03	4666.16	3174.0
		PII(W6)	68	2597.44	4605.99	4231.46	3141.0
		PII(W28)	71	2681.97	4673.99	4519.36	3054.0
	Placebo	PRE	35	4099.74	7402.20	8220.61	3796.0
		PII(W6)	32	4558.24	7917.41	8691.23	5174.0
		PII(W28)	35	4052.37	7128.23	8140.40	4332.0
		PIII(W30)	34	4143.01	7557.12	9229.14	3970.5

p17	3-Doses HIV	PIII(W48)	32	3889.80	6109.56	6920.80	4014.5
		PRE	38	596.53	2079.68	3614.92	858.0
		PII(W6)	33	707.56	2796.52	4634.88	829.0
		PII(W28)	31	623.91	2700.58	5134.15	707.0
		PIII(W30)	34	636.63	2887.68	6245.28	510.0
	2-Doses HIV	PIII(W48)	35	778.82	2622.31	5022.90	818.0
		PRE	37	1172.01	3128.57	5527.67	1212.0
		PII(W6)	36	1205.00	3522.14	6572.61	1478.5
		PII(W28)	40	1154.67	3476.93	7656.96	1419.0
		PIII(W30)	36	1073.83	3315.11	5966.95	1467.0
	HIV	PIII(W48)	37	1006.62	3602.30	7887.70	1669.0
		PRE	75	832.39	2597.13	4655.88	991.0
		PII(W6)	69	934.12	3175.10	5698.90	1085.0
	Placebo	PII(W28)	71	882.54	3137.96	6641.69	1055.0
		PRE	35	1607.63	4240.49	5314.19	2246.0
		PII(W6)	32	1636.99	4422.78	5914.19	1681.5
		PII(W28)	35	1335.99	3653.14	4954.57	1613.0
		PIII(W30)	34	1411.75	3751.94	5034.52	1524.0
p24	3-Doses HIV	PIII(W48)	32	1489.05	3850.22	5266.68	1494.0
		PRE	38	3886.10	7622.45	8678.04	5364.0
		PII(W6)	33	3919.76	7322.82	9878.18	4972.0
		PII(W28)	31	4541.47	8173.65	9927.53	6273.0
		PIII(W30)	35	3951.95	6127.00	4935.18	5525.0
	2-Doses HIV	PIII(W48)	35	4202.35	6496.94	5332.16	5900.0
		PRE	37	4732.17	11070.78	12918.64	8630.0
		PII(W6)	36	5013.43	11351.36	15491.01	6826.0
		PII(W28)	40	4264.78	9947.68	14950.50	5465.5
		PIII(W30)	36	4376.41	9187.92	10564.93	5064.0
	HIV	PIII(W48)	37	4740.94	10467.49	13974.78	6371.0
		PRE	75	4282.69	9323.63	11038.88	6248.0
		PII(W6)	69	4456.78	9424.67	13173.58	5610.0
	Placebo	PII(W28)	71	4383.45	9173.10	12944.29	6181.0
		PRE	35	6743.82	15682.00	24014.02	8435.0
		PII(W6)	32	7502.58	18756.50	28152.16	10328.0
		PII(W28)	35	6565.07	14257.34	21769.86	8207.0
		PIII(W30)	34	7114.23	16761.03	26564.38	8923.5
RT	3-Doses HIV	PIII(W48)	32	5976.81	14535.59	21550.41	7410.0
		PRE	38	3835.44	6445.32	7436.06	3724.5
		PII(W6)	32	3507.65	5750.84	5834.95	3699.5
		PII(W28)	31	4244.97	7952.87	10047.08	6187.0
		PIII(W30)	35	3366.30	5229.63	5636.95	3262.0
	2-Doses HIV	PIII(W48)	36	3625.69	5793.58	7016.26	3299.5
		PRE	37	3718.78	5577.49	5532.77	3073.0
		PII(W6)	36	3915.33	5890.28	5937.72	3418.0
		PII(W28)	40	3655.83	5785.13	5784.42	2860.5
		PIII(W30)	36	4078.03	6099.64	5856.23	3747.5
	HIV	PIII(W48)	38	3962.44	6555.95	7041.40	3462.5
		PRE	75	3777.44	6017.19	6536.85	3556.0
		PII(W6)	68	3717.89	5824.66	5845.98	3490.0
	Placebo	PII(W28)	71	3902.27	6731.61	7942.02	3663.0
		PRE	35	3466.53	5749.77	5291.70	4395.0
		PII(W6)	33	3913.34	6431.76	5077.70	4715.0
		PII(W28)	35	3684.72	5282.17	4199.10	4292.0
		PIII(W30)	34	4239.27	5777.00	4116.25	4538.0
		PIII(W48)	31	3908.67	5330.61	3687.04	4565.0

*\*F4co-Computed = Frequency of CD8+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD8+ T cells to each of the 4 antigens (Nef, p17, p24, RT)*

N = number of subjects with available results

GM = Geometric Mean

SD = Standard Deviation

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Number (%) of responders to at least 1, 2, 3 and all 4 antigens: CD40L+CD4+ T cells expressing at least one cytokine (ATP cohort for immunogenicity)

Group	Timing	Number of antigens	Responder Rate				
			N	n	%	95% CI	
						LL	UL
3-Doses HIV	PRE	At least 1 antigen	38	30	78.9	62.7	90.4
		At least 2 antigens	38	19	50.0	33.4	66.6
		At least 3 antigens	38	11	28.9	15.4	45.9
		All 4 antigens	38	4	10.5	2.9	24.8
	PII(W6)	At least 1 antigen	32	28	87.5	71.0	96.5
		At least 2 antigens	32	24	75.0	56.6	88.5
		At least 3 antigens	32	12	37.5	21.1	56.3
		All 4 antigens	32	6	18.8	7.2	36.4
	PII(W28)	At least 1 antigen	31	19	61.3	42.2	78.2
		At least 2 antigens	31	13	41.9	24.5	60.9
		At least 3 antigens	31	4	12.9	3.6	29.8
		All 4 antigens	31	2	6.5	0.8	21.4
	PIII(W30)	At least 1 antigen	34	30	88.2	72.5	96.7
		At least 2 antigens	34	24	70.6	52.5	84.9
		At least 3 antigens	34	15	44.1	27.2	62.1
		All 4 antigens	34	8	23.5	10.7	41.2
	PIII(W48)	At least 1 antigen	35	23	65.7	47.8	80.9
		At least 2 antigens	35	17	48.6	31.4	66.0
		At least 3 antigens	35	5	14.3	4.8	30.3
		All 4 antigens	35	4	11.4	3.2	26.7
2-Doses HIV	PRE	At least 1 antigen	37	25	67.6	50.2	82.0
		At least 2 antigens	37	16	43.2	27.1	60.5
		At least 3 antigens	37	8	21.6	9.8	38.2
		All 4 antigens	37	3	8.1	1.7	21.9
	PII(W6)	At least 1 antigen	36	32	88.9	73.9	96.9
		At least 2 antigens	36	24	66.7	49.0	81.4
		At least 3 antigens	36	12	33.3	18.6	51.0
		All 4 antigens	36	6	16.7	6.4	32.8
	PII(W28)	At least 1 antigen	40	22	55.0	38.5	70.7
		At least 2 antigens	40	11	27.5	14.6	43.9
		At least 3 antigens	40	4	10.0	2.8	23.7
		All 4 antigens	40	3	7.5	1.6	20.4
	PIII(W30)	At least 1 antigen	35	20	57.1	39.4	73.7
		At least 2 antigens	35	11	31.4	16.9	49.3
		At least 3 antigens	35	6	17.1	6.6	33.6
		All 4 antigens	35	2	5.7	0.7	19.2
	PIII(W48)	At least 1 antigen	36	19	52.8	35.5	69.6
		At least 2 antigens	36	7	19.4	8.2	36.0
		At least 3 antigens	36	4	11.1	3.1	26.1
		All 4 antigens	36	1	2.8	0.1	14.5
F4co	PRE	At least 1 antigen	75	55	73.3	61.9	82.9

		At least 2 antigens	75	35	46.7	35.1	58.6
		At least 3 antigens	75	19	25.3	16.0	36.7
		All 4 antigens	75	7	9.3	3.8	18.3
	PII(W6)	At least 1 antigen	68	60	88.2	78.1	94.8
		At least 2 antigens	68	48	70.6	58.3	81.0
		At least 3 antigens	68	24	35.3	24.1	47.8
		All 4 antigens	68	12	17.6	9.5	28.8
	PII(W28)	At least 1 antigen	71	41	57.7	45.4	69.4
		At least 2 antigens	71	24	33.8	23.0	46.0
		At least 3 antigens	71	8	11.3	5.0	21.0
		All 4 antigens	71	5	7.0	2.3	15.7
Placebo	PRE	At least 1 antigen	35	25	71.4	53.7	85.4
		At least 2 antigens	35	18	51.4	34.0	68.6
		At least 3 antigens	35	8	22.9	10.4	40.1
		All 4 antigens	35	3	8.6	1.8	23.1
	PII(W6)	At least 1 antigen	32	9	28.1	13.7	46.7
		At least 2 antigens	32	2	6.3	0.8	20.8
		At least 3 antigens	32	1	3.1	0.1	16.2
		All 4 antigens	32	0	0.0	0.0	10.9
	PII(W28)	At least 1 antigen	35	7	20.0	8.4	36.9
		At least 2 antigens	35	4	11.4	3.2	26.7
		At least 3 antigens	35	2	5.7	0.7	19.2
		All 4 antigens	35	1	2.9	0.1	14.9
	PIII(W30)	At least 1 antigen	34	14	41.2	24.6	59.3
		At least 2 antigens	34	5	14.7	5.0	31.1
		At least 3 antigens	34	3	8.8	1.9	23.7
		All 4 antigens	34	0	0.0	0.0	10.3
	PIII(W48)	At least 1 antigen	31	13	41.9	24.5	60.9
		At least 2 antigens	31	3	9.7	2.0	25.8
		At least 3 antigens	31	2	6.5	0.8	21.4
		All 4 antigens	31	0	0.0	0.0	11.2

N = number of subjects with available results to all 4 antigens

n/% = number/percentage of subjects in the specified category

95% CI = 95% CI confidence interval ; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Immuno-marker co-expression profile of the F4co-Computed\* and each antigen-specific CD4+ T cells (ATP cohort for immunogenicity)

Antigen	Immune marker	Group	Timing	N	Mean	SD	Median
F4co-Computed	CD40L	3-Doses HIV	PRE	41	1214.95	1567.09	772.0
			PII(W6)	35	747.06	929.95	355.0
			PII(W28)	34	951.18	1457.58	560.5
			PIII(W30)	37	874.05	1331.13	452.0
			PIII(W48)	35	697.23	1046.42	383.0
		2-Doses HIV	PRE	38	938.92	1329.52	299.5
			PII(W6)	37	759.30	886.99	472.0
			PII(W28)	42	724.57	953.87	453.0
			PIII(W30)	36	1019.69	1009.00	760.5
			PIII(W48)	36	1007.75	1143.83	481.5
		HIV	PRE	79	1082.18	1455.04	453.0
			PII(W6)	72	753.35	901.71	427.0
			PII(W28)	76	825.95	1202.10	506.5
		Placebo	PRE	36	891.53	970.15	493.0



IL-2	3-Doses HIV	PII(W6)	34	519.00	715.68	153.0
		PII(W28)	37	620.65	708.47	442.0
		PIII(W30)	36	945.17	946.77	716.5
		PIII(W48)	31	907.84	911.92	653.0
		PRE	41	160.68	162.81	118.0
	2-Doses HIV	PII(W6)	35	182.77	229.57	127.0
		PII(W28)	34	99.44	123.35	63.0
		PIII(W30)	37	268.68	382.72	103.0
		PIII(W48)	35	91.40	90.18	74.0
		PRE	38	103.18	158.39	45.5
	HIV	PII(W6)	37	162.30	270.17	72.0
		PII(W28)	42	139.48	170.52	59.0
		PIII(W30)	36	108.56	113.88	92.5
		PIII(W48)	36	138.58	291.77	58.0
		PRE	79	133.03	162.26	70.0
	Placebo	PII(W6)	72	172.25	249.71	91.5
		PII(W28)	76	121.57	151.63	63.0
		PRE	36	103.14	85.14	93.5
		PII(W6)	34	100.59	147.38	58.0
		PII(W28)	37	67.84	74.58	34.0
TNF- $\alpha$	3-Doses HIV	PIII(W30)	36	90.94	116.12	46.5
		PIII(W48)	31	89.84	91.43	86.0
		PRE	41	487.66	844.02	250.0
		PII(W6)	35	405.09	327.50	346.0
		PII(W28)	34	478.91	765.57	242.0
	2-Doses HIV	PIII(W30)	37	592.46	647.75	389.0
		PIII(W48)	35	553.20	596.67	341.0
		PRE	38	426.34	532.63	251.5
		PII(W6)	37	530.68	718.21	251.0
		PII(W28)	42	172.21	185.32	135.5
	HIV	PIII(W30)	36	325.47	476.21	101.5
		PIII(W48)	36	440.17	1188.11	192.5
		PRE	79	458.16	707.70	250.0
		PII(W6)	72	469.63	562.94	277.5
		PII(W28)	76	309.42	547.92	163.0
	Placebo	PRE	36	578.58	904.92	178.5
		PII(W6)	34	353.35	698.35	166.5
		PII(W28)	37	407.68	673.08	216.0
		PIII(W30)	36	494.14	684.19	223.0
		PIII(W48)	31	607.13	1284.49	182.0
IFN- $\gamma$	3-Doses HIV	PRE	41	713.73	1894.19	352.0
		PII(W6)	35	534.46	423.63	411.0
		PII(W28)	34	623.06	1585.36	289.5
		PIII(W30)	37	557.08	452.46	439.0
		PIII(W48)	35	450.11	478.05	329.0
	2-Doses HIV	PRE	38	565.21	575.44	396.5
		PII(W6)	37	657.78	814.27	448.0
		PII(W28)	42	589.93	616.60	454.0
		PIII(W30)	36	679.83	663.84	432.5
		PIII(W48)	36	575.14	654.14	418.5
	HIV	PRE	79	642.29	1415.14	383.0
		PII(W6)	72	597.83	652.67	426.0
		PII(W28)	76	604.75	1146.30	377.5
	Placebo	PRE	36	913.50	1283.13	446.0
		PII(W6)	34	1123.76	1459.26	563.5
		PII(W28)	37	816.08	820.01	536.0

		PIII(W30)	36	912.75	1186.05	479.0
		PIII(W48)	31	765.26	565.75	487.0
CD40L_IL-2	3-Doses HIV	PRE	41	198.20	182.40	149.0
		PII(W6)	35	754.43	748.84	499.0
		PII(W28)	34	287.71	251.45	199.0
		PIII(W30)	37	633.65	599.77	377.0
		PIII(W48)	35	248.37	274.19	172.0
	2-Doses HIV	PRE	38	156.95	126.34	149.5
		PII(W6)	37	583.14	705.35	320.0
		PII(W28)	42	242.64	241.29	196.0
		PIII(W30)	36	258.44	263.86	142.5
		PIII(W48)	36	237.06	219.35	218.0
	HIV	PRE	79	178.35	158.32	149.0
		PII(W6)	72	666.40	726.79	430.5
		PII(W28)	76	262.80	245.27	198.0
	Placebo	PRE	36	120.03	139.08	77.5
		PII(W6)	34	153.53	153.76	127.5
		PII(W28)	37	81.51	79.91	56.0
		PIII(W30)	36	136.17	126.02	96.0
		PIII(W48)	31	115.26	108.88	102.0
CD40L_TNF- $\alpha$	3-Doses HIV	PRE	41	249.98	245.94	201.0
		PII(W6)	35	482.69	408.87	416.0
		PII(W28)	34	218.06	194.70	152.5
		PIII(W30)	37	561.38	469.59	413.0
		PIII(W48)	35	212.00	200.32	164.0
	2-Doses HIV	PRE	38	200.32	252.87	116.0
		PII(W6)	37	337.05	273.21	275.0
		PII(W28)	42	159.14	155.04	101.0
		PIII(W30)	36	177.25	148.34	144.5
		PIII(W48)	36	206.28	205.07	160.5
	HIV	PRE	79	226.09	248.95	154.0
		PII(W6)	72	407.85	351.10	374.5
		PII(W28)	76	185.50	175.19	129.5
	Placebo	PRE	36	174.31	265.30	88.5
		PII(W6)	34	179.53	187.30	110.0
		PII(W28)	37	198.73	200.86	130.0
		PIII(W30)	36	217.36	190.43	195.5
		PIII(W48)	31	250.48	216.12	201.0
CD40L_IFN- $\gamma$	3-Doses HIV	PRE	41	262.20	179.59	229.0
		PII(W6)	35	445.31	353.23	375.0
		PII(W28)	34	244.94	202.67	180.5
		PIII(W30)	37	507.35	458.66	325.0
		PIII(W48)	35	288.77	262.18	202.0
	2-Doses HIV	PRE	38	323.05	358.13	208.5
		PII(W6)	37	406.22	376.93	233.0
		PII(W28)	42	262.14	216.54	186.5
		PIII(W30)	36	326.86	298.94	195.5
		PIII(W48)	36	293.86	332.54	202.0
	HIV	PRE	79	291.47	279.85	224.0
		PII(W6)	72	425.22	363.56	280.5
		PII(W28)	76	254.45	209.24	181.5
	Placebo	PRE	36	392.83	411.67	209.0
		PII(W6)	34	469.76	569.93	307.0
		PII(W28)	37	433.22	548.19	239.0
		PIII(W30)	36	456.14	614.95	254.5
		PIII(W48)	31	336.55	341.39	227.0

TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	41	43.22	70.55	23.0
		PII(W6)	35	172.31	273.38	54.0
		PII(W28)	34	76.38	108.11	45.5
		PIII(W30)	37	210.51	337.80	76.0
		PIII(W48)	35	77.11	98.13	36.0
	2-Doses HIV	PRE	38	35.05	70.61	4.0
		PII(W6)	37	129.89	299.20	65.0
		PII(W28)	42	61.43	116.67	20.5
		PIII(W30)	36	35.36	48.49	17.0
		PIII(W48)	36	25.61	40.27	4.0
	HIV	PRE	79	39.29	70.25	20.0
		PII(W6)	72	150.51	285.72	60.0
		PII(W28)	76	68.12	112.43	27.5
	Placebo	PRE	36	27.11	38.73	4.0
		PII(W6)	34	16.71	17.12	4.0
		PII(W28)	37	30.68	31.64	24.0
		PIII(W30)	36	25.28	26.25	10.5
		PIII(W48)	31	29.29	39.24	6.0
IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	10.07	12.74	4.0
		PII(W6)	35	46.17	87.02	19.0
		PII(W28)	34	11.21	14.93	4.0
		PIII(W30)	37	61.86	95.48	28.0
		PIII(W48)	35	19.89	28.75	4.0
	2-Doses HIV	PRE	38	10.55	12.89	4.0
		PII(W6)	37	43.68	75.39	27.0
		PII(W28)	42	19.31	27.72	4.0
		PIII(W30)	36	21.22	29.84	4.0
		PIII(W48)	36	24.39	24.83	4.0
	HIV	PRE	79	10.30	12.73	4.0
		PII(W6)	72	44.89	80.68	21.5
		PII(W28)	76	15.68	23.12	4.0
	Placebo	PRE	36	19.22	26.68	4.0
		PII(W6)	34	15.74	25.04	4.0
		PII(W28)	37	13.59	17.32	4.0
		PIII(W30)	36	13.61	23.86	4.0
		PIII(W48)	31	11.90	15.66	4.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	41	218.34	611.29	94.0
		PII(W6)	35	167.54	152.67	132.0
		PII(W28)	34	147.00	199.03	111.5
		PIII(W30)	37	194.49	297.48	110.0
		PIII(W48)	35	124.23	149.32	72.0
	2-Doses HIV	PRE	38	206.95	349.69	92.0
		PII(W6)	37	208.68	288.92	123.0
		PII(W28)	42	197.29	257.17	141.5
		PIII(W30)	36	253.69	354.23	127.0
		PIII(W48)	36	228.69	506.23	98.5
	HIV	PRE	79	212.86	499.67	93.0
		PII(W6)	72	188.68	232.20	127.0
		PII(W28)	76	174.79	232.84	129.5
	Placebo	PRE	36	383.89	659.79	149.5
		PII(W6)	34	436.59	721.80	165.0
		PII(W28)	37	393.05	671.65	90.0
		PIII(W30)	36	473.61	956.21	153.5
		PIII(W48)	31	291.65	365.23	143.0
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	41	132.15	115.83	110.0
		PII(W6)	35	1318.69	1245.70	889.0

			PII(W28)	34	631.12	719.71	312.0
			PIII(W30)	37	1653.97	2102.94	953.0
			PIII(W48)	35	647.60	628.41	367.0
		2-Doses HIV	PRE	38	139.84	120.03	109.5
			PII(W6)	37	894.30	1080.38	529.0
			PII(W28)	42	387.07	482.56	247.0
			PIII(W30)	36	354.78	385.93	244.5
			PIII(W48)	36	302.58	410.50	174.0
		HIV	PRE	79	135.85	117.17	110.0
			PII(W6)	72	1100.60	1174.97	730.5
			PII(W28)	76	496.25	608.38	286.5
		Placebo	PRE	36	157.61	135.24	126.0
			PII(W6)	34	148.50	112.34	134.0
			PII(W28)	37	131.68	94.09	114.0
			PIII(W30)	36	180.03	131.40	182.5
			PIII(W48)	31	136.03	148.45	81.0
CD40L_IFN- $\gamma$ IL-2		3-Doses HIV	PRE	41	55.44	47.78	46.0
			PII(W6)	35	417.74	543.55	331.0
			PII(W28)	34	119.56	215.77	88.0
			PIII(W30)	37	452.81	578.51	336.0
			PIII(W48)	35	162.31	337.38	92.0
		2-Doses HIV	PRE	38	74.26	85.23	45.0
			PII(W6)	37	416.27	558.46	208.0
			PII(W28)	42	125.98	133.80	87.5
			PIII(W30)	36	123.08	126.79	77.5
			PIII(W48)	36	105.19	121.85	58.0
		HIV	PRE	79	64.49	68.60	46.0
			PII(W6)	72	416.99	547.37	253.0
			PII(W28)	76	123.11	174.02	87.5
		Placebo	PRE	36	68.14	57.22	43.0
			PII(W6)	34	84.68	71.55	68.5
			PII(W28)	37	54.43	55.29	37.0
			PIII(W30)	36	74.47	72.34	55.0
			PIII(W48)	31	72.06	69.90	53.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$		3-Doses HIV	PRE	41	205.27	204.14	149.0
			PII(W6)	35	434.11	399.54	341.0
			PII(W28)	34	176.47	145.77	123.5
			PIII(W30)	37	482.73	648.68	291.0
			PIII(W48)	35	272.29	417.98	187.0
		2-Doses HIV	PRE	38	216.18	265.16	152.5
			PII(W6)	37	338.03	316.09	264.0
			PII(W28)	42	237.64	266.90	131.0
			PIII(W30)	36	274.08	332.18	149.5
			PIII(W48)	36	266.72	408.92	129.5
		HIV	PRE	79	210.52	233.99	150.0
			PII(W6)	72	384.74	359.78	289.0
			PII(W28)	76	210.28	221.88	131.0
		Placebo	PRE	36	366.25	592.35	154.5
			PII(W6)	34	472.88	780.24	172.5
			PII(W28)	37	577.70	1055.31	154.0
			PIII(W30)	36	498.00	851.20	142.0
			PIII(W48)	31	367.81	563.59	121.0
TNF- $\alpha$ _IFN- $\gamma$ IL-2		3-Doses HIV	PRE	41	18.05	24.07	4.0
			PII(W6)	35	105.71	202.95	40.0
			PII(W28)	34	37.59	71.25	13.0
			PIII(W30)	37	215.70	487.48	36.0
			PIII(W48)	31	18.05	24.07	4.0

		2-Doses HIV	PIII(W48)	35	51.14	86.34	18.0
			PRE	38	17.42	30.52	4.0
			PII(W6)	37	65.68	147.18	21.0
			PII(W28)	42	29.12	38.53	10.5
			PIII(W30)	36	26.28	45.17	4.0
			PIII(W48)	36	31.17	59.03	4.0
		HIV	PRE	79	17.75	27.19	4.0
			PII(W6)	72	85.14	176.39	32.5
			PII(W28)	76	32.91	55.35	12.0
		Placebo	PRE	36	21.50	43.16	4.0
			PII(W6)	34	24.00	35.32	4.0
			PII(W28)	37	23.11	44.40	4.0
			PIII(W30)	36	14.72	29.77	4.0
			PIII(W48)	31	23.94	37.91	4.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	133.54	117.35	106.0
			PII(W6)	35	1103.66	1715.43	624.0
			PII(W28)	34	456.29	1028.82	235.5
			PIII(W30)	37	2018.92	3813.38	747.0
			PIII(W48)	35	764.69	1830.77	367.0
		2-Doses HIV	PRE	38	134.61	164.23	93.0
			PII(W6)	37	845.27	1020.54	441.0
			PII(W28)	42	275.52	314.77	147.0
			PIII(W30)	36	321.03	372.59	110.5
			PIII(W48)	36	274.06	338.17	132.0
		HIV	PRE	79	134.05	140.91	95.0
			PII(W6)	72	970.88	1397.92	532.0
			PII(W28)	76	356.39	726.69	205.5
		Placebo	PRE	36	146.42	137.56	131.5
			PII(W6)	34	203.12	178.66	146.5
			PII(W28)	37	176.65	232.31	91.0
			PIII(W30)	36	152.86	164.05	108.0
			PIII(W48)	31	130.32	121.64	72.0
Nef	CD40L	3-Doses HIV	PRE	41	246.12	435.45	1.0
			PII(W6)	35	145.54	250.47	1.0
			PII(W28)	34	142.88	332.17	1.0
			PIII(W30)	38	162.82	334.95	1.0
			PIII(W48)	36	119.06	250.95	1.0
		2-Doses HIV	PRE	38	193.42	342.41	1.0
			PII(W6)	38	144.92	205.62	1.0
			PII(W28)	42	160.71	293.60	1.0
			PIII(W30)	36	228.19	320.17	98.5
			PIII(W48)	37	210.00	290.25	1.0
		HIV	PRE	79	220.77	391.86	1.0
			PII(W6)	73	145.22	226.61	1.0
			PII(W28)	76	152.74	309.44	1.0
		Placebo	PRE	37	218.00	293.05	1.0
			PII(W6)	34	63.03	148.16	1.0
			PII(W28)	37	101.49	197.17	1.0
			PIII(W30)	36	182.64	333.81	1.0
			PIII(W48)	32	139.06	250.72	1.0
	IL-2	3-Doses HIV	PRE	41	34.20	59.92	14.0
			PII(W6)	35	45.63	86.12	22.0
			PII(W28)	34	29.41	49.62	4.0
			PIII(W30)	38	108.08	238.67	19.0
			PIII(W48)	36	17.56	34.82	1.0
		2-Doses HIV	PRE	38	18.74	30.18	1.0

			PII(W6)	38	39.68	81.79	7.0
			PII(W28)	42	37.50	87.05	1.0
			PIII(W30)	36	30.67	64.84	1.0
			PIII(W48)	37	28.92	81.71	1.0
		HIV	PRE	79	26.76	48.31	1.0
			PII(W6)	73	42.53	83.36	14.0
			PII(W28)	76	33.88	72.40	1.5
		Placebo	PRE	37	17.27	23.57	1.0
			PII(W6)	34	35.71	107.88	1.0
			PII(W28)	37	17.03	25.72	1.0
			PIII(W30)	36	21.06	36.90	1.0
			PIII(W48)	32	20.59	40.67	1.0
	TNF- $\alpha$	3-Doses HIV	PRE	41	89.39	241.17	18.0
			PII(W6)	35	74.97	98.28	31.0
			PII(W28)	34	114.35	265.80	5.0
			PIII(W30)	38	142.50	231.61	43.5
			PIII(W48)	36	113.83	130.92	82.5
		2-Doses HIV	PRE	38	75.55	137.51	1.0
			PII(W6)	38	192.66	336.37	37.5
			PII(W28)	42	39.10	68.58	1.0
			PIII(W30)	36	85.08	164.14	7.5
			PIII(W48)	37	130.57	533.36	1.0
		HIV	PRE	79	82.73	197.09	1.0
			PII(W6)	73	136.23	257.31	32.0
			PII(W28)	76	72.76	187.28	1.0
		Placebo	PRE	37	149.89	350.96	1.0
			PII(W6)	34	64.38	227.09	1.0
			PII(W28)	37	43.00	79.40	1.0
			PIII(W30)	36	91.19	192.75	1.0
			PIII(W48)	32	147.56	280.35	1.0
	IFN- $\gamma$	3-Doses HIV	PRE	41	397.61	1866.28	84.0
			PII(W6)	35	134.34	128.43	101.0
			PII(W28)	34	312.38	1243.45	24.0
			PIII(W30)	38	127.68	151.30	83.0
			PIII(W48)	36	80.19	88.94	61.5
		2-Doses HIV	PRE	38	171.08	213.80	62.5
			PII(W6)	38	203.39	400.45	105.5
			PII(W28)	42	160.69	205.36	114.5
			PIII(W30)	36	207.61	268.27	118.5
			PIII(W48)	37	126.46	172.09	69.0
		HIV	PRE	79	288.65	1349.38	83.0
			PII(W6)	73	170.29	302.33	103.0
			PII(W28)	76	228.55	842.10	67.0
		Placebo	PRE	37	175.05	267.10	87.0
			PII(W6)	34	208.62	357.49	81.0
			PII(W28)	37	176.00	283.99	101.0
			PIII(W30)	36	239.11	459.77	99.5
			PIII(W48)	32	168.03	240.23	79.0
CD40L_IL-2		3-Doses HIV	PRE	41	28.56	42.45	1.0
			PII(W6)	35	241.74	371.38	111.0
			PII(W28)	34	76.26	116.69	25.0
			PIII(W30)	38	267.61	405.83	112.5
			PIII(W48)	36	66.33	106.12	1.0
		2-Doses HIV	PRE	38	29.29	52.56	2.0
			PII(W6)	38	154.08	244.42	65.5
			PII(W28)	42	51.14	87.10	9.5

		HIV	PIII(W30)	36	56.00	103.81	1.0
			PIII(W48)	37	46.97	67.45	15.0
			PRE	79	28.91	47.27	1.0
			PII(W6)	73	196.11	312.69	78.0
			PII(W28)	76	62.38	101.47	21.5
		Placebo	PRE	37	18.08	30.54	1.0
			PII(W6)	34	27.21	35.14	16.0
			PII(W28)	37	6.95	14.28	1.0
			PIII(W30)	36	18.00	42.58	1.0
			PIII(W48)	32	21.06	33.55	1.0
	CD40L_TNF- $\alpha$	3-Doses HIV	PRE	41	29.63	40.91	6.0
			PII(W6)	35	120.54	155.91	75.0
			PII(W28)	34	32.53	61.74	2.5
			PIII(W30)	38	182.42	215.95	141.0
			PIII(W48)	36	45.50	61.51	22.5
		2-Doses HIV	PRE	38	35.13	61.18	7.5
			PII(W6)	38	76.42	100.44	42.0
			PII(W28)	42	24.93	37.30	3.0
			PIII(W30)	36	31.42	49.27	1.0
			PIII(W48)	37	38.68	55.74	11.0
		HIV	PRE	79	32.28	51.39	6.0
			PII(W6)	73	97.58	130.98	46.0
			PII(W28)	76	28.33	49.52	3.0
		Placebo	PRE	37	19.05	55.69	1.0
			PII(W6)	34	29.44	60.15	1.0
			PII(W28)	37	19.41	31.74	1.0
			PIII(W30)	36	31.64	59.76	1.0
			PIII(W48)	32	25.22	40.22	1.0
CD40L_IFN- $\gamma$	3-Doses HIV		PRE	41	20.32	38.02	1.0
			PII(W6)	35	62.17	85.81	31.0
			PII(W28)	34	28.41	51.92	1.0
			PIII(W30)	38	93.63	119.72	59.0
			PIII(W48)	36	32.58	47.70	10.0
		2-Doses HIV	PRE	38	30.92	50.19	7.5
			PII(W6)	38	50.18	63.72	31.0
			PII(W28)	42	23.19	28.23	12.5
			PIII(W30)	36	24.47	42.22	1.0
			PIII(W48)	37	28.49	48.17	1.0
	HIV		PRE	79	25.42	44.33	1.0
			PII(W6)	73	55.93	74.83	31.0
			PII(W28)	76	25.53	40.35	1.0
	Placebo		PRE	37	56.97	138.90	20.0
			PII(W6)	34	63.35	186.83	1.0
			PII(W28)	37	70.70	176.96	1.0
			PIII(W30)	36	88.92	216.37	7.5
			PIII(W48)	32	30.22	67.34	1.0
TNF- $\alpha$ _IL-2	3-Doses HIV		PRE	41	4.95	12.79	1.0
			PII(W6)	35	39.91	98.45	1.0
			PII(W28)	34	22.03	30.65	15.0
			PIII(W30)	38	78.47	206.60	7.5
			PIII(W48)	36	14.03	22.23	1.0
	2-Doses HIV		PRE	38	6.05	16.10	1.0
			PII(W6)	38	35.11	132.66	1.0
			PII(W28)	42	13.07	23.81	1.0
			PIII(W30)	36	5.50	11.48	1.0
			PIII(W48)	37	8.49	28.65	1.0

IFN- $\gamma$ _IL-2	HIV	PRE	79	5.48	14.39	1.0
		PII(W6)	73	37.41	116.73	1.0
		PII(W28)	76	17.08	27.26	1.0
	Placebo	PRE	37	1.95	4.15	1.0
		PII(W6)	34	1.38	2.23	1.0
		PII(W28)	37	8.97	15.78	1.0
		PIII(W30)	36	4.11	9.61	1.0
		PIII(W48)	32	4.78	9.72	1.0
	3-Doses HIV	PRE	41	2.63	6.07	1.0
		PII(W6)	35	8.83	16.46	1.0
		PII(W28)	34	3.24	6.49	1.0
		PIII(W30)	38	12.50	31.23	1.0
		PIII(W48)	36	5.97	13.33	1.0
	2-Doses HIV	PRE	38	1.66	4.06	1.0
		PII(W6)	38	10.66	24.24	1.0
		PII(W28)	42	3.81	9.97	1.0
		PIII(W30)	36	4.94	12.31	1.0
		PIII(W48)	37	2.51	6.46	1.0
	HIV	PRE	79	2.16	5.19	1.0
		PII(W6)	73	9.78	20.76	1.0
		PII(W28)	76	3.55	8.54	1.0
	Placebo	PRE	37	4.05	9.05	1.0
		PII(W6)	34	1.62	3.60	1.0
		PII(W28)	37	1.57	3.45	1.0
		PIII(W30)	36	1.00	0.00	1.0
		PIII(W48)	32	3.75	8.84	1.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	41	114.02	586.08	1.0
		PII(W6)	35	38.23	50.96	26.0
		PII(W28)	34	64.12	199.33	18.0
		PIII(W30)	38	37.68	66.58	14.5
		PIII(W48)	36	27.56	47.92	1.0
	2-Doses HIV	PRE	38	47.47	75.16	21.5
		PII(W6)	38	50.42	82.48	8.0
		PII(W28)	42	47.43	65.25	3.0
		PIII(W30)	36	79.39	132.44	45.5
		PIII(W48)	37	41.03	68.52	13.0
	HIV	PRE	79	82.01	424.20	15.0
		PII(W6)	73	44.58	68.99	19.0
		PII(W28)	76	54.89	141.00	15.0
	Placebo	PRE	37	70.95	170.34	20.0
		PII(W6)	34	67.03	176.07	14.0
		PII(W28)	37	92.76	274.99	24.0
		PIII(W30)	36	107.42	302.78	17.5
		PIII(W48)	32	55.72	90.51	16.0
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	41	27.73	47.02	1.0
		PII(W6)	35	391.17	597.77	207.0
		PII(W28)	34	206.82	323.46	74.0
		PIII(W30)	38	685.63	1598.19	327.0
		PIII(W48)	36	186.03	231.39	78.5
	2-Doses HIV	PRE	38	22.68	38.67	1.0
		PII(W6)	38	191.61	322.71	110.5
		PII(W28)	42	105.00	182.51	57.5
		PIII(W30)	36	78.44	103.55	38.5
		PIII(W48)	37	86.95	171.38	32.0
	HIV	PRE	79	25.30	43.01	1.0
		PII(W6)	73	287.29	482.01	137.0



	Placebo	PII(W28)	76	150.55	258.54	67.5
		PRE	37	23.27	34.36	1.0
		PII(W6)	34	13.68	25.07	1.0
		PII(W28)	37	15.62	27.04	1.0
		PIII(W30)	36	28.72	40.48	1.5
CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV	PIII(W48)	32	15.38	34.45	1.0
		PRE	41	5.68	15.16	1.0
		PII(W6)	35	110.34	198.11	44.0
		PII(W28)	34	28.74	76.47	1.0
		PIII(W30)	38	138.84	231.50	74.5
	2-Doses HIV	PIII(W48)	36	35.11	78.31	1.0
		PRE	38	6.76	12.23	1.0
		PII(W6)	38	114.29	238.27	6.5
		PII(W28)	42	22.26	40.64	1.0
		PIII(W30)	36	24.00	52.93	1.0
	HIV	PIII(W48)	37	20.41	43.67	1.0
		PRE	79	6.20	13.75	1.0
		PII(W6)	73	112.40	218.43	22.0
	Placebo	PII(W28)	76	25.16	59.05	1.0
		PRE	37	5.41	12.63	1.0
		PII(W6)	34	6.44	11.00	1.0
		PII(W28)	37	3.54	7.48	1.0
		PIII(W30)	36	5.31	10.09	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PIII(W48)	32	7.03	17.33	1.0
		PRE	41	13.22	27.31	1.0
		PII(W6)	35	66.09	92.34	17.0
		PII(W28)	34	22.85	41.12	1.0
		PIII(W30)	38	89.74	162.36	43.0
	2-Doses HIV	PIII(W48)	36	37.17	93.18	1.0
		PRE	38	13.55	24.26	1.0
		PII(W6)	38	40.68	53.88	16.5
		PII(W28)	42	19.31	36.30	1.0
		PIII(W30)	36	24.94	45.60	1.0
	HIV	PIII(W48)	37	23.68	39.51	1.0
		PRE	79	13.38	25.72	1.0
		PII(W6)	73	52.86	75.38	17.0
	Placebo	PII(W28)	76	20.89	38.31	1.0
		PRE	37	61.59	199.83	1.0
		PII(W6)	34	57.35	159.37	1.0
		PII(W28)	37	107.35	374.29	1.0
		PIII(W30)	36	75.06	211.06	1.0
TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PIII(W48)	32	47.78	119.09	1.0
		PRE	41	1.46	2.97	1.0
		PII(W6)	35	20.11	48.08	1.0
		PII(W28)	34	6.74	15.51	1.0
		PIII(W30)	38	69.13	238.13	1.0
	2-Doses HIV	PIII(W48)	36	7.50	17.86	1.0
		PRE	38	1.00	0.00	1.0
		PII(W6)	38	9.79	41.22	1.0
		PII(W28)	42	4.93	12.47	1.0
		PIII(W30)	36	1.92	5.17	1.0
	HIV	PIII(W48)	37	3.54	9.75	1.0
		PRE	79	1.24	2.14	1.0
		PII(W6)	73	14.74	44.63	1.0
	Placebo	PII(W28)	76	5.74	13.84	1.0
		PRE	37	6.73	27.89	1.0

			PII(W6)	34	2.53	8.92	1.0
			PII(W28)	37	7.62	34.16	1.0
			PIII(W30)	36	6.22	27.80	1.0
			PIII(W48)	32	4.56	8.65	1.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	9.90	21.25	1.0
			PII(W6)	35	221.74	421.48	77.0
			PII(W28)	34	97.26	221.36	26.0
			PIII(W30)	38	671.61	1957.99	142.5
			PIII(W48)	36	167.86	367.57	43.0
		2-Doses HIV	PRE	38	8.53	16.69	1.0
			PII(W6)	38	155.79	302.16	53.0
			PII(W28)	42	52.86	103.37	7.5
			PIII(W30)	36	68.42	136.86	14.5
			PIII(W48)	37	48.65	98.50	1.0
		HIV	PRE	79	9.24	19.09	1.0
			PII(W6)	73	187.41	363.19	66.0
			PII(W28)	76	72.72	167.02	20.0
		Placebo	PRE	37	13.11	20.57	1.0
			PII(W6)	34	5.35	11.10	1.0
			PII(W28)	37	15.78	36.11	1.0
			PIII(W30)	36	8.53	21.79	1.0
			PIII(W48)	32	3.72	6.88	1.0
p17	CD40L	3-Doses HIV	PRE	41	317.49	456.84	180.0
			PII(W6)	36	141.03	257.43	1.0
			PII(W28)	34	284.82	496.54	100.0
			PIII(W30)	37	252.27	397.53	1.0
			PIII(W48)	35	198.94	367.84	1.0
		2-Doses HIV	PRE	38	182.24	322.43	1.0
			PII(W6)	38	167.66	238.50	1.0
			PII(W28)	42	124.67	176.96	60.5
			PIII(W30)	37	217.51	269.15	133.0
			PIII(W48)	37	223.16	273.25	72.0
		HIV	PRE	79	252.43	401.21	68.0
			PII(W6)	74	154.70	246.55	1.0
			PII(W28)	76	196.32	363.35	80.0
		Placebo	PRE	36	153.14	214.20	1.0
			PII(W6)	34	101.53	189.43	1.0
			PII(W28)	37	126.51	194.43	1.0
			PIII(W30)	36	277.81	341.21	198.0
			PIII(W48)	32	295.56	413.17	150.0
	IL-2	3-Doses HIV	PRE	41	40.78	58.32	1.0
			PII(W6)	36	22.69	37.78	1.5
			PII(W28)	34	18.65	44.30	1.0
			PIII(W30)	37	43.86	72.71	12.0
			PIII(W48)	35	19.26	32.58	1.0
		2-Doses HIV	PRE	38	27.97	65.00	1.0
			PII(W6)	38	57.29	120.27	20.0
			PII(W28)	42	38.29	50.64	27.5
			PIII(W30)	37	22.03	42.77	1.0
			PIII(W48)	37	38.65	82.22	9.0
		HIV	PRE	79	34.62	61.56	1.0
			PII(W6)	74	40.46	91.21	6.0
			PII(W28)	76	29.50	48.60	1.5
		Placebo	PRE	36	29.53	49.81	9.0
			PII(W6)	34	22.91	32.19	1.0
			PII(W28)	37	14.11	22.81	1.0

		PIII(W30)	36	17.25	31.10	1.0
		PIII(W48)	32	19.13	29.58	1.0
TNF- $\alpha$	3-Doses HIV	PRE	41	93.15	159.83	24.0
		PII(W6)	36	95.33	131.09	26.5
		PII(W28)	34	117.97	183.41	57.0
		PIII(W30)	37	106.43	144.80	51.0
		PIII(W48)	35	78.97	132.97	4.0
	2-Doses HIV	PRE	38	111.87	174.15	25.5
		PII(W6)	38	123.66	236.48	41.5
		PII(W28)	42	60.05	82.22	1.0
		PIII(W30)	37	71.00	151.52	1.0
		PIII(W48)	37	134.65	383.28	1.0
	HIV	PRE	79	102.15	166.06	25.0
		PII(W6)	74	109.88	191.80	36.0
		PII(W28)	76	85.96	139.06	26.0
	Placebo	PRE	36	121.06	188.20	13.5
		PII(W6)	34	121.35	202.70	31.5
		PII(W28)	37	77.76	111.60	27.0
		PIII(W30)	36	129.08	209.78	1.5
		PIII(W48)	32	140.38	296.93	1.0
IFN- $\gamma$	3-Doses HIV	PRE	41	80.85	112.21	51.0
		PII(W6)	36	89.58	82.04	88.5
		PII(W28)	34	64.09	78.68	44.0
		PIII(W30)	37	106.22	122.38	77.0
		PIII(W48)	35	79.37	68.90	72.0
	2-Doses HIV	PRE	38	99.26	121.88	71.0
		PII(W6)	38	117.84	144.07	75.5
		PII(W28)	42	121.98	129.97	82.0
		PIII(W30)	37	104.16	116.32	54.0
		PIII(W48)	37	97.73	98.89	74.0
	HIV	PRE	79	89.71	116.57	55.0
		PII(W6)	74	104.09	118.11	83.0
		PII(W28)	76	96.08	113.13	65.5
	Placebo	PRE	36	148.86	212.52	76.0
		PII(W6)	34	169.94	195.39	88.0
		PII(W28)	37	153.49	217.97	73.0
		PIII(W30)	36	137.36	210.85	57.5
		PIII(W48)	32	130.03	160.05	84.5
CD40L_IL-2	3-Doses HIV	PRE	41	39.90	44.86	31.0
		PII(W6)	36	101.19	162.41	58.5
		PII(W28)	34	55.26	69.58	34.5
		PIII(W30)	37	74.05	90.21	56.0
		PIII(W48)	35	29.49	50.24	1.0
	2-Doses HIV	PRE	38	30.53	39.52	6.0
		PII(W6)	38	73.84	137.10	21.5
		PII(W28)	42	40.38	72.28	20.0
		PIII(W30)	37	44.78	61.31	14.0
		PIII(W48)	37	55.41	66.97	42.0
	HIV	PRE	79	35.39	42.37	23.0
		PII(W6)	74	87.15	149.54	33.0
		PII(W28)	76	47.04	71.00	28.0
	Placebo	PRE	36	30.28	59.22	1.0
		PII(W6)	34	36.00	39.64	19.0
		PII(W28)	37	17.08	26.84	1.0
		PIII(W30)	36	27.64	44.91	1.0
		PIII(W48)	32	38.59	43.68	34.5

CD40L_TNF- $\alpha$	3-Doses HIV	PRE	41	48.46	62.76	24.0
		PII(W6)	36	84.22	84.11	58.5
		PII(W28)	34	56.65	60.95	39.5
		PIII(W30)	37	72.00	109.59	26.0
		PIII(W48)	35	33.26	48.61	11.0
	2-Doses HIV	PRE	38	55.37	88.83	16.0
		PII(W6)	38	63.53	81.57	34.5
		PII(W28)	42	37.48	56.61	6.0
		PIII(W30)	37	40.03	45.71	22.0
		PIII(W48)	37	50.97	68.30	20.0
	HIV	PRE	79	51.78	75.99	21.0
		PII(W6)	74	73.59	82.90	45.0
		PII(W28)	76	46.05	58.98	23.0
	Placebo	PRE	36	35.31	60.17	6.5
		PII(W6)	34	44.76	51.17	30.5
		PII(W28)	37	36.11	45.43	26.0
		PIII(W30)	36	49.14	60.88	21.5
		PIII(W48)	32	58.41	71.54	32.5
CD40L_IFN- $\gamma$	3-Doses HIV	PRE	41	67.80	77.91	41.0
		PII(W6)	36	100.11	94.06	76.0
		PII(W28)	34	55.15	65.10	33.5
		PIII(W30)	37	105.43	89.41	79.0
		PIII(W48)	35	66.34	64.43	44.0
	2-Doses HIV	PRE	38	76.45	102.79	42.0
		PII(W6)	38	77.53	89.71	42.0
		PII(W28)	42	85.69	102.38	49.0
		PIII(W30)	37	93.03	137.17	35.0
		PIII(W48)	37	74.30	93.34	43.0
	HIV	PRE	79	71.96	90.24	41.0
		PII(W6)	74	88.51	91.92	56.0
		PII(W28)	76	72.03	88.48	41.0
	Placebo	PRE	36	101.39	157.51	48.0
		PII(W6)	34	113.06	119.46	70.0
		PII(W28)	37	104.70	110.78	64.0
		PIII(W30)	36	108.67	134.09	56.0
		PIII(W48)	32	79.63	101.19	49.0
TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	41	15.46	32.13	1.0
		PII(W6)	36	14.03	25.37	1.0
		PII(W28)	34	8.76	13.56	1.0
		PIII(W30)	37	24.19	60.36	1.0
		PIII(W48)	35	17.83	34.24	1.0
	2-Doses HIV	PRE	38	9.95	19.69	1.0
		PII(W6)	38	27.71	102.21	1.0
		PII(W28)	42	13.45	25.15	1.0
		PIII(W30)	37	11.00	22.28	1.0
		PIII(W48)	37	4.62	9.35	1.0
	HIV	PRE	79	12.81	26.85	1.0
		PII(W6)	74	21.05	75.18	1.0
		PII(W28)	76	11.36	20.79	1.0
	Placebo	PRE	36	10.58	24.57	1.0
		PII(W6)	34	6.29	11.22	1.0
		PII(W28)	37	4.86	8.30	1.0
		PIII(W30)	36	6.53	12.08	1.0
		PIII(W48)	32	9.53	15.48	1.0
IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	1.00	0.00	1.0
		PII(W6)	36	5.47	10.81	1.0

		2-Doses HIV	PII(W28)	34	1.62	3.60	1.0
			PIII(W30)	37	6.51	12.61	1.0
			PIII(W48)	35	7.46	16.34	1.0
			PRE	38	2.87	7.13	1.0
			PII(W6)	38	10.61	29.45	1.0
			PII(W28)	42	4.95	9.64	1.0
			PIII(W30)	37	3.16	7.99	1.0
			PIII(W48)	37	2.95	6.86	1.0
		HIV	PRE	79	1.90	5.00	1.0
			PII(W6)	74	8.11	22.41	1.0
			PII(W28)	76	3.46	7.70	1.0
		Placebo	PRE	36	8.42	18.83	1.0
			PII(W6)	34	1.62	3.60	1.0
			PII(W28)	37	2.08	6.58	1.0
			PIII(W30)	36	1.36	2.17	1.0
			PIII(W48)	32	3.25	7.27	1.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV		PRE	41	27.78	38.66	19.0
			PII(W6)	36	29.58	47.75	7.5
			PII(W28)	34	21.12	19.14	22.0
			PIII(W30)	37	26.78	52.56	1.0
			PIII(W48)	35	17.63	22.76	2.0
	2-Doses HIV		PRE	38	28.45	41.32	1.0
			PII(W6)	38	27.97	51.07	1.0
			PII(W28)	42	38.69	45.68	23.5
			PIII(W30)	37	42.03	76.85	20.0
			PIII(W48)	37	33.73	56.51	11.0
	HIV		PRE	79	28.10	39.70	16.0
			PII(W6)	74	28.76	49.15	1.0
			PII(W28)	76	30.83	37.14	22.0
	Placebo		PRE	36	59.25	97.49	26.5
			PII(W6)	34	104.29	213.50	22.0
			PII(W28)	37	64.51	133.30	1.0
			PIII(W30)	36	96.94	206.60	14.0
			PIII(W48)	32	51.72	101.36	24.0
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV		PRE	41	26.22	36.71	4.0
			PII(W6)	36	110.19	158.79	88.0
			PII(W28)	34	75.50	123.61	51.0
			PIII(W30)	37	136.68	189.40	44.0
			PIII(W48)	35	61.23	90.85	33.0
	2-Doses HIV		PRE	38	31.47	43.42	16.5
			PII(W6)	38	131.47	250.49	64.5
			PII(W28)	42	62.10	117.09	25.0
			PIII(W30)	37	62.76	106.06	33.0
			PIII(W48)	37	53.81	93.60	15.0
	HIV		PRE	79	28.75	39.90	10.0
			PII(W6)	74	121.12	209.77	73.5
			PII(W28)	76	68.09	119.43	31.5
	Placebo		PRE	36	38.25	45.09	26.0
			PII(W6)	34	29.94	31.02	25.0
			PII(W28)	37	25.97	37.70	6.0
			PIII(W30)	36	28.72	32.80	17.0
			PIII(W48)	32	19.22	33.98	1.0
CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV		PRE	41	15.66	21.25	1.0
			PII(W6)	36	53.28	103.80	26.5
			PII(W28)	34	18.41	41.05	1.0
			PIII(W30)	37	50.51	126.85	20.0

	CD40L_TNF- $\alpha$ _IFN- $\gamma$	2-Doses HIV	PIII(W48)	35	25.60	61.33	1.0
			PRE	38	21.97	36.40	1.0
			PII(W6)	38	50.11	87.08	25.0
			PII(W28)	42	24.40	31.78	18.5
			PIII(W30)	37	26.89	40.00	1.0
			PIII(W48)	37	16.95	35.47	1.0
		HIV	PRE	79	18.70	29.50	1.0
			PII(W6)	74	51.65	94.93	25.0
			PII(W28)	76	21.72	36.09	12.5
		Placebo	PRE	36	19.81	29.23	1.0
			PII(W6)	34	16.18	28.37	1.0
			PII(W28)	37	11.89	22.16	1.0
			PIII(W30)	36	15.58	22.56	1.0
			PIII(W48)	32	10.41	16.15	1.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	63.00	80.89	37.0
			PII(W6)	36	74.67	68.75	54.5
			PII(W28)	34	33.26	29.81	32.5
			PIII(W30)	37	72.92	68.96	59.0
			PIII(W48)	35	49.74	62.38	26.0
		2-Doses HIV	PRE	38	61.84	84.45	35.0
			PII(W6)	38	64.42	77.18	35.0
			PII(W28)	42	70.02	122.36	28.5
			PIII(W30)	37	85.73	145.25	40.0
			PIII(W48)	37	53.54	102.69	16.0
		HIV	PRE	79	62.44	82.09	35.0
			PII(W6)	74	69.41	72.88	42.0
			PII(W28)	76	53.58	94.41	30.5
		Placebo	PRE	36	96.00	162.26	37.0
			PII(W6)	34	135.15	244.35	37.5
			PII(W28)	37	125.95	246.64	26.0
			PIII(W30)	36	104.94	194.95	39.5
			PIII(W48)	32	79.88	135.94	22.0
	TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	5.17	10.83	1.0
			PII(W6)	36	8.36	17.68	1.0
			PII(W28)	34	2.18	4.93	1.0
			PIII(W30)	37	10.14	28.98	1.0
			PIII(W48)	35	6.71	11.53	1.0
		2-Doses HIV	PRE	38	5.76	15.08	1.0
			PII(W6)	38	17.68	73.97	1.0
			PII(W28)	42	6.24	15.19	1.0
			PIII(W30)	37	6.16	14.13	1.0
			PIII(W48)	37	9.76	22.02	1.0
		HIV	PRE	79	5.46	12.97	1.0
			PII(W6)	74	13.15	54.27	1.0
			PII(W28)	76	4.42	11.88	1.0
		Placebo	PRE	36	2.53	6.48	1.0
			PII(W6)	34	4.41	11.26	1.0
			PII(W28)	37	4.00	9.52	1.0
			PIII(W30)	36	1.72	3.02	1.0
			PIII(W48)	32	4.72	12.09	1.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	24.41	24.53	22.0
			PII(W6)	36	118.28	226.46	50.0
			PII(W28)	34	61.53	186.10	22.5
			PIII(W30)	37	151.32	382.82	46.0
			PIII(W48)	35	88.66	209.20	42.0
		2-Doses HIV	PRE	38	34.97	45.93	8.5

p24	CD40L		PII(W6)	38	127.58	187.80	71.5
			PII(W28)	42	47.45	77.63	8.5
			PIII(W30)	37	59.68	93.57	13.0
			PIII(W48)	37	49.00	73.59	25.0
			HIV	PRE	79	29.49	36.57
		HIV	PII(W6)	74	123.05	206.13	64.0
			PII(W28)	76	53.75	136.32	21.0
			Placebo	PRE	36	30.94	42.24
			PII(W6)	34	49.71	57.68	30.5
			PII(W28)	37	36.32	43.54	25.0
			PIII(W30)	36	35.47	38.21	27.5
			PIII(W48)	32	30.94	52.46	14.0
	IL-2	3-Doses HIV	PRE	41	300.00	456.66	115.0
			PII(W6)	36	232.81	342.04	86.0
			PII(W28)	34	303.21	472.63	125.0
			PIII(W30)	38	215.97	415.95	22.5
			PIII(W48)	35	186.34	320.57	1.0
		2-Doses HIV	PRE	38	260.47	358.10	65.0
			PII(W6)	38	260.45	327.72	140.5
			PII(W28)	42	254.64	332.56	194.0
			PIII(W30)	37	265.19	345.56	110.0
			PIII(W48)	37	345.35	442.76	160.0
		HIV	PRE	79	280.99	410.08	114.0
			PII(W6)	74	247.00	332.75	110.0
			PII(W28)	76	276.37	399.17	165.0
		Placebo	PRE	37	311.89	458.91	70.0
			PII(W6)	34	248.38	378.28	1.0
			PII(W28)	37	187.35	241.70	15.0
			PIII(W30)	36	272.69	353.50	130.5
			PIII(W48)	32	263.28	305.44	125.0
	TNF- $\alpha$	3-Doses HIV	PRE	41	44.15	57.39	21.0
			PII(W6)	36	34.72	50.60	1.0
			PII(W28)	34	17.62	24.61	2.5
			PIII(W30)	38	53.11	96.63	22.0
			PIII(W48)	35	18.06	29.57	1.0
		2-Doses HIV	PRE	38	23.32	28.53	3.0
			PII(W6)	38	22.87	30.52	6.0
			PII(W28)	42	32.52	54.01	1.0
			PIII(W30)	37	23.24	32.70	1.0
			PIII(W48)	37	31.62	70.98	1.0
		HIV	PRE	79	34.13	46.74	5.0
			PII(W6)	74	28.64	41.66	1.0
			PII(W28)	76	25.86	43.78	1.0
		Placebo	PRE	37	21.14	32.52	1.0
			PII(W6)	34	22.59	40.86	1.0
			PII(W28)	37	25.30	40.20	1.0
			PIII(W30)	36	20.28	34.53	1.0
			PIII(W48)	32	31.78	35.25	19.0
		3-Doses HIV	PRE	41	152.90	233.88	79.0
			PII(W6)	36	74.94	120.17	24.5
			PII(W28)	34	118.94	197.20	34.0
			PIII(W30)	38	179.08	265.02	65.0
			PIII(W48)	35	212.86	380.76	67.0
		2-Doses HIV	PRE	38	138.37	304.51	11.5
			PII(W6)	38	100.21	192.08	32.5
			PII(W28)	42	38.71	81.07	1.0

	HIV	PIII(W30)	37	81.76	126.66	1.0
		PIII(W48)	37	156.41	348.92	40.0
		PRE	79	145.91	268.50	58.0
		PII(W6)	74	87.92	160.58	32.0
		PII(W28)	76	74.61	149.39	4.5
	Placebo	PRE	37	117.03	172.24	21.0
		PII(W6)	34	69.91	113.24	1.0
		PII(W28)	37	100.00	121.35	39.0
		PIII(W30)	36	145.94	292.60	20.5
		PIII(W48)	32	142.50	310.88	12.0
IFN- $\gamma$	3-Doses HIV	PRE	41	174.54	168.61	124.0
		PII(W6)	36	183.39	176.49	139.0
		PII(W28)	34	163.09	195.33	99.5
		PIII(W30)	38	211.95	214.50	157.5
		PIII(W48)	35	186.09	217.94	96.0
	2-Doses HIV	PRE	38	217.26	296.65	112.0
		PII(W6)	38	236.16	304.50	125.0
		PII(W28)	42	235.05	353.20	118.5
		PIII(W30)	37	276.73	352.68	167.0
		PIII(W48)	37	279.27	430.76	171.0
	HIV	PRE	79	195.09	238.30	124.0
		PII(W6)	74	210.49	250.27	128.5
		PII(W28)	76	202.86	293.74	105.0
	Placebo	PRE	37	538.54	1111.22	164.0
		PII(W6)	34	658.06	1150.45	233.5
		PII(W28)	37	415.62	556.72	271.0
		PIII(W30)	36	468.31	793.70	224.5
		PIII(W48)	32	390.16	410.69	266.0
CD40L_IL-2	3-Doses HIV	PRE	41	60.73	72.54	43.0
		PII(W6)	36	93.81	116.98	45.5
		PII(W28)	34	53.65	63.47	31.0
		PIII(W30)	38	100.29	166.29	46.5
		PIII(W48)	35	59.43	78.97	30.0
	2-Doses HIV	PRE	38	33.97	41.40	22.0
		PII(W6)	38	85.55	118.93	36.5
		PII(W28)	42	56.60	68.79	31.5
		PIII(W30)	37	69.73	92.46	51.0
		PIII(W48)	37	56.70	69.81	34.0
	HIV	PRE	79	47.86	60.76	35.0
		PII(W6)	74	89.57	117.25	41.5
		PII(W28)	76	55.28	66.04	31.5
	Placebo	PRE	37	41.78	54.94	22.0
		PII(W6)	34	43.71	65.98	17.5
		PII(W28)	37	30.43	44.56	13.0
		PIII(W30)	36	42.94	62.25	9.5
		PIII(W48)	32	23.59	35.23	2.0
CD40L_TNF- $\alpha$	3-Doses HIV	PRE	41	95.95	101.84	68.0
		PII(W6)	36	85.64	135.78	55.0
		PII(W28)	34	64.26	68.28	49.0
		PIII(W30)	38	112.76	126.96	86.5
		PIII(W48)	35	77.40	74.89	63.0
	2-Doses HIV	PRE	38	53.95	70.50	30.0
		PII(W6)	38	77.66	67.91	72.0
		PII(W28)	42	38.05	45.93	13.0
		PIII(W30)	37	60.00	69.54	48.0
		PIII(W48)	37	66.97	82.69	6.0



CD40L_IFN- $\gamma$	HIV	PRE	79	75.75	90.12	58.0
		PII(W6)	74	81.54	105.80	64.5
		PII(W28)	76	49.78	58.11	29.5
	Placebo	PRE	37	67.24	101.60	38.0
		PII(W6)	34	57.32	73.13	26.0
		PII(W28)	37	81.35	114.97	46.0
		PIII(W30)	36	74.97	76.68	61.5
		PIII(W48)	32	73.41	82.91	48.0
	3-Doses HIV	PRE	41	141.80	115.77	127.0
		PII(W6)	36	165.83	171.97	122.5
		PII(W28)	34	135.79	119.98	87.5
		PIII(W30)	38	194.32	237.77	113.5
		PIII(W48)	35	150.74	163.80	79.0
	2-Doses HIV	PRE	38	172.37	219.76	96.5
		PII(W6)	38	159.00	176.26	81.5
		PII(W28)	42	125.50	126.74	94.0
		PIII(W30)	37	176.30	196.21	106.0
		PIII(W48)	37	165.05	197.44	102.0
	HIV	PRE	79	156.51	173.26	119.0
		PII(W6)	74	162.32	173.02	98.0
		PII(W28)	76	130.11	123.05	89.0
	Placebo	PRE	37	210.89	233.04	120.0
		PII(W6)	34	254.38	287.48	129.5
		PII(W28)	37	209.65	256.50	106.0
		PIII(W30)	36	211.06	265.29	137.5
		PIII(W48)	32	179.47	201.88	99.5
TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	41	11.00	23.21	1.0
		PII(W6)	36	17.44	35.45	1.0
		PII(W28)	34	13.35	27.45	1.0
		PIII(W30)	38	32.24	131.74	1.0
		PIII(W48)	35	14.46	25.72	1.0
	2-Doses HIV	PRE	38	9.84	20.65	1.0
		PII(W6)	38	20.37	31.31	1.5
		PII(W28)	42	17.12	57.39	1.0
		PIII(W30)	37	8.27	13.23	1.0
		PIII(W48)	37	7.81	13.36	1.0
	HIV	PRE	79	10.44	21.89	1.0
		PII(W6)	74	18.95	33.19	1.0
		PII(W28)	76	15.43	46.21	1.0
	Placebo	PRE	37	6.95	13.90	1.0
		PII(W6)	34	6.24	12.43	1.0
		PII(W28)	37	7.97	13.77	1.0
		PIII(W30)	36	8.17	17.76	1.0
		PIII(W48)	32	5.59	11.80	1.0
IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	4.93	11.56	1.0
		PII(W6)	36	6.00	14.51	1.0
		PII(W28)	34	2.15	6.69	1.0
		PIII(W30)	38	17.45	36.37	1.0
		PIII(W48)	35	3.14	10.02	1.0
	2-Doses HIV	PRE	38	3.61	6.95	1.0
		PII(W6)	38	9.11	18.14	1.0
		PII(W28)	42	6.88	14.37	1.0
		PIII(W30)	37	7.27	17.31	1.0
		PIII(W48)	37	8.59	16.16	1.0
	HIV	PRE	79	4.29	9.59	1.0
		PII(W6)	74	7.59	16.44	1.0

	Placebo	PII(W28)	76	4.76	11.76	1.0
		PRE	37	3.00	7.17	1.0
		PII(W6)	34	10.56	24.30	1.0
		PII(W28)	37	8.32	14.41	1.0
		PIII(W30)	36	7.11	22.16	1.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PIII(W48)	32	3.66	8.32	1.0
		PRE	41	51.32	74.52	22.0
		PII(W6)	36	59.39	75.50	34.0
		PII(W28)	34	42.53	47.07	28.0
		PIII(W30)	38	69.71	144.47	26.5
	2-Doses HIV	PIII(W48)	35	49.26	84.25	24.0
		PRE	38	109.82	258.50	42.0
		PII(W6)	38	83.47	193.21	34.0
		PII(W28)	42	89.67	177.43	41.5
		PIII(W30)	37	94.00	213.71	43.0
	HIV	PIII(W48)	37	119.35	372.80	40.0
		PRE	79	79.46	188.18	35.0
		PII(W6)	74	71.76	147.65	34.0
	Placebo	PII(W28)	76	68.58	136.90	33.5
		PRE	37	232.76	518.57	53.0
		PII(W6)	34	227.18	466.99	56.5
		PII(W28)	37	200.30	343.59	29.0
		PIII(W30)	36	222.53	449.43	52.0
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV	PIII(W48)	32	146.44	275.23	46.0
		PRE	41	37.59	43.27	19.0
		PII(W6)	36	143.47	200.22	98.0
		PII(W28)	34	99.68	155.98	41.5
		PIII(W30)	38	205.79	355.63	79.5
	2-Doses HIV	PIII(W48)	35	105.80	145.65	78.0
		PRE	38	35.76	41.16	20.5
		PII(W6)	38	135.26	216.92	80.0
		PII(W28)	42	69.86	95.82	36.0
		PIII(W30)	37	67.43	81.89	44.0
	HIV	PIII(W48)	37	58.95	76.65	31.0
		PRE	79	36.71	42.01	20.0
		PII(W6)	74	139.26	207.58	87.0
	Placebo	PII(W28)	76	83.20	126.28	39.0
		PRE	37	46.68	49.43	36.0
		PII(W6)	34	47.82	52.80	29.5
		PII(W28)	37	35.86	37.24	25.0
		PIII(W30)	36	52.19	54.14	32.5
CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV	PIII(W48)	32	57.69	66.24	45.0
		PRE	41	14.59	18.22	1.0
		PII(W6)	36	64.11	119.39	30.5
		PII(W28)	34	31.41	59.53	19.5
		PIII(W30)	38	84.34	132.21	41.0
	2-Doses HIV	PIII(W48)	35	41.49	81.30	1.0
		PRE	38	25.45	36.40	1.0
		PII(W6)	38	48.95	55.25	30.0
		PII(W28)	42	32.86	40.43	21.5
		PIII(W30)	37	34.51	40.83	14.0
	HIV	PIII(W48)	37	36.51	53.81	21.0
		PRE	79	19.81	28.78	1.0
		PII(W6)	74	56.32	91.87	30.5
	Placebo	PII(W28)	76	32.21	49.53	21.5
		PRE	37	25.00	32.93	16.0

CD40L_TNF- $\alpha$ _IFN- $\gamma$		PII(W6)	34	37.71	41.17	29.0
		PII(W28)	37	20.54	29.26	2.0
		PIII(W30)	36	28.75	36.61	17.0
		PIII(W48)	32	30.78	39.17	16.0
	3-Doses HIV	PRE	41	97.24	110.97	59.0
		PII(W6)	36	144.03	216.57	68.0
		PII(W28)	34	91.06	95.74	70.0
		PIII(W30)	38	168.58	328.57	83.5
		PIII(W48)	35	132.20	211.70	64.0
	2-Doses HIV	PRE	38	118.61	173.71	85.5
		PII(W6)	38	138.11	180.92	84.5
		PII(W28)	42	124.21	179.59	54.0
		PIII(W30)	37	129.86	206.11	57.0
		PIII(W48)	37	153.89	286.77	61.0
	HIV	PRE	79	107.52	144.03	72.0
		PII(W6)	74	140.99	197.70	74.5
		PII(W28)	76	109.38	148.12	58.5
	Placebo	PRE	37	208.46	345.40	71.0
		PII(W6)	34	245.97	458.75	62.5
		PII(W28)	37	300.11	525.16	59.0
		PIII(W30)	36	269.14	479.42	83.5
		PIII(W48)	32	189.84	324.16	68.0
TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	6.17	12.03	1.0
		PII(W6)	36	14.25	38.90	1.0
		PII(W28)	34	7.76	22.59	1.0
		PIII(W30)	38	31.34	120.00	1.0
		PIII(W48)	35	12.31	26.60	1.0
	2-Doses HIV	PRE	38	7.79	17.64	1.0
		PII(W6)	38	15.34	27.81	1.0
		PII(W28)	42	9.69	17.96	1.0
		PIII(W30)	37	7.35	15.21	1.0
		PIII(W48)	37	9.54	16.37	1.0
	HIV	PRE	79	6.95	14.91	1.0
		PII(W6)	74	14.81	33.43	1.0
		PII(W28)	76	8.83	20.04	1.0
	Placebo	PRE	37	12.51	24.23	1.0
		PII(W6)	34	8.21	17.04	1.0
		PII(W28)	37	6.57	13.58	1.0
		PIII(W30)	36	3.17	7.84	1.0
		PIII(W48)	32	8.66	21.61	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	61.93	80.78	41.0
		PII(W6)	36	162.11	434.32	62.5
		PII(W28)	34	114.32	315.51	52.0
		PIII(W30)	38	320.45	861.72	85.5
		PIII(W48)	35	143.63	394.79	57.0
	2-Doses HIV	PRE	38	59.39	92.96	38.0
		PII(W6)	38	114.97	169.19	58.0
		PII(W28)	42	48.29	51.91	41.0
		PIII(W30)	37	73.65	72.89	46.0
		PIII(W48)	37	81.14	106.05	53.0
	HIV	PRE	79	60.71	86.30	40.0
		PII(W6)	74	137.91	324.83	59.0
		PII(W28)	76	77.83	215.33	49.5
	Placebo	PRE	37	62.59	74.69	36.0
		PII(W6)	34	75.82	91.39	52.5
		PII(W28)	37	81.59	125.13	27.0

RT	CD40L		PIII(W30)	36	48.89	67.79	24.0
			PIII(W48)	32	53.22	63.52	24.0
		3-Doses HIV	PRE	41	351.34	498.23	24.0
			PII(W6)	35	233.57	339.34	1.0
			PII(W28)	34	220.26	425.38	1.0
			PIII(W30)	38	236.95	419.72	1.0
			PIII(W48)	36	230.61	361.60	1.0
		2-Doses HIV	PRE	38	302.79	454.70	78.5
			PII(W6)	37	186.78	307.85	40.0
			PII(W28)	42	184.55	380.08	1.0
			PIII(W30)	37	287.49	384.69	90.0
			PIII(W48)	38	259.87	360.36	44.5
		HIV	PRE	79	327.99	475.37	41.0
			PII(W6)	72	209.53	322.10	20.5
			PII(W28)	76	200.53	398.63	1.0
		Placebo	PRE	37	188.62	289.17	1.0
			PII(W6)	35	103.06	202.43	1.0
			PII(W28)	37	205.30	358.00	1.0
			PIII(W30)	36	212.03	250.19	135.0
			PIII(W48)	31	190.71	267.38	30.0
	IL-2	3-Doses HIV	PRE	41	41.56	57.19	21.0
			PII(W6)	35	80.89	149.77	34.0
			PII(W28)	34	33.76	53.98	1.0
			PIII(W30)	38	75.84	105.82	25.5
			PIII(W48)	36	35.08	46.22	20.0
		2-Doses HIV	PRE	38	33.16	73.12	1.0
			PII(W6)	37	43.81	77.68	12.0
			PII(W28)	42	31.17	47.88	1.0
			PIII(W30)	37	31.89	46.06	5.0
			PIII(W48)	38	39.55	74.72	8.0
		HIV	PRE	79	37.52	65.04	1.0
			PII(W6)	72	61.83	118.95	14.0
			PII(W28)	76	32.33	50.37	1.0
		Placebo	PRE	37	33.30	44.29	9.0
			PII(W6)	35	49.97	182.62	13.0
			PII(W28)	37	11.41	24.40	1.0
			PIII(W30)	36	32.36	52.33	1.0
			PIII(W48)	31	17.90	23.55	4.0
	TNF- $\alpha$	3-Doses HIV	PRE	41	152.22	325.92	61.0
			PII(W6)	35	156.03	180.50	78.0
			PII(W28)	34	127.65	242.63	40.0
			PIII(W30)	38	199.32	281.05	85.0
			PIII(W48)	36	140.33	190.52	59.5
		2-Doses HIV	PRE	38	100.55	136.99	18.0
			PII(W6)	37	110.16	184.01	69.0
			PII(W28)	42	34.36	53.90	1.0
			PIII(W30)	37	84.03	128.12	11.0
			PIII(W48)	38	64.87	118.59	1.0
		HIV	PRE	79	127.37	253.08	40.0
			PII(W6)	72	132.46	182.49	73.5
			PII(W28)	76	76.09	172.25	1.0
		Placebo	PRE	37	209.49	399.01	46.0
			PII(W6)	35	94.94	231.39	1.0
			PII(W28)	37	186.92	549.24	41.0
			PIII(W30)	36	127.92	207.51	41.0
			PIII(W48)	31	174.23	432.43	30.0

IFN- $\gamma$	3-Doses HIV	PRE	41	60.73	107.98	21.0
		PII(W6)	35	128.46	174.28	85.0
		PII(W28)	34	83.50	157.67	18.5
		PIII(W30)	38	107.24	156.73	57.5
		PIII(W48)	36	103.94	325.78	42.0
	2-Doses HIV	PRE	38	77.61	123.65	25.5
		PII(W6)	37	108.43	163.42	27.0
		PII(W28)	42	72.21	120.34	27.0
		PIII(W30)	37	91.38	155.11	40.0
		PIII(W48)	38	96.45	166.10	46.0
	HIV	PRE	79	68.85	115.35	23.0
		PII(W6)	72	118.17	167.89	65.0
		PII(W28)	76	77.26	137.43	21.5
	Placebo	PRE	37	65.92	94.95	45.0
		PII(W6)	35	84.69	173.29	28.0
		PII(W28)	37	70.97	77.48	44.0
		PIII(W30)	36	67.97	91.92	47.0
		PIII(W48)	31	63.65	72.88	55.0
CD40L_IL-2	3-Doses HIV	PRE	41	69.00	73.43	44.0
		PII(W6)	35	313.03	337.52	183.0
		PII(W28)	34	102.53	121.85	64.0
		PIII(W30)	38	256.00	334.55	118.5
		PIII(W48)	36	94.89	110.78	63.0
	2-Doses HIV	PRE	38	63.16	73.08	43.5
		PII(W6)	37	261.27	288.01	179.0
		PII(W28)	42	94.52	92.02	80.0
		PIII(W30)	37	89.95	91.10	57.0
		PIII(W48)	38	69.82	78.49	45.5
	HIV	PRE	79	66.19	72.85	44.0
		PII(W6)	72	286.43	311.91	181.0
		PII(W28)	76	98.11	105.73	77.5
	Placebo	PRE	37	30.32	42.41	11.0
		PII(W6)	35	58.17	86.56	27.0
		PII(W28)	37	27.05	39.58	15.0
		PIII(W30)	36	47.58	57.10	30.0
		PIII(W48)	31	34.23	45.03	3.0
CD40L_TNF- $\alpha$	3-Doses HIV	PRE	41	75.93	97.73	36.0
		PII(W6)	35	189.51	147.49	156.0
		PII(W28)	34	64.62	83.09	35.5
		PIII(W30)	38	192.18	202.90	175.0
		PIII(W48)	36	57.64	64.82	39.0
	2-Doses HIV	PRE	38	55.87	100.90	39.0
		PII(W6)	37	121.84	122.09	116.0
		PII(W28)	42	58.69	73.49	22.5
		PIII(W30)	37	43.54	52.84	23.0
		PIII(W48)	38	53.58	61.41	31.0
	HIV	PRE	79	66.28	99.14	37.0
		PII(W6)	72	154.74	138.33	132.5
		PII(W28)	76	61.34	77.45	30.5
	Placebo	PRE	37	57.70	82.20	30.0
		PII(W6)	35	46.66	64.95	32.0
		PII(W28)	37	61.86	76.19	28.0
		PIII(W30)	36	61.61	65.60	36.5
		PIII(W48)	31	90.13	106.75	39.0
CD40L_IFN- $\gamma$	3-Doses HIV	PRE	41	32.27	35.84	26.0
		PII(W6)	35	119.23	106.60	89.0

			P1I(W28)	34	25.59	30.67	15.5
			P1I(W30)	38	121.66	142.75	71.0
			P1I(W48)	36	38.72	49.03	31.0
		2-Doses HIV	PRE	38	43.32	61.74	17.5
			P1I(W6)	37	121.05	167.02	76.0
			P1I(W28)	42	27.76	35.36	1.0
			P1I(W30)	37	40.62	49.60	22.0
			P1I(W48)	38	27.58	39.81	7.5
			HIV	PRE	79	37.58	49.98
		P1I(W6)		72	120.17	139.95	81.0
		P1I(W28)		76	26.79	33.14	5.5
		Placebo	PRE	37	45.51	59.37	23.0
			P1I(W6)	35	39.69	41.37	31.0
			P1I(W28)	37	48.16	73.46	23.0
			P1I(W30)	36	47.50	61.31	28.0
			P1I(W48)	31	38.00	39.50	30.0
TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	41	11.80	24.11	1.0	
		P1I(W6)	35	101.77	225.00	22.0	
		P1I(W28)	34	32.24	71.00	1.0	
		P1I(W30)	38	71.68	161.12	7.5	
		P1I(W48)	36	29.61	50.94	1.0	
	2-Doses HIV	PRE	38	9.21	26.08	1.0	
		P1I(W6)	37	44.54	74.18	24.0	
		P1I(W28)	42	17.79	38.91	1.0	
		P1I(W30)	37	11.49	19.19	1.0	
		P1I(W48)	38	4.92	8.60	1.0	
	HIV	PRE	79	10.56	24.95	1.0	
		P1I(W6)	72	72.36	166.92	22.5	
		P1I(W28)	76	24.25	55.66	1.0	
	Placebo	PRE	37	8.76	16.82	1.0	
		P1I(W6)	35	2.74	6.02	1.0	
		P1I(W28)	37	8.86	15.41	1.0	
		P1I(W30)	36	6.47	12.73	1.0	
		P1I(W48)	31	8.84	17.02	1.0	
IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	1.51	3.28	1.0	
		P1I(W6)	35	25.60	74.48	1.0	
		P1I(W28)	34	4.21	9.32	1.0	
		P1I(W30)	38	24.97	59.88	1.0	
		P1I(W48)	36	3.11	8.56	1.0	
	2-Doses HIV	PRE	38	2.42	6.11	1.0	
		P1I(W6)	37	14.08	25.95	1.0	
		P1I(W28)	42	3.67	7.46	1.0	
		P1I(W30)	37	6.59	18.87	1.0	
		P1I(W48)	38	9.55	18.42	1.0	
	HIV	PRE	79	1.95	4.84	1.0	
		P1I(W6)	72	19.68	55.06	1.0	
		P1I(W28)	76	3.91	8.29	1.0	
	Placebo	PRE	37	3.59	9.97	1.0	
		P1I(W6)	35	1.91	5.41	1.0	
		P1I(W28)	37	1.62	3.78	1.0	
		P1I(W30)	36	4.14	8.97	1.0	
		P1I(W48)	31	1.00	0.00	1.0	
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	41	25.22	34.06	7.0	
		P1I(W6)	35	42.97	46.47	35.0	
		P1I(W28)	34	19.24	21.92	9.5	
		P1I(W30)	38	56.03	89.31	22.0	

	CD40L_TNF- $\alpha$ _IL-2	2-Doses HIV	PIII(W48)	36	28.25	59.43	1.0
			PRE	38	21.21	37.29	1.0
			PII(W6)	37	42.51	79.93	17.0
			PII(W28)	42	21.50	30.09	1.0
			PIII(W30)	37	37.54	89.05	16.0
			PIII(W48)	38	29.37	59.11	1.0
		HIV	PRE	79	23.29	35.48	1.0
			PII(W6)	72	42.74	65.37	27.5
			PII(W28)	76	20.49	26.60	1.0
		Placebo	PRE	37	32.73	51.77	1.0
			PII(W6)	35	37.03	70.76	1.0
			PII(W28)	37	35.49	85.61	19.0
			PIII(W30)	36	46.72	155.19	1.0
			PIII(W48)	31	29.68	42.40	13.0
	CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	41	40.61	50.98	23.0
			PII(W6)	35	674.51	675.17	476.0
			PII(W28)	34	249.12	337.70	142.0
			PIII(W30)	38	677.87	618.29	491.0
			PIII(W48)	36	281.25	328.77	185.0
		2-Doses HIV	PRE	38	49.92	71.99	25.5
			PII(W6)	37	427.54	451.41	315.0
			PII(W28)	42	150.12	158.71	95.0
			PIII(W30)	37	158.22	173.39	91.0
			PIII(W48)	38	100.68	135.46	66.0
		HIV	PRE	79	45.09	61.75	23.0
			PII(W6)	72	547.60	580.58	346.5
			PII(W28)	76	194.41	257.69	121.5
		Placebo	PRE	37	51.51	70.01	23.0
			PII(W6)	35	55.46	56.28	43.0
			PII(W28)	37	54.22	52.85	49.0
			PIII(W30)	36	70.39	56.47	76.0
			PIII(W48)	31	40.87	68.70	20.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	41	19.51	24.36	1.0
			PII(W6)	35	188.40	208.70	141.0
			PII(W28)	34	41.00	63.80	26.5
			PIII(W30)	38	191.71	211.54	131.0
			PIII(W48)	36	57.53	134.57	21.0
		2-Doses HIV	PRE	38	20.08	28.77	6.5
			PII(W6)	37	198.43	260.46	96.0
			PII(W28)	42	46.45	82.77	17.0
			PIII(W30)	37	36.73	45.30	20.0
			PIII(W48)	38	32.13	43.07	11.5
		HIV	PRE	79	19.78	26.40	1.0
			PII(W6)	72	193.56	235.12	123.5
			PII(W28)	76	44.01	74.46	21.0
		Placebo	PRE	37	18.11	23.43	9.0
			PII(W6)	35	23.69	28.76	14.0
			PII(W28)	37	18.46	30.68	1.0
			PIII(W30)	36	24.83	39.20	1.0
			PIII(W48)	31	22.39	33.38	1.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	41	31.80	46.31	18.0
			PII(W6)	35	150.31	120.07	141.0
			PII(W28)	34	29.29	40.18	14.5
			PIII(W30)	38	149.29	198.83	71.5
			PIII(W48)	36	53.75	107.58	25.5
		2-Doses HIV	PRE	38	22.18	35.63	1.5

			PII(W6)	37	92.22	102.53	64.0
			PII(W28)	42	24.10	28.23	17.5
			PIII(W30)	37	31.32	40.91	20.0
			PIII(W48)	38	31.76	39.70	21.5
			PRE	79	27.18	41.54	14.0
		HIV	PII(W6)	72	120.46	114.41	90.0
			PII(W28)	76	26.42	33.95	15.5
			PRE	37	42.08	55.50	27.0
		Placebo	PII(W6)	35	33.46	44.87	1.0
			PII(W28)	37	44.30	60.71	19.0
			PIII(W30)	36	48.86	77.07	22.0
			PIII(W48)	31	40.16	60.28	21.0
			PRE	41	5.24	13.65	1.0
	TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PII(W6)	35	62.40	153.25	18.0
			PII(W28)	34	20.91	61.22	1.0
			PIII(W30)	38	100.66	261.97	7.5
			PIII(W48)	36	23.78	51.72	1.0
			PRE	38	2.87	6.52	1.0
		2-Doses HIV	PII(W6)	37	21.78	33.60	1.0
			PII(W28)	42	8.26	21.19	1.0
			PIII(W30)	37	11.35	29.12	1.0
			PIII(W48)	38	8.29	30.06	1.0
			PRE	79	4.10	10.82	1.0
		HIV	PII(W6)	72	41.53	110.62	7.0
			PII(W28)	76	13.92	43.99	1.0
			PRE	37	1.78	3.38	1.0
		Placebo	PII(W6)	35	8.63	15.96	1.0
			PII(W28)	37	4.92	11.74	1.0
			PIII(W30)	36	3.61	8.36	1.0
			PIII(W48)	31	5.52	16.01	1.0
			PRE	41	37.29	42.94	29.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PII(W6)	35	598.00	763.99	371.0
			PII(W28)	34	183.18	341.36	100.5
			PIII(W30)	38	853.42	1311.80	459.5
			PIII(W48)	36	354.42	900.74	96.0
			PRE	38	31.71	44.43	14.0
		2-Doses HIV	PII(W6)	37	439.68	472.91	262.0
			PII(W28)	42	126.93	153.37	70.0
			PIII(W30)	37	128.22	167.41	48.0
			PIII(W48)	38	94.95	120.99	58.0
			PRE	79	34.61	43.47	20.0
		HIV	PII(W6)	72	516.64	631.86	337.0
			PII(W28)	76	152.09	254.80	85.5
			PRE	37	47.11	62.37	23.0
		Placebo	PII(W6)	35	70.20	73.32	56.0
			PII(W28)	37	42.95	64.20	18.0
			PIII(W30)	36	59.97	74.10	34.5
			PIII(W48)	31	39.71	41.96	33.0
			PRE	41	37.29	42.94	29.0

\*F4co-Computed = Frequency of CD4+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T cells to each of the 4 antigens (Nef, p17, p24, RT)

N = number of subjects with available results

GM = Geometric Mean

SD = Standard Deviation

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)



PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)							
PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)							
<b>Secondary Outcome Results:</b> Immuno-marker co-expression profile of the F4co-Computed* and each antigen-specific CD8+ T cells (ATP cohort for immunogenicity)							
Antigen	Immune marker	Group	Timing	N	Mean	SD	Median
F4co-Computed	CD40L	3-Doses HIV	PRE	38	151.61	198.97	79.5
			PII(W6)	32	131.25	174.30	76.0
			PII(W28)	31	179.81	143.02	167.0
			PIII(W30)	34	286.35	302.98	197.5
			PIII(W48)	35	180.03	247.34	83.0
		2-Doses HIV	PRE	37	236.08	240.61	204.0
			PII(W6)	36	254.11	312.28	110.5
			PII(W28)	40	258.23	298.78	200.0
			PIII(W30)	35	226.60	257.55	143.0
			PIII(W48)	36	208.22	309.62	64.0
		HIV	PRE	75	193.28	223.08	100.0
			PII(W6)	68	196.29	262.33	96.5
			PII(W28)	71	223.99	245.03	174.0
		Placebo	PRE	35	281.06	271.88	223.0
			PII(W6)	32	254.38	405.55	179.5
			PII(W28)	35	192.14	238.25	108.0
			PIII(W30)	34	204.94	378.90	95.0
			PIII(W48)	31	166.61	184.03	66.0
	IL-2	3-Doses HIV	PRE	38	127.16	172.30	71.0
			PII(W6)	32	311.13	855.59	93.5
			PII(W28)	31	164.39	144.91	192.0
			PIII(W30)	34	174.03	295.46	80.5
			PIII(W48)	35	180.20	236.65	84.0
		2-Doses HIV	PRE	37	171.03	195.81	98.0
			PII(W6)	36	192.33	236.81	149.0
			PII(W28)	40	253.65	465.32	114.5
			PIII(W30)	35	204.86	228.60	152.0
			PIII(W48)	36	153.64	275.82	83.5
		HIV	PRE	75	148.80	184.35	83.0
			PII(W6)	68	248.24	609.56	119.5
			PII(W28)	71	214.68	362.80	124.0
		Placebo	PRE	35	142.86	244.93	81.0
			PII(W6)	32	110.16	141.57	50.5
			PII(W28)	35	242.83	631.31	80.0
			PIII(W30)	34	199.68	390.93	74.5
			PIII(W48)	31	336.32	570.00	179.0
	TNF- $\alpha$	3-Doses HIV	PRE	38	292.89	336.61	183.5
			PII(W6)	32	248.50	254.71	227.0
			PII(W28)	31	266.32	237.11	195.0
			PIII(W30)	34	265.32	344.17	176.0
			PIII(W48)	35	300.54	264.13	246.0
		2-Doses HIV	PRE	37	313.92	395.97	213.0
			PII(W6)	36	365.47	348.11	267.5
			PII(W28)	40	308.80	499.14	158.5
			PIII(W30)	35	350.86	530.32	179.0
			PIII(W48)	36	417.97	617.04	200.5
		HIV	PRE	75	303.27	364.75	192.0
			PII(W6)	68	310.43	311.10	244.0
			PII(W28)	71	290.25	404.17	178.0
		Placebo	PRE	35	555.69	809.57	314.0
			PII(W6)	32	532.88	831.21	242.5

IFN- $\gamma$		PII(W28)	35	567.60	1186.63	227.0
		PIII(W30)	34	520.09	795.81	240.0
		PIII(W48)	31	376.94	417.89	273.0
	3-Doses HIV	PRE	38	17773.87	14944.02	13049.5
		PII(W6)	32	15990.00	11086.19	15467.0
		PII(W28)	31	20152.00	18765.23	16351.0
		PIII(W30)	34	16129.91	11742.35	13512.0
		PIII(W48)	35	17055.74	13618.27	14423.0
	2-Doses HIV	PRE	37	22289.00	17127.54	16362.0
		PII(W6)	36	23309.86	19293.12	17126.0
		PII(W28)	40	21348.35	20538.71	14143.0
		PIII(W30)	35	20618.94	15328.99	14730.0
		PIII(W48)	36	22353.39	18709.12	18658.0
	HIV	PRE	75	20001.33	16110.20	15324.0
		PII(W6)	68	19865.22	16274.50	16697.0
		PII(W28)	71	20826.00	19654.42	14770.0
	Placebo	PRE	35	28070.69	25107.07	21932.0
		PII(W6)	32	32247.69	28121.15	25219.0
		PII(W28)	35	25612.60	20877.56	21406.0
		PIII(W30)	34	28745.91	25822.93	25319.5
		PIII(W48)	31	25464.77	21147.29	20890.0
CD40L_IL-2	3-Doses HIV	PRE	38	6.95	9.76	4.0
		PII(W6)	32	5.72	5.48	4.0
		PII(W28)	31	7.81	9.09	4.0
		PIII(W30)	34	7.15	10.00	4.0
		PIII(W48)	35	9.80	14.26	4.0
	2-Doses HIV	PRE	37	8.81	11.38	4.0
		PII(W6)	36	6.69	7.80	4.0
		PII(W28)	40	9.15	11.24	4.0
		PIII(W30)	35	5.71	6.02	4.0
		PIII(W48)	36	8.17	9.09	4.0
	HIV	PRE	75	7.87	10.56	4.0
		PII(W6)	68	6.24	6.78	4.0
		PII(W28)	71	8.56	10.31	4.0
	Placebo	PRE	35	10.06	20.36	4.0
		PII(W6)	32	5.50	5.08	4.0
		PII(W28)	35	6.17	5.72	4.0
		PIII(W30)	34	10.24	11.00	4.0
		PIII(W48)	31	6.19	6.17	4.0
CD40L_TNF- $\alpha$	3-Doses HIV	PRE	38	13.26	28.84	4.0
		PII(W6)	32	14.63	24.23	4.0
		PII(W28)	31	9.39	9.66	4.0
		PIII(W30)	34	14.94	19.87	4.0
		PIII(W48)	35	14.17	16.87	4.0
	2-Doses HIV	PRE	37	9.89	10.93	4.0
		PII(W6)	36	9.28	9.11	4.0
		PII(W28)	40	12.98	20.87	4.0
		PIII(W30)	35	9.74	11.15	4.0
		PIII(W48)	36	12.31	15.40	4.0
	HIV	PRE	75	11.60	21.84	4.0
		PII(W6)	68	11.79	17.95	4.0
		PII(W28)	71	11.41	16.91	4.0
	Placebo	PRE	35	13.20	13.76	4.0
		PII(W6)	32	9.50	10.55	4.0
		PII(W28)	35	7.29	7.16	4.0
		PIII(W30)	34	16.00	22.01	4.0

CD40L_IFN- $\gamma$	3-Doses HIV	PIII(W48)	31	10.58	11.07	4.0
		PRE	38	34.50	46.55	19.5
		PII(W6)	32	41.81	44.79	27.0
		PII(W28)	31	40.74	57.59	23.0
		PIII(W30)	34	31.44	46.53	17.0
	2-Doses HIV	PIII(W48)	35	38.40	40.52	31.0
		PRE	37	47.14	70.82	21.0
		PII(W6)	36	37.50	42.70	24.0
		PII(W28)	40	31.90	42.70	19.0
		PIII(W30)	35	25.23	36.20	4.0
	HIV	PIII(W48)	36	38.69	50.44	21.5
		PRE	75	40.73	59.69	21.0
		PII(W6)	68	39.53	43.42	25.0
	Placebo	PII(W28)	71	35.76	49.56	21.0
		PRE	35	56.97	68.65	35.0
		PII(W6)	32	46.84	57.05	25.5
		PII(W28)	35	41.43	54.33	22.0
		PIII(W30)	34	65.03	82.08	45.5
		PIII(W48)	31	36.52	35.19	28.0
TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	38	11.87	18.88	4.0
		PII(W6)	32	10.50	13.66	4.0
		PII(W28)	31	8.81	8.40	4.0
		PIII(W30)	34	15.38	20.28	4.0
		PIII(W48)	35	9.74	15.89	4.0
	2-Doses HIV	PRE	37	8.38	8.70	4.0
		PII(W6)	36	11.39	18.74	4.0
		PII(W28)	40	7.33	7.44	4.0
		PIII(W30)	35	11.63	20.29	4.0
		PIII(W48)	36	11.11	14.21	4.0
	HIV	PRE	75	10.15	14.77	4.0
		PII(W6)	68	10.97	16.43	4.0
		PII(W28)	71	7.97	7.85	4.0
	Placebo	PRE	35	6.37	6.20	4.0
		PII(W6)	32	11.81	14.01	4.0
		PII(W28)	35	10.09	14.60	4.0
		PIII(W30)	34	11.65	14.48	4.0
		PIII(W48)	31	14.87	25.51	4.0
IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	144.71	186.42	72.0
		PII(W6)	32	106.53	136.34	70.0
		PII(W28)	31	101.71	98.10	76.0
		PIII(W30)	34	98.00	120.24	51.0
		PIII(W48)	35	104.09	112.84	68.0
	2-Doses HIV	PRE	37	137.76	125.10	102.0
		PII(W6)	36	144.72	144.85	111.0
		PII(W28)	40	154.53	188.98	66.5
		PIII(W30)	35	145.57	135.42	103.0
		PIII(W48)	36	191.42	283.08	80.0
	HIV	PRE	75	141.28	158.12	84.0
		PII(W6)	68	126.75	141.17	84.5
		PII(W28)	71	131.46	157.22	71.0
	Placebo	PRE	35	254.46	302.38	117.0
		PII(W6)	32	289.75	362.00	119.0
		PII(W28)	35	179.66	214.65	100.0
		PIII(W30)	34	241.41	352.11	74.5
		PIII(W48)	31	171.68	220.84	81.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	38	1714.24	1704.09	1049.5

			PII(W6)	32	1532.19	1322.47	957.5
			PII(W28)	31	2042.94	2298.43	1563.0
			PIII(W30)	34	1351.65	1170.48	985.0
			PIII(W48)	35	1672.29	1820.33	993.0
		2-Doses HIV	PRE	37	2008.05	1498.93	1820.0
			PII(W6)	36	1803.56	933.64	1864.5
			PII(W28)	40	2174.05	1762.51	1782.5
			PIII(W30)	35	2163.74	1529.90	1904.0
			PIII(W48)	36	2166.92	1679.15	1900.0
		HIV	PRE	75	1859.19	1602.14	1469.0
			PII(W6)	68	1675.85	1132.77	1610.5
			PII(W28)	71	2116.80	1999.77	1563.0
		Placebo	PRE	35	3823.29	4530.82	2095.0
			PII(W6)	32	4320.94	5044.39	2199.0
			PII(W28)	35	3556.20	4492.69	2012.0
			PIII(W30)	34	3904.09	4931.15	2260.0
			PIII(W48)	31	3391.97	4224.24	1787.0
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV		PRE	38	5.58	4.89	4.0
			PII(W6)	32	8.88	15.63	4.0
			PII(W28)	31	9.42	12.76	4.0
			PIII(W30)	34	14.32	32.41	4.0
			PIII(W48)	35	8.00	9.02	4.0
	2-Doses HIV		PRE	37	6.78	7.52	4.0
			PII(W6)	36	6.83	7.70	4.0
			PII(W28)	40	5.50	7.66	4.0
			PIII(W30)	35	5.20	7.10	4.0
			PIII(W48)	36	8.75	11.14	4.0
	HIV		PRE	75	6.17	6.31	4.0
			PII(W6)	68	7.79	12.04	4.0
			PII(W28)	71	7.21	10.31	4.0
	Placebo		PRE	35	6.31	6.77	4.0
			PII(W6)	32	5.78	5.70	4.0
			PII(W28)	35	6.11	6.79	4.0
			PIII(W30)	34	4.00	0.00	4.0
			PIII(W48)	31	5.84	5.37	4.0
CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV		PRE	38	4.89	3.88	4.0
			PII(W6)	32	5.41	6.14	4.0
			PII(W28)	31	7.00	7.34	4.0
			PIII(W30)	34	8.09	10.87	4.0
			PIII(W48)	35	5.71	5.78	4.0
	2-Doses HIV		PRE	37	5.03	6.25	4.0
			PII(W6)	36	6.00	5.19	4.0
			PII(W28)	40	5.95	6.21	4.0
			PIII(W30)	35	4.49	2.87	4.0
			PIII(W48)	36	5.11	4.70	4.0
	HIV		PRE	75	4.96	5.15	4.0
			PII(W6)	68	5.72	5.62	4.0
			PII(W28)	71	6.41	6.70	4.0
	Placebo		PRE	35	6.71	6.37	4.0
			PII(W6)	32	8.53	11.49	4.0
			PII(W28)	35	6.89	7.20	4.0
			PIII(W30)	34	5.65	8.02	4.0
			PIII(W48)	31	8.71	18.76	4.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV		PRE	38	15.00	20.43	4.0
			PII(W6)	32	11.69	15.34	4.0
			PII(W28)	31	10.39	13.06	4.0

		2-Doses HIV	PIII(W30)	34	16.35	26.76	4.0
			PIII(W48)	35	11.31	12.32	4.0
			PRE	37	9.35	10.98	4.0
			PII(W6)	36	8.72	9.33	4.0
			PII(W28)	40	8.68	9.70	4.0
			PIII(W30)	35	12.14	14.02	4.0
		HIV	PIII(W48)	36	10.03	13.02	4.0
			PRE	75	12.21	16.59	4.0
			PII(W6)	68	10.12	12.51	4.0
		Placebo	PII(W28)	71	9.42	11.23	4.0
			PRE	35	23.54	27.94	4.0
			PII(W6)	32	15.81	16.62	4.0
			PII(W28)	35	10.69	12.07	4.0
			PIII(W30)	34	17.38	20.28	4.5
			PIII(W48)	31	24.74	26.33	17.0
	TNF- $\alpha$ _IFN_IL-2	3-Doses HIV	PRE	38	41.26	59.77	17.0
			PII(W6)	32	35.81	51.78	9.5
			PII(W28)	31	29.74	32.68	15.0
			PIII(W30)	34	30.21	58.84	4.0
			PIII(W48)	35	38.17	45.32	33.0
		2-Doses HIV	PRE	37	66.16	81.79	36.0
			PII(W6)	36	53.50	74.50	18.5
			PII(W28)	40	55.48	94.39	19.0
			PIII(W30)	35	75.83	102.06	22.0
			PIII(W48)	36	64.17	126.83	19.5
		HIV	PRE	75	53.55	72.10	30.0
			PII(W6)	68	45.18	64.96	16.0
			PII(W28)	71	44.24	74.75	17.0
		Placebo	PRE	35	96.74	124.24	40.0
			PII(W6)	32	115.50	152.00	58.0
			PII(W28)	35	68.94	90.17	21.0
			PIII(W30)	34	99.21	151.02	30.5
			PIII(W48)	31	75.94	114.95	26.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	4.74	3.37	4.0
			PII(W6)	32	10.88	15.81	4.0
			PII(W28)	31	7.45	9.14	4.0
			PIII(W30)	34	29.94	82.22	4.0
			PIII(W48)	35	8.11	11.08	4.0
		2-Doses HIV	PRE	37	5.00	6.08	4.0
			PII(W6)	36	5.83	5.62	4.0
			PII(W28)	40	5.70	9.01	4.0
			PIII(W30)	35	6.09	5.55	4.0
			PIII(W48)	36	6.22	6.82	4.0
		HIV	PRE	75	4.87	4.87	4.0
			PII(W6)	68	8.21	11.77	4.0
			PII(W28)	71	6.46	9.04	4.0
		Placebo	PRE	35	7.57	9.96	4.0
			PII(W6)	32	8.13	10.92	4.0
			PII(W28)	35	4.40	2.37	4.0
			PIII(W30)	34	6.76	10.23	4.0
			PIII(W48)	31	6.16	6.12	4.0
Nef	CD40L	3-Doses HIV	PRE	38	21.89	38.91	1.0
			PII(W6)	32	52.84	95.71	1.0
			PII(W28)	31	57.42	76.29	16.0
			PIII(W30)	35	70.46	110.92	5.0
			PIII(W48)	36	32.56	65.87	1.0

	IL-2	2-Doses HIV	PRE	37	44.35	73.45	1.0
			PII(W6)	36	53.67	76.19	1.0
			PII(W28)	40	62.18	86.33	12.5
			PIII(W30)	35	50.43	90.04	1.0
			PIII(W48)	37	45.73	83.56	1.0
		HIV	PRE	75	32.97	59.24	1.0
			PII(W6)	68	53.28	85.27	1.0
			PII(W28)	71	60.10	81.56	16.0
		Placebo	PRE	35	84.71	94.42	51.0
			PII(W6)	32	56.94	78.54	1.0
			PII(W28)	35	35.03	65.04	1.0
			PIII(W30)	34	44.65	117.72	1.0
			PIII(W48)	32	33.97	47.45	1.0
		3-Doses HIV	PRE	38	34.87	82.16	1.0
			PII(W6)	32	127.91	513.97	1.0
			PII(W28)	31	27.74	48.06	1.0
			PIII(W30)	35	31.77	64.70	1.0
			PIII(W48)	36	28.69	46.91	1.0
		2-Doses HIV	PRE	37	37.59	55.13	4.0
			PII(W6)	36	50.61	69.19	6.0
			PII(W28)	40	52.43	103.10	14.0
			PIII(W30)	35	59.83	85.30	35.0
			PIII(W48)	37	19.27	31.39	1.0
		HIV	PRE	75	36.21	69.68	1.0
			PII(W6)	68	86.99	355.30	1.0
			PII(W28)	71	41.65	84.05	1.0
		Placebo	PRE	35	23.77	47.15	1.0
			PII(W6)	32	29.66	87.05	1.0
			PII(W28)	35	68.06	170.15	19.0
			PIII(W30)	34	65.44	162.56	1.0
			PIII(W48)	32	61.00	143.91	4.5
TNF- $\alpha$		3-Doses HIV	PRE	38	44.34	69.14	1.0
			PII(W6)	32	50.44	67.02	32.0
			PII(W28)	31	60.97	92.51	12.0
			PIII(W30)	35	44.37	68.64	1.0
			PIII(W48)	36	57.14	81.52	18.0
		2-Doses HIV	PRE	37	63.76	132.41	21.0
			PII(W6)	36	79.03	120.95	31.5
			PII(W28)	40	63.65	141.69	9.5
			PIII(W30)	35	80.86	179.34	1.0
			PIII(W48)	37	105.30	173.41	11.0
		HIV	PRE	75	53.92	104.95	1.0
			PII(W6)	68	65.57	99.64	32.0
			PII(W28)	71	62.48	121.88	12.0
		Placebo	PRE	35	165.91	323.33	39.0
			PII(W6)	32	128.72	286.00	42.5
			PII(W28)	35	143.94	358.81	29.0
			PIII(W30)	34	150.68	301.25	50.0
			PIII(W48)	32	72.59	87.24	26.5
	IFN- $\gamma$	3-Doses HIV	PRE	38	3608.00	3197.49	2947.0
			PII(W6)	32	3417.06	3192.10	2942.0
			PII(W28)	31	3576.74	3459.58	2396.0
			PIII(W30)	35	3717.66	4599.19	2586.0
			PIII(W48)	36	4046.25	6149.57	2236.5
		2-Doses HIV	PRE	37	4744.43	5273.04	2150.0
			PII(W6)	36	4635.39	4471.32	2951.0

			PII(W28)	40	4563.88	4627.52	2850.0
			PIII(W30)	35	4471.74	4166.14	2778.0
			PIII(W48)	37	4479.11	4666.77	2228.0
		HIV	PRE	75	4168.64	4354.98	2646.0
			PII(W6)	68	4062.06	3941.30	2942.0
			PII(W28)	71	4132.87	4159.71	2748.0
		Placebo	PRE	35	6156.40	6639.50	3224.0
			PII(W6)	32	6693.19	7382.14	4330.0
			PII(W28)	35	5884.49	6537.93	3449.0
			PIII(W30)	34	6238.94	7360.87	3469.0
			PIII(W48)	32	5062.75	5332.65	3584.0
CD40L_IL-2	3-Doses HIV		PRE	38	1.68	2.95	1.0
			PII(W6)	32	2.72	5.48	1.0
			PII(W28)	31	1.29	1.62	1.0
			PIII(W30)	35	1.91	5.41	1.0
			PIII(W48)	36	3.31	8.38	1.0
	2-Doses HIV		PRE	37	2.30	5.74	1.0
			PII(W6)	36	1.61	3.67	1.0
			PII(W28)	40	1.28	1.74	1.0
			PIII(W30)	35	2.06	4.88	1.0
			PIII(W48)	37	3.00	6.26	1.0
	HIV		PRE	75	1.99	4.53	1.0
			PII(W6)	68	2.13	4.61	1.0
			PII(W28)	71	1.28	1.67	1.0
	Placebo		PRE	35	1.00	0.00	1.0
			PII(W6)	32	2.25	4.94	1.0
			PII(W28)	35	1.63	2.59	1.0
			PIII(W30)	34	1.41	2.40	1.0
			PIII(W48)	32	1.00	0.00	1.0
CD40L_TNF- $\alpha$	3-Doses HIV		PRE	38	2.53	9.41	1.0
			PII(W6)	32	3.84	10.15	1.0
			PII(W28)	31	3.16	6.93	1.0
			PIII(W30)	35	1.66	3.89	1.0
			PIII(W48)	36	2.97	5.09	1.0
	2-Doses HIV		PRE	37	3.35	7.65	1.0
			PII(W6)	36	3.11	6.31	1.0
			PII(W28)	40	4.30	10.76	1.0
			PIII(W30)	35	1.97	4.03	1.0
			PIII(W48)	37	3.00	12.17	1.0
	HIV		PRE	75	2.93	8.54	1.0
			PII(W6)	68	3.46	8.28	1.0
			PII(W28)	71	3.80	9.24	1.0
	Placebo		PRE	35	2.37	4.59	1.0
			PII(W6)	32	2.03	4.06	1.0
			PII(W28)	35	1.66	2.71	1.0
			PIII(W30)	34	5.00	10.44	1.0
			PIII(W48)	32	2.22	3.95	1.0
CD40L_IFN- $\gamma$	3-Doses HIV		PRE	38	9.87	24.40	1.0
			PII(W6)	32	11.88	25.04	1.0
			PII(W28)	31	17.77	50.81	1.0
			PIII(W30)	35	6.31	15.09	1.0
			PIII(W48)	36	9.06	19.90	1.0
	2-Doses HIV		PRE	37	10.30	22.08	1.0
			PII(W6)	36	10.33	21.68	1.0
			PII(W28)	40	10.08	24.68	1.0
			PIII(W30)	35	7.00	21.84	1.0

TNF- $\alpha$ _IL-2	HIV	PIII(W48)	37	11.32	24.50	1.0
		PRE	75	10.08	23.12	1.0
		PII(W6)	68	11.06	23.15	1.0
		PII(W28)	71	13.44	38.22	1.0
	Placebo	PRE	35	7.34	12.36	1.0
		PII(W6)	32	9.03	12.25	1.0
		PII(W28)	35	7.49	9.45	1.0
		PIII(W30)	34	9.47	16.61	1.0
		PIII(W48)	32	6.06	9.52	1.0
	3-Doses HIV	PRE	38	2.87	6.74	1.0
		PII(W6)	32	5.06	12.79	1.0
		PII(W28)	31	3.29	7.38	1.0
		PIII(W30)	35	4.69	9.69	1.0
		PIII(W48)	36	1.53	3.17	1.0
IFN- $\gamma$ _IL-2	2-Doses HIV	PRE	37	2.41	4.86	1.0
		PII(W6)	36	3.47	9.06	1.0
		PII(W28)	40	1.00	0.00	1.0
		PIII(W30)	35	1.06	0.34	1.0
		PIII(W48)	37	2.05	3.76	1.0
	HIV	PRE	75	2.64	5.85	1.0
		PII(W6)	68	4.22	10.92	1.0
		PII(W28)	71	2.00	4.96	1.0
	Placebo	PRE	35	1.37	2.20	1.0
		PII(W6)	32	4.31	6.67	1.0
		PII(W28)	35	1.86	3.61	1.0
		PIII(W30)	34	1.62	3.60	1.0
		PIII(W48)	32	5.25	10.51	1.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	38	36.13	60.73	1.0
		PII(W6)	32	30.41	59.72	1.0
		PII(W28)	31	31.61	47.55	1.0
		PIII(W30)	35	30.94	51.82	1.0
		PIII(W48)	36	27.44	38.24	8.0
	2-Doses HIV	PRE	37	45.46	67.72	1.0
		PII(W6)	36	35.25	56.47	11.5
		PII(W28)	40	48.00	68.16	19.5
		PIII(W30)	35	43.71	61.42	18.0
		PIII(W48)	37	44.68	62.61	19.0
	HIV	PRE	75	40.73	64.00	1.0
		PII(W6)	68	32.97	57.64	1.0
		PII(W28)	71	40.85	60.20	17.0
	Placebo	PRE	35	47.69	84.15	16.0
		PII(W6)	32	46.09	83.18	22.5
		PII(W28)	35	37.31	70.01	13.0
		PIII(W30)	34	58.85	141.53	12.5
		PIII(W48)	32	32.47	80.72	1.0
TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	38	285.53	362.70	157.5
		PII(W6)	32	273.44	357.74	152.5
		PII(W28)	31	291.48	360.55	161.0
		PIII(W30)	35	282.26	414.65	138.0
		PIII(W48)	36	367.39	811.96	110.0
	2-Doses HIV	PRE	37	379.57	457.06	174.0
		PII(W6)	36	362.94	456.58	216.5
		PII(W28)	40	406.70	601.60	191.5
		PIII(W30)	35	366.31	406.17	256.0
		PIII(W48)	37	391.24	498.50	156.0
	HIV	PRE	75	331.92	411.88	160.0



	Placebo	PII(W6)	68	320.82	412.48	156.5
		PII(W28)	71	356.39	510.56	175.0
		PRE	35	965.89	1514.00	259.0
		PII(W6)	32	972.19	1288.08	345.5
		PII(W28)	35	958.09	1544.11	333.0
		PIII(W30)	34	991.74	1678.81	292.5
		PIII(W48)	32	843.97	1562.02	293.5
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	38	1.34	2.11	1.0
		PII(W6)	32	2.66	7.49	1.0
		PII(W28)	31	3.03	8.44	1.0
		PIII(W30)	35	1.91	4.35	1.0
		PIII(W48)	36	1.83	3.49	1.0
	2-Doses HIV	PRE	37	1.27	1.64	1.0
		PII(W6)	36	1.00	0.00	1.0
		PII(W28)	40	1.63	3.95	1.0
		PIII(W30)	35	1.00	0.00	1.0
		PIII(W48)	37	2.41	4.89	1.0
	HIV	PRE	75	1.31	1.88	1.0
		PII(W6)	68	1.78	5.16	1.0
		PII(W28)	71	2.24	6.30	1.0
	Placebo	PRE	35	1.00	0.00	1.0
		PII(W6)	32	1.00	0.00	1.0
		PII(W28)	35	1.31	1.86	1.0
		PIII(W30)	34	1.00	0.00	1.0
		PIII(W48)	32	1.00	0.00	1.0
CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	1.39	2.43	1.0
		PII(W6)	32	1.50	2.83	1.0
		PII(W28)	31	2.00	3.87	1.0
		PIII(W30)	35	4.37	8.99	1.0
		PIII(W48)	36	1.47	2.83	1.0
	2-Doses HIV	PRE	37	1.00	0.00	1.0
		PII(W6)	36	1.00	0.00	1.0
		PII(W28)	40	1.73	4.59	1.0
		PIII(W30)	35	1.00	0.00	1.0
		PIII(W48)	37	1.00	0.00	1.0
	HIV	PRE	75	1.20	1.73	1.0
		PII(W6)	68	1.24	1.94	1.0
		PII(W28)	71	1.85	4.26	1.0
	Placebo	PRE	35	1.37	2.20	1.0
		PII(W6)	32	1.00	0.00	1.0
		PII(W28)	35	1.71	3.23	1.0
		PIII(W30)	34	1.00	0.00	1.0
		PIII(W48)	32	1.34	1.94	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	38	3.66	9.60	1.0
		PII(W6)	32	3.56	7.96	1.0
		PII(W28)	31	3.19	7.62	1.0
		PIII(W30)	35	4.89	14.80	1.0
		PIII(W48)	36	2.83	7.04	1.0
	2-Doses HIV	PRE	37	1.19	1.15	1.0
		PII(W6)	36	2.44	7.02	1.0
		PII(W28)	40	2.15	3.68	1.0
		PIII(W30)	35	2.37	4.92	1.0
		PIII(W48)	37	1.92	5.59	1.0
	HIV	PRE	75	2.44	6.94	1.0
		PII(W6)	68	2.97	7.44	1.0
		PII(W28)	71	2.61	5.72	1.0

p17	TNF- $\alpha$ _IFN- $\gamma$ _IL-2	Placebo	PRE	35	3.34	9.59	1.0
			PII(W6)	32	3.94	10.45	1.0
			PII(W28)	35	2.43	4.20	1.0
			PIII(W30)	34	2.06	3.45	1.0
			PIII(W48)	32	3.44	6.91	1.0
		3-Doses HIV	PRE	38	10.26	22.82	1.0
			PII(W6)	32	6.16	16.37	1.0
			PII(W28)	31	7.19	13.05	1.0
			PIII(W30)	35	10.74	19.22	1.0
			PIII(W48)	36	8.00	15.21	1.0
		2-Doses HIV	PRE	37	15.84	25.96	1.0
			PII(W6)	36	10.72	27.21	1.0
			PII(W28)	40	13.50	23.86	1.0
			PIII(W30)	35	16.17	29.56	1.0
			PIII(W48)	37	9.16	19.09	1.0
		HIV	PRE	75	13.01	24.41	1.0
			PII(W6)	68	8.57	22.72	1.0
			PII(W28)	71	10.75	20.00	1.0
		Placebo	PRE	35	22.51	45.55	1.0
			PII(W6)	32	23.00	41.92	7.0
			PII(W28)	35	17.26	32.25	1.0
			PIII(W30)	34	27.68	60.67	1.0
			PIII(W48)	32	14.63	36.86	1.0
	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	1.00	0.00	1.0
			PII(W6)	32	3.44	8.58	1.0
			PII(W28)	31	1.52	2.87	1.0
			PIII(W30)	35	4.60	9.99	1.0
			PIII(W48)	36	1.33	2.00	1.0
		2-Doses HIV	PRE	37	1.00	0.00	1.0
			PII(W6)	36	1.00	0.00	1.0
			PII(W28)	40	2.00	4.77	1.0
			PIII(W30)	35	1.00	0.00	1.0
			PIII(W48)	37	1.24	1.48	1.0
		HIV	PRE	75	1.00	0.00	1.0
			PII(W6)	68	2.15	5.97	1.0
			PII(W28)	71	1.79	4.04	1.0
		Placebo	PRE	35	2.23	4.15	1.0
			PII(W6)	32	1.00	0.00	1.0
			PII(W28)	35	1.00	0.00	1.0
			PIII(W30)	34	2.24	5.39	1.0
			PIII(W48)	32	1.84	4.77	1.0
	CD40L	3-Doses HIV	PRE	38	49.21	74.60	1.0
			PII(W6)	33	23.52	40.90	1.0
			PII(W28)	31	57.77	72.69	15.0
			PIII(W30)	34	65.74	110.69	1.0
			PIII(W48)	35	34.49	62.31	1.0
		2-Doses HIV	PRE	37	51.70	76.75	9.0
			PII(W6)	36	68.22	94.88	23.0
			PII(W28)	40	61.60	79.20	42.5
			PIII(W30)	36	65.94	96.54	3.0
			PIII(W48)	37	47.03	89.68	1.0
		HIV	PRE	75	50.44	75.17	7.0
			PII(W6)	69	46.84	76.98	2.0
			PII(W28)	71	59.93	75.91	40.0
		Placebo	PRE	35	58.54	75.31	20.0
			PII(W6)	32	67.78	113.95	17.0

IL-2		PII(W28)	35	50.06	73.32	4.0
		PIII(W30)	34	51.29	130.16	1.0
		PIII(W48)	32	61.72	104.19	1.0
	3-Doses HIV	PRE	38	29.68	46.42	1.0
		PII(W6)	33	47.45	64.05	17.0
		PII(W28)	31	56.16	65.85	19.0
		PIII(W30)	34	40.24	100.71	1.0
		PIII(W48)	35	54.20	99.19	2.0
	2-Doses HIV	PRE	37	60.03	84.84	29.0
		PII(W6)	36	36.33	87.98	16.0
		PII(W28)	40	59.65	78.98	37.5
		PIII(W30)	36	41.92	68.03	1.0
		PIII(W48)	37	34.00	66.88	1.0
	HIV	PRE	75	44.65	69.37	7.0
		PII(W6)	69	41.65	77.11	17.0
		PII(W28)	71	58.13	73.05	37.0
	Placebo	PRE	35	33.77	54.32	1.0
		PII(W6)	32	34.69	65.45	4.5
		PII(W28)	35	81.69	285.48	1.0
		PIII(W30)	34	64.97	172.08	22.0
		PIII(W48)	32	116.63	246.81	21.0
TNF- $\alpha$	3-Doses HIV	PRE	38	61.63	134.81	11.5
		PII(W6)	33	52.03	76.51	25.0
		PII(W28)	31	36.74	56.12	1.0
		PIII(W30)	34	49.56	111.69	2.5
		PIII(W48)	35	58.91	88.31	11.0
	2-Doses HIV	PRE	37	43.95	60.67	27.0
		PII(W6)	36	55.67	73.94	39.5
		PII(W28)	40	42.53	70.03	6.0
		PIII(W30)	36	33.28	63.90	1.0
		PIII(W48)	37	80.05	128.07	17.0
	HIV	PRE	75	52.91	104.67	13.0
		PII(W6)	69	53.93	74.64	29.0
		PII(W28)	71	40.00	63.96	5.0
	Placebo	PRE	35	74.00	93.80	29.0
		PII(W6)	32	79.84	128.99	19.0
		PII(W28)	35	51.06	77.86	1.0
		PIII(W30)	34	63.00	95.57	11.0
		PIII(W48)	32	44.78	84.15	1.0
IFN- $\gamma$	3-Doses HIV	PRE	38	1826.32	3422.06	497.0
		PII(W6)	33	2513.79	4348.64	642.0
		PII(W28)	31	2416.39	4833.82	694.0
		PIII(W30)	34	2579.56	5834.57	276.0
		PIII(W48)	35	2285.74	4593.33	406.0
	2-Doses HIV	PRE	37	2791.03	5357.44	901.0
		PII(W6)	36	3175.36	6371.71	1144.0
		PII(W28)	40	3077.03	7114.23	1070.0
		PIII(W30)	36	2917.22	5489.20	1199.5
		PIII(W48)	37	3226.11	7533.22	1049.0
	HIV	PRE	75	2302.24	4478.19	811.0
		PII(W6)	69	2858.96	5468.66	733.0
		PII(W28)	71	2788.58	6190.41	880.0
	Placebo	PRE	35	3635.26	4799.96	1617.0
		PII(W6)	32	3771.13	5315.74	1450.5
		PII(W28)	35	3128.03	4552.28	994.0
		PIII(W30)	34	3221.59	4611.99	1279.0

		PIII(W48)	32	3246.50	4799.79	1059.0
CD40L_IL-2	3-Doses HIV	PRE	38	1.37	2.27	1.0
		PII(W6)	33	1.79	4.53	1.0
		PII(W28)	31	1.84	3.49	1.0
		PIII(W30)	34	1.00	0.00	1.0
		PIII(W48)	35	1.00	0.00	1.0
	2-Doses HIV	PRE	37	1.76	3.24	1.0
		PII(W6)	36	1.58	3.50	1.0
		PII(W28)	40	2.68	5.89	1.0
		PIII(W30)	36	1.00	0.00	1.0
		PIII(W48)	37	1.97	4.13	1.0
	HIV	PRE	75	1.56	2.78	1.0
		PII(W6)	69	1.68	3.99	1.0
		PII(W28)	71	2.31	4.97	1.0
	Placebo	PRE	35	1.00	0.00	1.0
		PII(W6)	32	1.25	1.41	1.0
		PII(W28)	35	2.06	4.56	1.0
		PIII(W30)	34	2.00	4.41	1.0
		PIII(W48)	32	2.22	5.07	1.0
CD40L_TNF- $\alpha$	3-Doses HIV	PRE	38	2.32	4.58	1.0
		PII(W6)	33	5.15	14.74	1.0
		PII(W28)	31	2.06	4.67	1.0
		PIII(W30)	34	3.35	6.51	1.0
		PIII(W48)	35	3.20	6.74	1.0
	2-Doses HIV	PRE	37	3.49	7.77	1.0
		PII(W6)	36	2.69	6.01	1.0
		PII(W28)	40	1.00	0.00	1.0
		PIII(W30)	36	2.53	4.63	1.0
		PIII(W48)	37	2.54	5.46	1.0
	HIV	PRE	75	2.89	6.34	1.0
		PII(W6)	69	3.87	11.07	1.0
		PII(W28)	71	1.46	3.10	1.0
	Placebo	PRE	35	3.60	7.59	1.0
		PII(W6)	32	4.25	7.38	1.0
		PII(W28)	35	1.29	1.69	1.0
		PIII(W30)	34	4.91	8.13	1.0
		PIII(W48)	32	3.97	8.88	1.0
CD40L_IFN- $\gamma$	3-Doses HIV	PRE	38	4.24	7.67	1.0
		PII(W6)	33	7.76	12.39	1.0
		PII(W28)	31	4.77	8.04	1.0
		PIII(W30)	34	8.62	20.41	1.0
		PIII(W48)	35	9.00	17.81	1.0
	2-Doses HIV	PRE	37	7.68	19.00	1.0
		PII(W6)	36	6.17	12.08	1.0
		PII(W28)	40	6.30	11.39	1.0
		PIII(W30)	36	3.39	7.35	1.0
		PIII(W48)	37	8.65	13.05	1.0
	HIV	PRE	75	5.93	14.42	1.0
		PII(W6)	69	6.93	12.16	1.0
		PII(W28)	71	5.63	10.03	1.0
	Placebo	PRE	35	12.00	21.38	1.0
		PII(W6)	32	5.13	8.00	1.0
		PII(W28)	35	9.06	21.27	1.0
		PIII(W30)	34	12.26	20.19	1.0
		PIII(W48)	32	6.59	15.85	1.0
TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	38	3.18	7.01	1.0

		PII(W6)	33	1.97	4.07	1.0
		PII(W28)	31	1.87	3.39	1.0
		PIII(W30)	34	2.15	3.94	1.0
		PIII(W48)	35	1.46	2.70	1.0
	2-Doses HIV	PRE	37	2.05	4.90	1.0
		PII(W6)	36	3.25	8.02	1.0
		PII(W28)	40	1.98	3.62	1.0
		PIII(W30)	36	5.25	11.99	1.0
		PIII(W48)	37	1.78	3.33	1.0
	HIV	PRE	75	2.63	6.05	1.0
		PII(W6)	69	2.64	6.43	1.0
		PII(W28)	71	1.93	3.50	1.0
	Placebo	PRE	35	1.66	3.89	1.0
		PII(W6)	32	3.31	8.07	1.0
		PII(W28)	35	3.46	8.61	1.0
		PIII(W30)	34	2.09	4.79	1.0
PIII(W48)		32	3.84	6.85	1.0	
IFN- $\gamma$ IL-2	3-Doses HIV	PRE	38	17.58	40.98	1.0
		PII(W6)	33	13.30	28.46	1.0
		PII(W28)	31	13.48	46.68	1.0
		PIII(W30)	34	15.62	37.32	1.0
		PIII(W48)	35	25.43	62.76	1.0
	2-Doses HIV	PRE	37	11.59	19.50	1.0
		PII(W6)	36	11.28	23.36	1.0
		PII(W28)	40	16.93	33.36	1.0
		PIII(W30)	36	12.83	26.11	1.0
		PIII(W48)	37	17.27	31.94	1.0
	HIV	PRE	75	14.63	32.15	1.0
		PII(W6)	69	12.25	25.75	1.0
		PII(W28)	71	15.42	39.46	1.0
	Placebo	PRE	35	38.51	79.44	1.0
		PII(W6)	32	39.50	92.24	7.0
		PII(W28)	35	28.46	70.68	1.0
		PIII(W30)	34	28.18	59.42	1.0
		PIII(W48)	32	21.03	50.24	1.0
TNF- $\alpha$ IFN- $\gamma$	3-Doses HIV	PRE	38	123.05	190.58	47.0
		PII(W6)	33	146.18	238.83	52.0
		PII(W28)	31	153.97	285.55	69.0
		PIII(W30)	34	177.68	402.41	67.5
		PIII(W48)	35	172.00	422.24	66.0
	2-Doses HIV	PRE	37	195.41	315.99	60.0
		PII(W6)	36	219.08	281.29	107.0
		PII(W28)	40	257.58	569.78	61.0
		PIII(W30)	36	279.53	486.47	76.5
		PIII(W48)	37	219.11	375.06	111.0
	HIV	PRE	75	158.75	260.88	49.0
		PII(W6)	69	184.22	262.52	66.0
		PII(W28)	71	212.34	467.44	63.0
	Placebo	PRE	35	413.69	525.76	164.0
		PII(W6)	32	464.94	643.27	130.0
		PII(W28)	35	330.29	481.80	110.0
		PIII(W30)	34	330.97	511.98	128.0
		PIII(W48)	32	378.94	579.22	130.0
CD40L TNF- $\alpha$ IL-2	3-Doses HIV	PRE	38	1.26	1.62	1.0
		PII(W6)	33	1.00	0.00	1.0
		PII(W28)	31	2.23	3.96	1.0

		2-Doses HIV	PIII(W30)	34	2.06	4.47	1.0
			PIII(W48)	35	1.51	3.04	1.0
			PRE	37	1.57	2.43	1.0
			PII(W6)	36	2.17	4.06	1.0
			PII(W28)	40	1.60	2.66	1.0
			PIII(W30)	36	1.00	0.00	1.0
		HIV	PIII(W48)	37	1.86	5.26	1.0
			PRE	75	1.41	2.05	1.0
			PII(W6)	69	1.61	2.97	1.0
		Placebo	PII(W28)	71	1.87	3.28	1.0
			PRE	35	1.86	3.54	1.0
			PII(W6)	32	1.63	3.54	1.0
			PII(W28)	35	1.51	3.04	1.0
			PIII(W30)	34	1.00	0.00	1.0
			PIII(W48)	32	2.03	3.29	1.0
CD40L_IFN- $\gamma$ _IL-2	3-Doses HIV		PRE	38	1.00	0.00	1.0
			PII(W6)	33	1.00	0.00	1.0
			PII(W28)	31	1.00	0.00	1.0
			PIII(W30)	34	1.62	3.60	1.0
			PIII(W48)	35	1.00	0.00	1.0
	2-Doses HIV		PRE	37	1.00	0.00	1.0
			PII(W6)	36	1.00	0.00	1.0
			PII(W28)	40	1.33	2.06	1.0
			PIII(W30)	36	1.47	2.83	1.0
			PIII(W48)	37	1.00	0.00	1.0
	HIV		PRE	75	1.00	0.00	1.0
			PII(W6)	69	1.00	0.00	1.0
			PII(W28)	71	1.18	1.54	1.0
	Placebo		PRE	35	1.80	3.33	1.0
			PII(W6)	32	1.00	0.00	1.0
			PII(W28)	35	2.49	5.50	1.0
			PIII(W30)	34	1.00	0.00	1.0
			PIII(W48)	32	1.00	0.00	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV		PRE	38	2.26	7.79	1.0
			PII(W6)	33	1.42	2.44	1.0
			PII(W28)	31	1.00	0.00	1.0
			PIII(W30)	34	2.65	5.65	1.0
			PIII(W48)	35	2.43	4.74	1.0
	2-Doses HIV		PRE	37	1.43	2.63	1.0
			PII(W6)	36	1.47	2.83	1.0
			PII(W28)	40	1.75	3.38	1.0
			PIII(W30)	36	2.39	3.99	1.0
			PIII(W48)	37	1.16	0.99	1.0
	HIV		PRE	75	1.85	5.82	1.0
			PII(W6)	69	1.45	2.63	1.0
			PII(W28)	71	1.42	2.55	1.0
	Placebo		PRE	35	4.69	8.37	1.0
			PII(W6)	32	1.69	2.72	1.0
			PII(W28)	35	3.77	8.99	1.0
			PIII(W30)	34	6.35	14.81	1.0
			PIII(W48)	32	4.53	11.32	1.0
TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV		PRE	38	4.79	9.36	1.0
			PII(W6)	33	1.91	5.22	1.0
			PII(W28)	31	6.42	15.16	1.0
			PIII(W30)	34	1.32	1.89	1.0
			PIII(W48)	35	4.91	10.03	1.0

p24	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	2-Doses HIV	PRE	37	6.59	17.22	1.0
			PII(W6)	36	5.08	15.63	1.0
			PII(W28)	40	5.60	14.36	1.0
			PIII(W30)	36	11.31	28.61	1.0
			PIII(W48)	37	4.92	9.68	1.0
		HIV	PRE	75	5.68	13.74	1.0
			PII(W6)	69	3.57	11.88	1.0
			PII(W28)	71	5.96	14.61	1.0
		Placebo	PRE	35	17.14	58.89	1.0
			PII(W6)	32	12.81	31.87	1.0
			PII(W28)	35	9.00	18.85	1.0
			PIII(W30)	34	12.24	28.10	1.0
			PIII(W48)	32	16.78	45.54	1.0
	CD40L	3-Doses HIV	PRE	38	1.00	0.00	1.0
			PII(W6)	33	1.76	4.35	1.0
			PII(W28)	31	2.65	5.12	1.0
			PIII(W30)	34	2.26	7.37	1.0
			PIII(W48)	35	1.51	3.04	1.0
		2-Doses HIV	PRE	37	1.00	0.00	1.0
			PII(W6)	36	1.00	0.00	1.0
			PII(W28)	40	1.00	0.00	1.0
			PIII(W30)	36	2.00	4.35	1.0
			PIII(W48)	37	1.86	5.26	1.0
		HIV	PRE	75	1.00	0.00	1.0
			PII(W6)	69	1.36	3.01	1.0
			PII(W28)	71	1.72	3.45	1.0
		Placebo	PRE	35	1.51	3.04	1.0
			PII(W6)	32	1.63	2.51	1.0
			PII(W28)	35	1.00	0.00	1.0
			PIII(W30)	34	1.38	2.23	1.0
			PIII(W48)	32	1.38	2.12	1.0
	IL-2	3-Doses HIV	PRE	38	41.42	83.83	1.0
			PII(W6)	33	23.09	42.08	1.0
			PII(W28)	31	32.74	52.71	1.0
			PIII(W30)	35	82.37	98.57	38.0
			PIII(W48)	35	64.54	125.78	1.0
		2-Doses HIV	PRE	37	58.78	72.83	26.0
			PII(W6)	36	64.50	96.71	10.0
			PII(W28)	40	66.25	84.56	25.5
			PIII(W30)	36	56.28	97.65	18.0
			PIII(W48)	37	53.43	85.65	1.0
		HIV	PRE	75	49.99	78.55	3.0
			PII(W6)	69	44.70	77.98	1.0
			PII(W28)	71	51.62	73.85	7.0
		Placebo	PRE	35	71.40	94.20	54.0
			PII(W6)	32	64.38	120.87	26.5
			PII(W28)	35	55.89	76.24	28.0
			PIII(W30)	34	68.15	122.78	1.5
			PIII(W48)	32	37.94	57.29	1.0
		3-Doses HIV	PRE	38	38.21	83.22	1.0
			PII(W6)	33	55.85	148.96	1.0
			PII(W28)	31	34.61	51.87	1.0
			PIII(W30)	35	49.37	84.04	8.0
			PIII(W48)	35	46.60	72.37	1.0
		2-Doses HIV	PRE	37	46.27	96.32	2.0
			PII(W6)	36	52.06	115.70	5.5

			PII(W28)	40	96.63	386.52	21.5
			PIII(W30)	36	45.53	52.24	35.5
			PIII(W48)	37	74.41	232.50	4.0
		HIV	PRE	75	42.19	89.40	1.0
			PII(W6)	69	53.87	131.66	2.0
			PII(W28)	71	69.55	292.14	12.0
		Placebo	PRE	35	54.09	226.03	1.0
			PII(W6)	32	18.22	32.45	1.0
			PII(W28)	35	55.54	164.91	1.0
			PIII(W30)	34	23.47	56.08	1.0
			PIII(W48)	32	40.75	64.45	11.0
	TNF- $\alpha$	3-Doses HIV	PRE	38	85.13	96.79	54.5
			PII(W6)	33	71.67	91.42	37.0
			PII(W28)	31	88.84	96.30	69.0
			PIII(W30)	35	93.09	146.24	29.0
			PIII(W48)	35	88.00	97.56	53.0
		2-Doses HIV	PRE	37	92.24	120.88	50.0
			PII(W6)	36	114.78	117.23	82.5
			PII(W28)	40	74.68	124.31	40.5
			PIII(W30)	36	98.75	150.45	19.0
			PIII(W48)	37	108.78	204.07	37.0
		HIV	PRE	75	88.64	108.65	51.0
			PII(W6)	69	94.16	107.13	71.0
			PII(W28)	71	80.86	112.40	47.0
		Placebo	PRE	35	143.74	236.61	89.0
			PII(W6)	32	137.84	275.91	40.0
			PII(W28)	35	159.20	413.14	48.0
			PIII(W30)	34	132.15	235.63	74.5
			PIII(W48)	32	93.56	136.66	17.5
	IFN- $\gamma$	3-Doses HIV	PRE	38	6777.84	7872.49	4897.0
			PII(W6)	33	6494.76	8716.90	4570.0
			PII(W28)	31	7259.71	8793.82	5862.0
			PIII(W30)	35	5547.91	4570.96	5056.0
			PIII(W48)	35	5818.86	4885.59	5122.0
		2-Doses HIV	PRE	37	9952.51	12661.92	6910.0
			PII(W6)	36	10428.47	15232.23	5096.0
			PII(W28)	40	8872.60	14576.58	4345.0
			PIII(W30)	36	8182.50	10131.53	4358.0
			PIII(W48)	37	9441.59	13622.16	4974.0
		HIV	PRE	75	8344.01	10561.10	5933.0
			PII(W6)	69	8547.13	12613.40	4657.0
			PII(W28)	71	8168.38	12335.75	5268.0
		Placebo	PRE	35	13547.66	20988.21	6749.0
			PII(W6)	32	16288.69	24300.39	9141.5
			PII(W28)	35	12380.00	18881.16	6198.0
			PIII(W30)	34	14569.65	22652.78	7770.0
			PIII(W48)	32	12694.59	18392.76	6070.0
CD40L_IL-2		3-Doses HIV	PRE	38	2.58	8.23	1.0
			PII(W6)	33	1.00	0.00	1.0
			PII(W28)	31	2.35	4.26	1.0
			PIII(W30)	35	1.74	4.39	1.0
			PIII(W48)	35	2.37	4.55	1.0
		2-Doses HIV	PRE	37	3.14	6.46	1.0
			PII(W6)	36	2.50	6.29	1.0
			PII(W28)	40	1.75	4.28	1.0
			PIII(W30)	36	1.61	3.67	1.0



CD40L_TNF- $\alpha$	HIV	PIII(W48)	37	1.62	2.66	1.0
		PRE	75	2.85	7.37	1.0
		PII(W6)	69	1.78	4.58	1.0
		PII(W28)	71	2.01	4.25	1.0
	Placebo	PRE	35	4.86	11.85	1.0
		PII(W6)	32	1.00	0.00	1.0
		PII(W28)	35	1.49	2.87	1.0
		PIII(W30)	34	4.44	8.28	1.0
		PIII(W48)	32	1.91	3.68	1.0
	3-Doses HIV	PRE	38	2.16	4.98	1.0
		PII(W6)	33	1.48	2.79	1.0
		PII(W28)	31	2.19	4.00	1.0
		PIII(W30)	35	3.17	6.39	1.0
		PIII(W48)	35	3.77	8.23	1.0
	2-Doses HIV	PRE	37	2.05	4.81	1.0
		PII(W6)	36	1.00	0.00	1.0
		PII(W28)	40	2.80	5.58	1.0
		PIII(W30)	36	1.61	2.60	1.0
		PIII(W48)	37	3.00	5.91	1.0
CD40L_IFN- $\gamma$	HIV	PRE	75	2.11	4.86	1.0
		PII(W6)	69	1.23	1.93	1.0
		PII(W28)	71	2.54	4.93	1.0
	Placebo	PRE	35	3.37	6.77	1.0
		PII(W6)	32	2.22	4.88	1.0
		PII(W28)	35	1.83	3.43	1.0
		PIII(W30)	34	3.21	5.79	1.0
		PIII(W48)	32	1.38	2.12	1.0
	3-Doses HIV	PRE	38	12.76	18.65	1.0
		PII(W6)	33	12.70	18.15	1.0
		PII(W28)	31	8.94	14.28	1.0
		PIII(W30)	35	11.57	26.71	1.0
		PIII(W48)	35	10.03	22.32	1.0
	2-Doses HIV	PRE	37	17.27	46.11	1.0
		PII(W6)	36	14.50	30.73	1.0
		PII(W28)	40	10.13	20.28	1.0
		PIII(W30)	36	8.78	19.05	1.0
		PIII(W48)	37	14.32	27.60	1.0
TNF- $\alpha$ _IL-2	HIV	PRE	75	14.99	34.83	1.0
		PII(W6)	69	13.64	25.34	1.0
		PII(W28)	71	9.61	17.80	1.0
	Placebo	PRE	35	29.20	57.07	1.0
		PII(W6)	32	26.56	52.32	1.0
		PII(W28)	35	20.00	43.29	1.0
		PIII(W30)	34	35.18	60.86	11.5
		PIII(W48)	32	16.28	31.39	1.0
	3-Doses HIV	PRE	38	2.29	5.97	1.0
		PII(W6)	33	1.30	1.74	1.0
		PII(W28)	31	1.84	3.29	1.0
		PIII(W30)	35	1.43	2.54	1.0
		PIII(W48)	35	2.57	7.88	1.0
	2-Doses HIV	PRE	37	1.92	3.90	1.0
		PII(W6)	36	2.50	6.29	1.0
		PII(W28)	40	2.65	5.46	1.0
		PIII(W30)	36	2.19	5.01	1.0
		PIII(W48)	37	5.14	12.85	1.0
TNF- $\alpha$ _IL-2	HIV	PRE	75	2.11	5.03	1.0

IFN- $\gamma$ _IL-2	Placebo	PII(W6)	69	1.93	4.71	1.0
		PII(W28)	71	2.30	4.62	1.0
		PRE	35	1.63	2.77	1.0
		PII(W6)	32	1.44	2.47	1.0
		PII(W28)	35	3.03	6.38	1.0
		PIII(W30)	34	1.79	4.63	1.0
		PIII(W48)	32	4.94	9.15	1.0
	3-Doses HIV	PRE	38	51.92	110.21	7.5
		PII(W6)	33	27.88	51.18	1.0
		PII(W28)	31	19.65	24.83	1.0
		PIII(W30)	35	31.00	55.18	11.0
		PIII(W48)	35	25.63	54.63	1.0
	2-Doses HIV	PRE	37	37.81	46.27	26.0
		PII(W6)	36	48.75	71.84	19.0
		PII(W28)	40	35.20	45.51	20.5
		PIII(W30)	36	42.03	60.05	18.5
		PIII(W48)	37	43.27	65.75	2.0
TNF- $\alpha$ _IFN- $\gamma$	HIV	PRE	75	44.96	84.65	19.0
		PII(W6)	69	38.77	63.24	1.0
		PII(W28)	71	28.41	38.45	18.0
	Placebo	PRE	35	100.91	176.49	28.0
		PII(W6)	32	155.41	282.67	22.0
		PII(W28)	35	81.11	138.81	22.0
		PIII(W30)	34	113.76	251.87	25.0
		PIII(W48)	32	83.16	162.29	1.0
	3-Doses HIV	PRE	38	626.50	861.66	291.5
		PII(W6)	33	629.67	1171.82	236.0
		PII(W28)	31	739.23	1144.04	471.0
		PIII(W30)	35	361.17	380.13	246.0
		PIII(W48)	35	479.03	500.58	299.0
	2-Doses HIV	PRE	37	888.92	1229.96	586.0
		PII(W6)	36	663.44	699.95	390.5
		PII(W28)	40	832.53	1135.52	492.0
		PIII(W30)	36	776.94	927.40	313.5
		PIII(W48)	37	752.49	818.12	423.0
	HIV	PRE	75	755.96	1060.49	319.0
		PII(W6)	69	647.29	947.98	283.0
		PII(W28)	71	791.79	1132.03	471.0
	Placebo	PRE	35	1738.83	3447.05	705.0
		PII(W6)	32	2049.50	3878.21	751.5
		PII(W28)	35	1517.83	3023.85	484.0
		PIII(W30)	34	1821.94	3843.69	761.0
		PIII(W48)	32	1550.53	3237.82	497.0
CD40L_TNF- $\alpha$ _IL-2	3-Doses HIV	PRE	38	1.97	4.26	1.0
		PII(W6)	33	2.24	7.14	1.0
		PII(W28)	31	2.16	3.78	1.0
		PIII(W30)	35	3.43	12.59	1.0
		PIII(W48)	35	1.49	2.87	1.0
	2-Doses HIV	PRE	37	2.24	5.52	1.0
		PII(W6)	36	1.42	2.50	1.0
		PII(W28)	40	1.00	0.00	1.0
		PIII(W30)	36	2.17	7.00	1.0
		PIII(W48)	37	1.41	2.47	1.0
	HIV	PRE	75	2.11	4.90	1.0
		PII(W6)	69	1.81	5.23	1.0
		PII(W28)	71	1.51	2.54	1.0

CD40L_IFN- $\gamma$ _IL-2	Placebo	PRE	35	1.00	0.00	1.0
		PII(W6)	32	2.16	4.64	1.0
		PII(W28)	35	2.29	5.99	1.0
		PIII(W30)	34	1.00	0.00	1.0
		PIII(W48)	32	1.75	2.96	1.0
	3-Doses HIV	PRE	38	1.00	0.00	1.0
		PII(W6)	33	1.00	0.00	1.0
		PII(W28)	31	1.55	3.05	1.0
		PIII(W30)	35	1.00	0.00	1.0
		PIII(W48)	35	1.26	1.52	1.0
	2-Doses HIV	PRE	37	1.70	4.27	1.0
		PII(W6)	36	2.00	4.19	1.0
		PII(W28)	40	1.45	2.85	1.0
		PIII(W30)	36	1.00	0.00	1.0
		PIII(W48)	37	1.62	3.78	1.0
	HIV	PRE	75	1.35	3.00	1.0
		PII(W6)	69	1.52	3.05	1.0
		PII(W28)	71	1.49	2.92	1.0
	Placebo	PRE	35	2.54	5.39	1.0
		PII(W6)	32	5.22	11.47	1.0
		PII(W28)	35	1.69	4.06	1.0
		PIII(W30)	34	2.65	8.02	1.0
		PIII(W48)	32	3.66	9.99	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$	3-Doses HIV	PRE	38	4.71	11.26	1.0
		PII(W6)	33	4.79	11.98	1.0
		PII(W28)	31	2.65	5.74	1.0
		PIII(W30)	35	5.17	13.90	1.0
		PIII(W48)	35	2.74	5.10	1.0
	2-Doses HIV	PRE	37	4.59	9.69	1.0
		PII(W6)	36	3.44	6.27	1.0
		PII(W28)	40	2.73	7.08	1.0
		PIII(W30)	36	4.00	8.34	1.0
		PIII(W48)	37	7.16	12.37	1.0
	HIV	PRE	75	4.65	10.44	1.0
		PII(W6)	69	4.09	9.39	1.0
		PII(W28)	71	2.69	6.49	1.0
	Placebo	PRE	35	12.71	23.60	1.0
		PII(W6)	32	8.50	11.22	1.0
		PII(W28)	35	3.17	7.06	1.0
		PIII(W30)	34	6.97	14.10	1.0
		PIII(W48)	32	11.25	18.17	1.0
TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	14.13	35.26	1.0
		PII(W6)	33	15.67	27.15	1.0
		PII(W28)	31	8.42	15.10	1.0
		PIII(W30)	35	11.11	39.31	1.0
		PIII(W48)	35	12.37	28.66	1.0
	2-Doses HIV	PRE	37	18.11	37.19	1.0
		PII(W6)	36	14.97	29.92	1.0
		PII(W28)	40	11.85	26.72	1.0
		PIII(W30)	36	19.42	38.51	1.0
		PIII(W48)	37	10.86	22.23	1.0
	HIV	PRE	75	16.09	36.04	1.0
		PII(W6)	69	15.30	28.42	1.0
		PII(W28)	71	10.35	22.33	1.0
	Placebo	PRE	35	38.63	68.98	1.0
		PII(W6)	32	55.97	111.42	8.5

	CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2		PII(W28)	35	28.77	63.88	1.0		
			PIII(W30)	34	42.68	109.15	1.0		
			PIII(W48)	32	29.97	66.50	1.0		
		3-Doses HIV	PRE	38	1.24	1.46	1.0		
			PII(W6)	33	2.82	8.07	1.0		
			PII(W28)	31	1.52	2.87	1.0		
			PIII(W30)	35	5.83	18.35	1.0		
			PIII(W48)	35	2.23	5.90	1.0		
		2-Doses HIV	PRE	37	2.00	6.08	1.0		
			PII(W6)	36	1.53	3.17	1.0		
			PII(W28)	40	1.70	4.43	1.0		
			PIII(W30)	36	1.39	2.33	1.0		
			PIII(W48)	37	1.81	3.47	1.0		
		HIV	PRE	75	1.61	4.38	1.0		
			PII(W6)	69	2.14	6.02	1.0		
			PII(W28)	71	1.62	3.80	1.0		
		Placebo	PRE	35	2.83	7.85	1.0		
			PII(W6)	32	3.78	10.25	1.0		
			PII(W28)	35	1.40	2.37	1.0		
			PIII(W30)	34	2.15	6.69	1.0		
			PIII(W48)	32	1.88	3.45	1.0		
		RT	CD40L	3-Doses HIV	PRE	38	39.08	70.66	1.0
					PII(W6)	32	30.41	70.34	1.0
					PII(W28)	31	31.87	49.35	1.0
					PIII(W30)	35	61.57	109.88	19.0
					PIII(W48)	36	50.14	92.71	1.0
				2-Doses HIV	PRE	37	81.24	98.44	60.0
					PII(W6)	36	67.72	105.55	15.0
PII(W28)	40				68.20	107.97	1.0		
PIII(W30)	36				51.22	83.36	1.0		
PIII(W48)	38				69.92	124.86	1.0		
HIV	PRE			75	59.88	87.53	1.0		
	PII(W6)			68	50.16	91.99	1.0		
	PII(W28)			71	52.34	88.70	1.0		
Placebo	PRE			35	66.40	89.65	12.0		
	PII(W6)			33	63.33	139.55	35.0		
	PII(W28)			35	51.17	90.66	1.0		
	PIII(W30)			34	40.85	69.53	1.0		
	PIII(W48)			31	28.77	40.58	1.0		
IL-2	3-Doses HIV			PRE	38	24.39	43.36	1.0	
				PII(W6)	32	77.44	205.83	1.0	
				PII(W28)	31	45.87	83.48	1.0	
				PIII(W30)	35	48.91	110.82	1.0	
				PIII(W48)	36	48.56	82.92	2.0	
	2-Doses HIV			PRE	37	27.14	33.79	1.0	
				PII(W6)	36	53.33	88.79	1.0	
				PII(W28)	40	44.95	62.92	15.5	
				PIII(W30)	36	57.42	79.95	21.5	
				PIII(W48)	38	27.37	42.81	1.0	
	HIV	PRE	75	25.75	38.70	1.0			
		PII(W6)	68	64.68	154.49	1.0			
		PII(W28)	71	45.35	72.06	13.0			
	Placebo	PRE	35	31.23	52.51	1.0			
		PII(W6)	33	26.97	62.80	1.0			
		PII(W28)	35	37.54	84.05	2.0			
		PIII(W30)	34	45.79	74.62	12.5			

TNF- $\alpha$	3-Doses HIV	PIII(W48)	31	111.26	200.27	40.0
		PRE	38	101.79	123.28	71.5
		PII(W6)	32	77.94	89.86	61.0
		PII(W28)	31	79.77	97.91	42.0
		PIII(W30)	35	72.23	99.44	33.0
	2-Doses HIV	PIII(W48)	36	96.64	106.65	63.5
		PRE	37	113.97	197.85	67.0
		PII(W6)	36	116.00	169.15	70.0
		PII(W28)	40	127.95	240.91	50.0
		PIII(W30)	36	145.25	265.19	76.0
	HIV	PIII(W48)	38	128.45	217.48	63.0
		PRE	75	107.80	163.34	68.0
		PII(W6)	68	98.09	138.02	63.0
	Placebo	PII(W28)	71	106.92	192.41	48.0
		PRE	35	172.03	282.29	84.0
		PII(W6)	33	180.85	308.59	82.0
		PII(W28)	35	213.40	463.56	80.0
		PIII(W30)	34	174.26	265.63	97.0
		PIII(W48)	31	159.29	211.15	109.0
IFN- $\gamma$	3-Doses HIV	PRE	38	5561.71	6626.88	3370.0
		PII(W6)	32	4849.19	5137.37	3474.0
		PII(W28)	31	6899.16	8906.59	5410.0
		PIII(W30)	35	4512.89	4988.99	2959.0
		PIII(W48)	36	4936.92	6055.67	3081.0
	2-Doses HIV	PRE	37	4801.03	5107.88	2161.0
		PII(W6)	36	5070.64	5468.04	2885.0
		PII(W28)	40	4834.85	5244.44	2355.5
		PIII(W30)	36	5033.25	5193.62	2824.5
		PIII(W48)	38	5431.08	6087.81	3187.0
	HIV	PRE	75	5186.44	5898.90	3138.0
		PII(W6)	68	4966.43	5276.65	3050.5
		PII(W28)	71	5736.17	7098.19	3079.0
	Placebo	PRE	35	4731.37	4438.79	3950.0
		PII(W6)	33	5328.21	4147.37	4012.0
		PII(W28)	35	4220.09	2973.84	3595.0
		PIII(W30)	34	4715.74	3298.95	4000.0
		PIII(W48)	31	4410.90	2998.37	4294.0
CD40L_IL-2	3-Doses HIV	PRE	38	1.32	1.95	1.0
		PII(W6)	32	1.00	0.00	1.0
		PII(W28)	31	2.32	5.79	1.0
		PIII(W30)	35	3.31	9.03	1.0
		PIII(W48)	36	3.00	6.88	1.0
	2-Doses HIV	PRE	37	1.62	3.78	1.0
		PII(W6)	36	1.00	0.00	1.0
		PII(W28)	40	3.45	8.07	1.0
		PIII(W30)	36	1.03	0.17	1.0
		PIII(W48)	38	1.45	2.76	1.0
	HIV	PRE	75	1.47	2.98	1.0
		PII(W6)	68	1.00	0.00	1.0
		PII(W28)	71	2.96	7.14	1.0
	Placebo	PRE	35	3.20	9.69	1.0
		PII(W6)	33	1.00	0.00	1.0
		PII(W28)	35	1.00	0.00	1.0
		PIII(W30)	34	2.38	4.62	1.0
		PIII(W48)	31	1.00	0.00	1.0
CD40L_TNF- $\alpha$	3-Doses HIV	PRE	38	6.26	19.20	1.0

		P1I(W6)	32	4.00	9.68	1.0	
		P1I(W28)	31	1.97	5.39	1.0	
		P1II(W30)	35	6.51	15.81	1.0	
		P1II(W48)	36	4.08	8.44	1.0	
	2-Doses HIV	PRE	37	1.00	0.00	1.0	
		P1I(W6)	36	2.47	5.09	1.0	
		P1I(W28)	40	4.88	11.14	1.0	
		P1II(W30)	36	3.50	8.57	1.0	
	HIV	P1II(W48)	38	3.47	6.03	1.0	
		PRE	75	3.67	13.83	1.0	
		P1I(W6)	68	3.19	7.58	1.0	
	Placebo	P1I(W28)	71	3.61	9.15	1.0	
		PRE	35	3.86	9.13	1.0	
		P1I(W6)	33	1.00	0.00	1.0	
		P1I(W28)	35	2.51	5.26	1.0	
	CD40L_IFN- $\gamma$	3-Doses HIV	P1II(W30)	34	2.88	6.24	1.0
			P1II(W48)	31	2.87	5.21	1.0
PRE			38	7.63	14.37	1.0	
P1I(W6)			32	10.28	16.58	1.0	
P1I(W28)			31	9.26	15.25	1.0	
2-Doses HIV		P1II(W30)	35	6.54	14.82	1.0	
		P1II(W48)	36	11.36	15.21	1.0	
		PRE	37	11.89	19.50	1.0	
		P1I(W6)	36	6.50	16.44	1.0	
		P1I(W28)	40	5.40	13.01	1.0	
HIV		P1II(W30)	36	5.64	10.70	1.0	
		P1II(W48)	38	5.11	8.13	1.0	
		PRE	75	9.73	17.11	1.0	
Placebo		P1I(W6)	68	8.28	16.49	1.0	
		P1I(W28)	71	7.08	14.06	1.0	
		PRE	35	8.43	17.53	1.0	
		P1I(W6)	33	5.97	10.75	1.0	
TNF- $\alpha$ _IL-2	3-Doses HIV	P1I(W28)	35	4.89	9.12	1.0	
		P1II(W30)	34	8.12	18.60	1.0	
		P1II(W48)	31	6.74	10.82	1.0	
		PRE	38	3.53	8.77	1.0	
		P1I(W6)	32	2.13	4.46	1.0	
	2-Doses HIV	P1I(W28)	31	1.81	3.19	1.0	
		P1II(W30)	35	6.83	16.24	1.0	
		P1II(W48)	36	4.08	9.14	1.0	
		PRE	37	2.00	3.65	1.0	
		P1I(W6)	36	2.17	3.99	1.0	
	HIV	P1I(W28)	40	1.70	4.43	1.0	
		P1II(W30)	36	2.92	6.29	1.0	
		P1II(W48)	38	1.92	4.10	1.0	
	Placebo	PRE	75	2.77	6.75	1.0	
		P1I(W6)	68	2.15	4.18	1.0	
		P1I(W28)	71	1.75	3.91	1.0	
		PRE	35	1.71	3.89	1.0	
IFN- $\gamma$ _IL-2	3-Doses HIV	P1I(W6)	33	2.70	5.54	1.0	
		P1I(W28)	35	1.74	4.39	1.0	
		P1II(W30)	34	6.15	13.53	1.0	
		P1II(W48)	31	2.55	8.62	1.0	
		PRE	38	39.08	59.01	14.5	
		P1I(W6)	32	36.00	68.31	1.0	
		P1I(W28)	31	36.97	53.96	16.0	

		2-Doses HIV	PIII(W30)	35	23.66	29.88	1.0
			PIII(W48)	36	24.17	32.87	17.0
			PRE	37	42.89	66.08	17.0
			PII(W6)	36	49.44	79.02	28.0
			PII(W28)	40	54.40	111.03	7.0
			PIII(W30)	36	48.25	86.00	11.5
		HIV	PIII(W48)	38	81.76	185.32	8.0
			PRE	75	40.96	62.20	17.0
			PII(W6)	68	43.12	73.94	23.5
		Placebo	PII(W28)	71	46.79	90.51	13.0
			PRE	35	67.34	127.93	18.0
			PII(W6)	33	47.30	92.07	16.0
			PII(W28)	35	32.77	50.55	16.0
			PIII(W30)	34	40.62	60.90	19.0
			PIII(W48)	31	30.71	33.59	18.0
TNF- $\alpha$ _IFN- $\gamma$		3-Doses HIV	PRE	38	679.16	911.00	271.0
			PII(W6)	32	666.72	828.39	301.0
			PII(W28)	31	858.26	1173.49	372.0
			PIII(W30)	35	513.86	662.36	232.0
			PIII(W48)	36	641.22	996.01	250.5
		2-Doses HIV	PRE	37	544.16	578.39	314.0
			PII(W6)	36	558.08	528.44	360.0
			PII(W28)	40	677.25	771.64	455.0
			PIII(W30)	36	767.78	824.46	542.5
			PIII(W48)	38	831.32	1057.54	483.5
		HIV	PRE	75	612.56	763.10	300.0
			PII(W6)	68	609.21	682.91	339.0
			PII(W28)	71	756.28	964.41	454.0
		Placebo	PRE	35	704.89	1038.69	410.0
			PII(W6)	33	809.06	1124.45	471.0
			PII(W28)	35	750.00	1288.83	366.0
			PIII(W30)	34	759.44	885.89	490.0
			PIII(W48)	31	583.00	732.47	404.0
CD40L_TNF- $\alpha$ _IL-2		3-Doses HIV	PRE	38	1.00	0.00	1.0
			PII(W6)	32	2.94	10.96	1.0
			PII(W28)	31	2.00	5.57	1.0
			PIII(W30)	35	6.66	19.34	1.0
			PIII(W48)	36	3.08	7.75	1.0
		2-Doses HIV	PRE	37	1.70	3.06	1.0
			PII(W6)	36	2.25	4.29	1.0
			PII(W28)	40	1.28	1.74	1.0
			PIII(W30)	36	1.00	0.00	1.0
			PIII(W48)	38	2.89	7.73	1.0
		HIV	PRE	75	1.35	2.17	1.0
			PII(W6)	68	2.57	8.08	1.0
			PII(W28)	71	1.59	3.89	1.0
		Placebo	PRE	35	2.46	4.85	1.0
			PII(W6)	33	1.00	0.00	1.0
			PII(W28)	35	1.00	0.00	1.0
			PIII(W30)	34	1.00	0.00	1.0
			PIII(W48)	31	1.00	0.00	1.0
CD40L_IFN- $\gamma$ _IL-2		3-Doses HIV	PRE	38	1.50	3.08	1.0
			PII(W6)	32	1.91	3.62	1.0
			PII(W28)	31	2.45	4.52	1.0
			PIII(W30)	35	1.00	0.00	1.0
			PIII(W48)	36	1.94	4.39	1.0

CD40L_TNF- $\alpha$ _IFN- $\gamma$	2-Doses HIV	PRE	37	1.32	1.97	1.0
		PII(W6)	36	2.00	3.39	1.0
		PII(W28)	40	1.45	2.85	1.0
		PIII(W30)	36	1.00	0.00	1.0
		PIII(W48)	38	1.45	2.76	1.0
	HIV	PRE	75	1.41	2.58	1.0
		PII(W6)	68	1.96	3.47	1.0
		PII(W28)	71	1.89	3.67	1.0
	Placebo	PRE	35	1.00	0.00	1.0
		PII(W6)	33	1.30	1.74	1.0
		PII(W28)	35	1.00	0.00	1.0
		PIII(W30)	34	1.00	0.00	1.0
		PIII(W48)	31	2.61	8.98	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	4.37	8.71	1.0
		PII(W6)	32	3.50	7.70	1.0
		PII(W28)	31	3.55	8.76	1.0
		PIII(W30)	35	3.34	8.67	1.0
		PIII(W48)	36	3.19	6.68	1.0
	2-Doses HIV	PRE	37	2.14	3.96	1.0
		PII(W6)	36	1.36	2.17	1.0
		PII(W28)	40	2.05	3.82	1.0
		PIII(W30)	36	3.19	6.87	1.0
		PIII(W48)	38	1.00	0.00	1.0
	HIV	PRE	75	3.27	6.84	1.0
		PII(W6)	68	2.37	5.57	1.0
		PII(W28)	71	2.70	6.45	1.0
	Placebo	PRE	35	2.80	5.37	1.0
		PII(W6)	33	1.67	2.68	1.0
		PII(W28)	35	1.31	1.86	1.0
		PIII(W30)	34	2.00	3.36	1.0
		PIII(W48)	31	5.00	9.91	1.0
TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	12.08	24.20	1.0
		PII(W6)	32	15.03	30.04	1.0
		PII(W28)	31	7.71	17.68	1.0
		PIII(W30)	35	7.34	17.83	1.0
		PIII(W48)	36	12.36	21.76	1.0
	2-Doses HIV	PRE	37	25.62	68.85	1.0
		PII(W6)	36	22.72	50.13	1.0
		PII(W28)	40	24.53	67.84	1.0
		PIII(W30)	36	27.78	58.14	5.0
		PIII(W48)	38	37.45	111.02	1.0
	HIV	PRE	75	18.76	51.44	1.0
		PII(W6)	68	19.10	41.77	1.0
		PII(W28)	71	17.18	52.62	1.0
	Placebo	PRE	35	18.46	35.40	1.0
		PII(W6)	33	23.03	41.99	10.0
		PII(W28)	35	13.91	22.33	1.0
		PIII(W30)	34	16.62	30.58	1.0
		PIII(W48)	31	12.68	21.92	1.0
CD40L_TNF- $\alpha$ _IFN- $\gamma$ _IL-2	3-Doses HIV	PRE	38	1.50	3.08	1.0
		PII(W6)	32	2.78	7.02	1.0
		PII(W28)	31	1.77	3.26	1.0
		PIII(W30)	35	16.54	56.66	1.0
		PIII(W48)	36	2.97	6.75	1.0
	2-Doses HIV	PRE	37	1.00	0.00	1.0
		PII(W6)	36	2.31	4.80	1.0



			PII(W28)	40	1.00	0.00	1.0
			PIII(W30)	36	1.64	2.88	1.0
			PIII(W48)	38	1.24	1.46	1.0
		HIV	PRE	75	1.25	2.19	1.0
			PII(W6)	68	2.53	5.91	1.0
			PII(W28)	71	1.34	2.17	1.0
		Placebo	PRE	35	1.00	0.00	1.0
			PII(W6)	33	1.70	4.00	1.0
			PII(W28)	35	1.00	0.00	1.0
			PIII(W30)	34	1.00	0.00	1.0
			PIII(W48)	31	1.00	0.00	1.0

\*F4co-Computed = Frequency of CD8+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD8+ T cells to each of the 4 antigens (Nef, p17, p24, RT)

N = number of subjects with available results

GM = Geometric Mean

SD = Standard Deviation

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results: Seropositivity rates and GMCs for Anti-p17 antibodies (ATP cohort for immunogenicity)**

				≥ 187 mEL.U/mL				GMC (mEL.U/mL)		
						95% CI				95% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
Anti-HIV-1 p17	3-Doses HIV	PRE	44	35	79.5	64.7	90.2	1438.6	719.6	2876.1
		PII(W6)	44	39	88.6	75.4	96.2	1705.5	926.8	3138.3
		PII(W28)	44	37	84.1	69.9	93.4	1408.1	758.6	2614.0
		PIII(W30)	43	41	95.3	84.2	99.4	2247.0	1314.3	3841.6
		PIII(W48)	39	31	79.5	63.5	90.7	1446.7	743.7	2814.2
	2-Doses HIV	PRE	45	38	84.4	70.5	93.5	2476.4	1255.4	4884.7
		PII(W6)	43	37	86.0	72.1	94.7	2432.7	1240.6	4770.4
		PII(W28)	45	38	84.4	70.5	93.5	2468.5	1235.4	4932.5
		PIII(W30)	42	35	83.3	68.6	93.0	2622.5	1266.2	5431.4
		PIII(W48)	43	33	76.7	61.4	88.2	2012.2	953.4	4246.7
	HIV	PRE	89	73	82.0	72.5	89.4	1893.2	1172.8	3056.2
		PII(W6)	87	76	87.4	78.5	93.5	2032.8	1301.2	3175.7
		PII(W28)	89	75	84.3	75.0	91.1	1870.3	1181.3	2961.1
	Placebo	PRE	40	34	85.0	70.2	94.3	1274.5	681.0	2385.0
		PII(W6)	40	33	82.5	67.2	92.7	1127.1	607.5	2091.3
		PII(W28)	39	32	82.1	66.5	92.5	1086.3	579.3	2037.1
		PIII(W30)	38	31	81.6	65.7	92.3	1021.7	549.8	1898.9
		PIII(W48)	37	31	83.8	68.0	93.8	935.3	515.5	1696.9

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results: Seropositivity rates and GMCs for Anti-p24 antibodies (ATP cohort for immunogenicity)**

				≥ 119 mEL.U/mL				GMC (mEL.U/mL)		
						95% CI				95% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL

Anti-HIV-1 p24	3-Doses HIV	PRE	44	42	95.5	84.5	99.4	10102.5	4146.2	24615.3
		PII(W6)	44	43	97.7	88.0	99.9	13717.9	5954.7	31602.1
		PII(W28)	44	43	97.7	88.0	99.9	11519.8	4600.2	28847.3
		PIII(W30)	43	43	100	91.8	100	15711.6	6974.2	35395.4
		PIII(W48)	39	39	100	91.0	100	13956.2	5523.2	35265.4
	2-Doses HIV	PRE	45	45	100	92.1	100	18601.1	8849.9	39096.7
		PII(W6)	43	43	100	91.8	100	18130.6	9266.8	35472.8
		PII(W28)	45	44	97.8	88.2	99.9	19104.9	8681.3	42044.0
		PIII(W30)	42	41	97.6	87.4	99.9	18086.4	8059.8	40586.2
		PIII(W48)	43	42	97.7	87.7	99.9	18315.2	8285.1	40487.8
	HIV	PRE	89	87	97.8	92.1	99.7	13755.4	7772.4	24343.9
		PII(W6)	87	86	98.9	93.8	100	15745.4	9297.5	26665.0
		PII(W28)	89	87	97.8	92.1	99.7	14877.5	8209.7	26960.8
	Placebo	PRE	40	38	95.0	83.1	99.4	16687.1	7205.5	38645.7
		PII(W6)	40	38	95.0	83.1	99.4	19471.4	8306.8	45641.6
		PII(W28)	39	37	94.9	82.7	99.4	19683.5	8344.0	46433.2
		PIII(W30)	38	36	94.7	82.3	99.4	19617.0	8033.4	47903.3
		PIII(W48)	37	35	94.6	81.8	99.3	23970.6	9535.0	60260.9

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Seropositivity rates and GMCs for Anti-Nef antibodies (ATP cohort for immunogenicity)

				≥ 494 mEL.U/mL			GMC (mEL.U/mL)				
						95% CI				95% CI	
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	
Anti-HIV-1 Nef	3-Doses HIV	PRE	44	22	50.0	34.6	65.4	720.6	473.5	1096.5	
		PII(W6)	44	38	86.4	72.6	94.8	1292.9	931.5	1794.6	
		PII(W28)	44	24	54.5	38.8	69.6	703.9	478.4	1035.8	
		PIII(W30)	43	42	97.7	87.7	99.9	6629.0	4147.9	10594.1	
		PIII(W48)	39	33	84.6	69.5	94.1	1454.8	986.1	2146.4	
	2-Doses HIV	PRE	45	28	62.2	46.5	76.2	821.1	579.3	1163.9	
		PII(W6)	43	35	81.4	66.6	91.6	1251.5	857.7	1826.3	
		PII(W28)	45	31	68.9	53.4	81.8	946.8	668.7	1340.5	
		PIII(W30)	42	28	66.7	50.5	80.4	983.9	666.0	1453.8	
		PIII(W48)	43	27	62.8	46.7	77.0	849.3	589.3	1224.0	
	HIV	PRE	89	50	56.2	45.3	66.7	769.8	589.2	1005.7	
		PII(W6)	87	73	83.9	74.5	90.9	1272.3	996.1	1625.0	
		PII(W28)	89	55	61.8	50.9	71.9	817.7	632.8	1056.7	
	Placebo	PRE	40	21	52.5	36.1	68.5	846.2	523.3	1368.1	
		PII(W6)	40	17	42.5	27.0	59.1	609.3	391.6	948.2	
		PII(W28)	39	20	51.3	34.8	67.6	698.8	446.5	1093.8	
		PIII(W30)	38	20	52.6	35.8	69.0	773.1	492.9	1212.6	
		PIII(W48)	37	18	48.6	31.9	65.6	803.2	478.5	1348.0	

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Seropositivity rates and GMCs for Anti-RT antibodies (ATP cohort for immunogenicity)

				≥ 125 mEL.U/mL				GMC (mEL.U/mL)		
						95% CI			95% CI	
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
Anti-HIV-1 RT	3-Doses HIV	PRE	40	40	100	91.2	100	39262.5	22416.4	68768.5
		PII(W6)	43	43	100	91.8	100	32570.1	18257.0	58104.5
		PII(W28)	44	44	100	92.0	100	28280.6	15886.8	50343.1
		PIII(W30)	42	42	100	91.6	100	47009.5	29212.0	75650.3
		PIII(W48)	38	38	100	90.7	100	27654.7	15451.7	49495.1
	2-Doses HIV	PRE	42	42	100	91.6	100	50147.7	31155.5	80717.6
		PII(W6)	42	42	100	91.6	100	39330.0	23651.6	65401.6
		PII(W28)	45	45	100	92.1	100	37081.7	22119.6	62164.4
		PIII(W30)	41	41	100	91.4	100	42025.5	25368.7	69619.0
		PIII(W48)	41	41	100	91.4	100	35510.7	20611.6	61179.7
	HIV	PRE	82	82	100	95.6	100	44505.2	31070.2	63749.6
		PII(W6)	85	85	100	95.8	100	35751.2	24487.8	52195.2
		PII(W28)	89	89	100	95.9	100	32432.8	22178.0	47429.4
	Placebo	PRE	39	39	100	91.0	100	56998.1	35973.6	90310.3
		PII(W6)	40	40	100	91.2	100	42858.3	26115.6	70334.6
PII(W28)		38	38	100	90.7	100	49618.3	30792.1	79955.0	
PIII(W30)		38	38	100	90.7	100	66228.6	42601.7	102959.1	
PIII(W48)		37	37	100	90.5	100	53607.0	33211.4	86527.6	

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Secondary Outcome Results:** Seropositivity rates and GMCs for Anti-F4co antibodies (ATP cohort for immunogenicity)

				≥ 42 mEL.U/mL				GMC (mEL.U/mL)		
						95% CI				95% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
Anti-HIV-1 F4co	3-Doses HIV	PRE	44	44	100	92.0	100	25140.6	13998.5	45151.4
		PII(W6)	44	44	100	92.0	100	33615.3	18829.8	60010.9
		PII(W28)	44	44	100	92.0	100	27434.5	15359.3	49002.8
		PIII(W30)	43	43	100	91.8	100	42435.0	25178.4	71518.7
		PIII(W48)	39	39	100	91.0	100	32130.7	18572.2	55587.5
	2-Doses HIV	PRE	45	45	100	92.1	100	36300.9	22786.9	57829.6
		PII(W6)	43	43	100	91.8	100	40535.9	26342.7	62376.4
		PII(W28)	45	45	100	92.1	100	35772.5	21900.7	58430.6
		PIII(W30)	42	42	100	91.6	100	39431.6	23443.1	66324.5
		PIII(W48)	43	43	100	91.8	100	38384.8	23066.6	63875.6
	HIV	PRE	89	89	100	95.9	100	30272.1	20957.0	43727.6
		PII(W6)	87	87	100	95.8	100	36874.1	25840.1	52619.8
		PII(W28)	89	89	100	95.9	100	31374.0	21612.7	45543.9
	Placebo	PRE	40	40	100	91.2	100	37340.1	23713.1	58797.8
		PII(W6)	40	40	100	91.2	100	44449.6	28350.2	69691.4
		PII(W28)	39	39	100	91.0	100	39639.6	25732.5	61062.7
		PIII(W30)	38	38	100	90.7	100	46885.3	29384.8	74808.4
		PIII(W48)	37	37	100	90.5	100	44728.5	27564.3	72580.8

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre Dose 1

PII(W6) = Post-Dose 2 (6 weeks post Dose 1)

PII(W28) = Post-Dose 2 (28 weeks post Dose 1)

PIII(W30) = Post-Dose 3 (30 weeks post Dose 1)

PIII(W48) = Post-Dose 3 (48 weeks post Dose 1)

**Safety Results:** Percentage of subjects reporting the occurrence of unsolicited symptoms following injection Dose 1 and Dose 2 within the 28-day (Days 0-27) post-vaccination period (Total Vaccinated cohort)

<b>Most frequent adverse events – On-Therapy (occurring within Days 0-27 following vaccination)</b>	<b>HIV Group N = 126</b>	<b>Placebo Group N = 64</b>
Subjects with any AE(s), n (%)	58 (46.0)	29 (45.3)
Subjects with any AE(s) with Grade $\geq 3$ , n (%)	9 (7.1)	3 (4.7)
Subjects with any related AE(s), n (%)	6 (4.8)	2 (3.1)
Subjects with any related AE(s) with Grade $\geq 3$ , n (%)	1 (0.8)	0 (0.0)
Subjects with any AE(s) requiring medically attended visit, n (%)	17 (13.5)	13 (20.3)
Nasopharyngitis	7 (5.6)	1 (1.6)
Headache	4 (3.2)	3 (4.7)
Upper respiratory tract infection	3 (2.4)	2 (3.1)
Pharyngitis	2 (1.6)	2 (3.1)
Pyrexia	2 (1.6)	2 (3.1)
Abdominal pain upper	3 (2.4)	-
Nausea	3 (2.4)	-
Oral herpes	3 (2.4)	-
Rash	3 (2.4)	-
Toothache	3 (2.4)	-
Cough	-	2 (3.1)
Feeling cold	2 (1.6)	-
Hypertension	2 (1.6)	-
Influenza	2 (1.6)	-
Myalgia	-	2 (3.1)
Abscess limb	-	1 (1.6)
Anal fissure	-	1 (1.6)
Arthralgia	-	1 (1.6)
Back pain	-	1 (1.6)
Cellulitis	-	1 (1.6)
Cervical root pain	-	1 (1.6)
Conjunctivitis	-	1 (1.6)
Depression	-	1 (1.6)
Diarrhoea	-	1 (1.6)
Dry skin	-	1 (1.6)
Eczema	-	1 (1.6)
Epistaxis	-	1 (1.6)
Groin pain	-	1 (1.6)
Haemoglobin decreased	-	1 (1.6)
Herpes virus infection	-	1 (1.6)
Infection	-	1 (1.6)
Influenza like illness	-	1 (1.6)
Ligament sprain	-	1 (1.6)
Muscle contracture	-	1 (1.6)
Odynophagia	-	1 (1.6)
Oral disorder	-	1 (1.6)
Oropharyngeal pain	-	1 (1.6)
Otitis externa	-	1 (1.6)
Pain in extremity	-	1 (1.6)
Paraesthesia	-	1 (1.6)
Periodontitis	-	1 (1.6)
Rhinitis	-	1 (1.6)

Rhinorrhoea	-	1 (1.6)
Sinus congestion	-	1 (1.6)
Skin papilloma	-	1 (1.6)
Syphilis	-	1 (1.6)
Thrombocytopenia	-	1 (1.6)
Tonsillitis	-	1 (1.6)
Tooth abscess	-	1 (1.6)
Vision blurred	-	1 (1.6)

Counting rule applied: As there were more than 30 subjects per treatment group and  $\leq 3$  groups, only the 10 most frequent events in each treatment group are to be listed.

- : Implies that adverse event was not reported in the particular group or that the adverse event was reported in the particular group but did not fall within the pre-defined counting rule of 10 most frequent events for that group

Grade 3 = event which prevented normal activities

Related = event assessed by the investigator as causally related to the study vaccination

**Safety Results:** Percentage of subjects reporting the occurrence of unsolicited symptoms following injection Dose 3 within the 28-day (Days 0-27) post-vaccination period (Total vaccinated cohort)

<b>Most frequent adverse events – On-Therapy (occurring within Days 0-27 following vaccination)</b>	<b>3-Doses HIV Group N = 56</b>	<b>2-Doses HIV Group N = 60</b>	<b>Placebo Group N = 56</b>
Subjects with any AE(s), n (%)	30 (53.6)	42 (70.0)	34 (60.7)
Subjects with any AE(s) with Grade $\geq 3$ , n (%)	3 (5.4)	7 (11.7)	3 (5.4)
Subjects with any related AE(s), n (%)	2 (3.6)	6 (10.0)	2 (3.6)
Subjects with any related AE(s) with Grade $\geq 3$ , n (%)	0 (0.0)	1 (1.7)	0 (0.0)
Subjects with any AE(s) requiring medically attended	11 (19.6)	14 (23.3)	15 (26.8)
Nasopharyngitis	4 (7.1)	4 (6.7)	4 (7.1)
Headache	2 (3.6)	2 (3.3)	3 (5.4)
Upper respiratory tract infection	2 (3.6)	2 (3.3)	2 (3.6)
Toothache	3 (5.4)	2 (3.3)	-
Abdominal pain upper	2 (3.6)	2 (3.3)	-
Eczema	2 (3.6)	2 (3.3)	-
Nausea	2 (3.6)	2 (3.3)	-
Cough	1 (1.8)	-	2 (3.6)
Diarrhoea	1 (1.8)	-	2 (3.6)
Influenza	3 (5.4)	-	-
Myalgia	1 (1.8)	-	2 (3.6)
Oropharyngeal pain	1 (1.8)	2 (3.3)	-
Pharyngitis	1 (1.8)	-	2 (3.6)
Pyrexia	1 (1.8)	-	2 (3.6)
Rash	1 (1.8)	2 (3.3)	-
Dyspepsia	-	2 (3.3)	-
Feeling cold	-	2 (3.3)	-
Hypertension	-	2 (3.3)	-
Influenza like illness	-	-	2 (3.6)
Oral herpes	2 (3.6)	-	-
Otitis externa	-	-	2 (3.6)
Proctitis	-	2 (3.3)	-
Rhinitis	-	-	2 (3.6)
Syphilis	-	-	2 (3.6)
Tonsillitis	-	2 (3.3)	-
Acne	1 (1.8)	-	-
Alanine aminotransferase increased	1 (1.8)	-	-
Constipation	1 (1.8)	-	-
Dizziness	1 (1.8)	-	-
Dry mouth	1 (1.8)	-	-
Erythema	1 (1.8)	-	-
Gastroenteritis shigella	1 (1.8)	-	-
Gastrointestinal disorder	1 (1.8)	-	-
Gingivitis	1 (1.8)	-	-

Haematoma	1 (1.8)	-	-
Herpes simplex	1 (1.8)	-	-
Herpes virus infection	1 (1.8)	-	-
Injection site warmth	1 (1.8)	-	-
Migraine	1 (1.8)	-	-
Muscle strain	1 (1.8)	-	-
Non-alcoholic steatohepatitis	1 (1.8)	-	-
Odynophagia	1 (1.8)	-	-
Otitis media	1 (1.8)	-	-
Pain in extremity	1 (1.8)	-	-
Paraesthesia	1 (1.8)	-	-
Pruritus	1 (1.8)	-	-
Seborrhoeic dermatitis	1 (1.8)	-	-
Sinusitis	1 (1.8)	-	-

Counting rule applied: As there were more than 30 subjects per treatment group and ≤ 3 groups, only the 10 most frequent events in each treatment group are to be listed.

- : Implies that adverse event was not reported in the particular group or that the adverse event was reported in the particular group but did not fall within the pre-defined counting rule of 10 most frequent events for that group

Grade 3 = event which prevented normal activities

Related = event assessed by the investigator as causally related to the study vaccination

**Safety Results:** Percentage of subjects reporting the occurrence of unsolicited symptoms following any injection within the 28-day (Days 0-27) post-vaccination period (Total vaccinated cohort)

<b>Most frequent adverse events – On-Therapy (occurring within Days 0-27 following vaccination)</b>	<b>3-Doses HIV Group N = 62</b>	<b>2-Doses HIV Group N = 64</b>	<b>Placebo Group N = 64</b>
Subjects with any AE(s), n (%)	30 (48.4)	42 (65.6)	34 (53.1)
Subjects with any AE(s) with Grade ≥ 3, n (%)	3 (4.8)	7 (10.9)	3 (4.7)
Subjects with any related AE(s), n (%)	2 (3.2)	6 (9.4)	2 (3.1)
Subjects with any related AE(s) with Grade ≥ 3, n (%)	0 (0.0)	1 (1.6)	0 (0.0)
Subjects with any AE(s) requiring medically attended	11 (17.7)	14 (21.9)	15 (23.4)
Nasopharyngitis	4 (6.5)	4 (6.3)	4 (6.3)
Headache	2 (3.2)	2 (3.1)	3 (4.7)
Upper respiratory tract infection	2 (3.2)	2 (3.1)	2 (3.1)
Toothache	3 (4.8)	2 (3.1)	-
Abdominal pain upper	2 (3.2)	2 (3.1)	-
Eczema	2 (3.2)	2 (3.1)	-
Nausea	2 (3.2)	2 (3.1)	-
Cough	1 (1.6)	-	2 (3.1)
Diarrhoea	1 (1.6)	-	2 (3.1)
Influenza	3 (4.8)	-	-
Myalgia	1 (1.6)	-	2 (3.1)
Oropharyngeal pain	1 (1.6)	2 (3.1)	-
Pharyngitis	1 (1.6)	-	2 (3.1)
Pyrexia	1 (1.6)	-	2 (3.1)
Rash	1 (1.6)	2 (3.1)	-
Dyspepsia	-	2 (3.1)	-
Feeling cold	-	2 (3.1)	-
Hypertension	-	2 (3.1)	-
Influenza like illness	-	-	2 (3.1)
Oral herpes	2 (3.2)	-	-
Otitis externa	-	-	2 (3.1)
Proctitis	-	2 (3.1)	-
Rhinitis	-	-	2 (3.1)
Syphilis	-	-	2 (3.1)
Tonsillitis	-	2 (3.1)	-
Acne	1 (1.6)	-	-
Alanine aminotransferase increased	1 (1.6)	-	-
Constipation	1 (1.6)	-	-

Dizziness	1 (1.6)	-	-
Dry mouth	1 (1.6)	-	-
Erythema	1 (1.6)	-	-
Gastroenteritis shigella	1 (1.6)	-	-
Gastrointestinal disorder	1 (1.6)	-	-
Gingivitis	1 (1.6)	-	-
Haematoma	1 (1.6)	-	-
Herpes simplex	1 (1.6)	-	-
Herpes virus infection	1 (1.6)	-	-
Injection site warmth	1 (1.6)	-	-
Migraine	1 (1.6)	-	-
Muscle strain	1 (1.6)	-	-
Non-alcoholic steatohepatitis	1 (1.6)	-	-
Odynophagia	1 (1.6)	-	-
Otitis media	1 (1.6)	-	-
Pain in extremity	1 (1.6)	-	-
Paraesthesia	1 (1.6)	-	-
Pruritus	1 (1.6)	-	-
Seborrhoeic dermatitis	1 (1.6)	-	-
Sinusitis	1 (1.6)	-	-

Counting rule applied: As there were more than 30 subjects per treatment group and  $\leq 3$  groups, only the 10 most frequent events in each treatment group are to be listed.

- : Implies that adverse event was not reported in the particular group or that the adverse event was reported in the particular group but did not fall within the pre-defined counting rule of 10 most frequent events for that group

Grade 3 = event which prevented normal activities

Related = event assessed by the investigator as causally related to the study vaccination

**Safety Results:** : Number (%) of subjects with serious adverse events (SAEs) during the entire study period (Total Vaccinated cohort)

**Serious adverse event, n (%) [n considered by the investigator to be related to study medication]**

<b>All SAEs</b>	<b>3-Doses HIV Group N = 62</b>	<b>2-Doses HIV Group N = 64</b>	<b>Placebo Group N = 64</b>
Subjects with any SAE(s), n (%) [n assessed by the investigator as related]	1 (1.6) [0]	3 (4.7) [1]	2 (3.1) [0]
Anaemia	0 (0.0) [0]	0 (0.0) [0]	1 (1.6) [0]
Angioedema	0 (0.0) [0]	1 (1.6) [1]	0 (0.0) [0]
Anxiety	0 (0.0) [0]	1 (1.6) [0]	0 (0.0) [0]
Appendicitis	1 (1.6) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastroenteritis shigella	1 (1.6) [0]	0 (0.0) [0]	0 (0.0) [0]
Haemorrhage intracranial	0 (0.0) [0]	0 (0.0) [0]	1 (1.6) [0]
Hepatitis C	0 (0.0) [0]	1 (1.6) [0]	0 (0.0) [0]
Hydrocephalus	0 (0.0) [0]	0 (0.0) [0]	1 (1.6) [0]
Hydronephrosis	0 (0.0) [0]	0 (0.0) [0]	1 (1.6) [0]
Lymph node tuberculosis	0 (0.0) [0]	1 (1.6) [0]	0 (0.0) [0]
Pre-eclampsia	0 (0.0) [0]	0 (0.0) [0]	1 (1.6) [0]
Skull fracture	0 (0.0) [0]	0 (0.0) [0]	1 (1.6) [0]
<b>Fatal SAEs</b>	<b>3-Doses HIV Group N = 62</b>	<b>2-Doses HIV Group N = 64</b>	<b>Placebo Group N = 64</b>
Subjects with fatal SAE(s), n (%) [n assessed by the investigator as related]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]

**Conclusion:**

HIV-1 viral load (VL)

At the Week 48 time point, the mean difference in change from baseline of Log-transformed HIV-1 VL was -0.096 (97.5% CI: -0.257 to 0.065) for the comparison 3-Doses HIV Group minus Placebo Group, and 0.073 (97.5% CI: -0.088 to 0.235) for the comparison 2-Doses HIV Group minus Placebo Group.

As a consequence, the primary objective of the study as regards VL was not met: the 97.5% CIs for the differences in change from baseline of Log-transformed HIV-1 VL between the 3-Doses HIV and Placebo groups and between the 2-Doses HIV and

Placebo groups were both including 0.

At the Week 48 time point, the ratio comparing changes from baseline of Log-transformed HIV-1 VL was 0.801 (97.5% CI: 0.553 to 1.162) for the comparison 3-Doses HIV Group over Placebo Group, and 1.184 (97.5% CI: 0.816 to 1.717) for the comparison 2-Doses HIV Group over Placebo Group.

## Safety

### *Solicited local symptoms*

The most frequently reported solicited local symptom during the 7-day (Days 0-6) post-vaccination, across doses, was pain, reported for up to 93.5% of subjects (in the 3-Doses HIV Group). During the same period, the most frequently reported Grade 3 solicited local symptom was pain, reported for up to 24.2% of subjects (in the 3-Doses HIV Group). No subject reported any solicited local symptom requiring medical attention during the post-vaccination follow-up period.

### *Solicited general symptoms*

The most frequently reported solicited general symptom during the 7-day (Days 0-6) post-vaccination, across doses, was fatigue, reported for up to 69.4% of subjects (in the 3-Doses HIV Group). During the same period, fatigue was the most frequently reported solicited general symptom of Grade 3 intensity – Grade 3 occurrences of the symptom being reported for up to 12.9% of subjects (in the 3-Doses HIV Group) – as well as the most frequently reported solicited general symptom related to study vaccination as per assessment by the study investigators – vaccine/placebo-related occurrences of the symptom being reported for up to 38.7% of subjects (in the 3-Doses HIV Group).

During the same period, myalgia was the most frequently reported related solicited general symptom of Grade 3 intensity, being reported for up to 6.3% of subjects (in the 2-Doses HIV Group) and abdominal pain was the most frequently reported solicited general symptom requiring medical attention, being reported for up to 4.8% of subjects (in the 3-Doses HIV Group).

### *pIMDs and biochemical and hematological abnormalities*

The majority of subjects from all treatment groups had hematological and biochemistry parameters graded DAIDS category 1 or below.

During the entire study period, one pIMD was reported for one (1.6%) subject in the 2-Doses HIV Group.

### *Unsolicited Adverse Events (AEs)*

Within the 28-day (Days 0-27) post-vaccination period with Doses 1 and 2, across doses (N = 126 and 64 in the HIV and Placebo groups respectively), at least one unsolicited AE was reported by 58 (46.0%) and 29 (45.3%) subjects in the HIV and Placebo groups, respectively. During the same period, across doses, for these same Doses 1 and 2, at least one unsolicited AE of Grade 3 intensity was reported by 9 (7.1%) and 3 (4.7%) subjects in the HIV and Placebo groups, respectively, and at least one unsolicited AE assessed by the investigators as related to study vaccination was reported by 6 (4.8%) and 2 (3.1%) subjects in the HIV and Placebo groups, respectively. During the same time frame, across doses, for these same Doses 1 and 2, at least one unsolicited AE of Grade 3 intensity assessed by the investigators as related to study vaccination was reported for one (0.8%) subject in the HIV Group, and at least one unsolicited AE requiring medical attention was reported for 17 (13.5%) and 13 (20.3%) subjects in the HIV and Placebo groups, respectively.

Within the 28-day (Days 0-27) post-vaccination period with Dose 3 (N = 56, 60 and 56 in the 3-Doses HIV, 2-Doses HIV and Placebo groups respectively), at least one unsolicited AE was reported by 30 (53.6%), 42 (70.0%) and 34 (60.7%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively. During the same period, post Dose 3 vaccination, at least one unsolicited AE of Grade 3 intensity was reported by 3 (5.4%), 7 (11.7%), and 3 (5.4%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively, and at least one unsolicited AE assessed by the investigators as related to study vaccination was reported by 2 (3.6%), 6 (10.0%) and 2 (3.6%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively. During the same time frame, post Dose 3, across doses, at least one unsolicited AE of Grade 3 intensity assessed by the investigators as related to study vaccination was reported, for one (1.7%) subject in the 2-Doses HIV Group, and at least one unsolicited AE requiring medical attention was reported for 11 (19.6%), 14 (23.3%) and 15 (26.8%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively.

Within the 28-day (Days 0-27) post-vaccination period, across all doses administered (N = 62, 64 and 64 in the 3-Doses HIV, 2-Doses HIV and Placebo groups respectively), at least one unsolicited AE was reported by 30 (48.4%), 42 (65.6%), and 34 (53.1%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively. During the same period, across all doses administered, at least one unsolicited AE of Grade 3 intensity was reported by 3 (4.8%), 7 (10.9%), and 3 (4.7%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively, and at least one unsolicited AE assessed by the investigators as related to study vaccination was reported by 2 (3.2%), 6 (9.4%) and 2 (3.1%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively. During the same time frame, across all doses administered, at least one unsolicited AE of Grade 3 intensity assessed by the investigators as related to study vaccination was reported, for one (1.6%) subject in the 2-Doses HIV Group, and at least one unsolicited AE requiring medical attention was reported for 11 (17.7%), 14 (21.9%) and 15 (23.4%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively.

### *SAEs*



During the entire study period, SAEs were reported for 1 (1.6%), 3 (4.7%) and 2 (3.1%) subjects in the 3-Doses HIV, 2-Doses HIV and Placebo groups, respectively. One SAE assessed by the investigators as related to study vaccination was reported, for one (1.6%) subject in the 2-Doses HIV Group. No fatal SAE was reported during the entire study period.

Date updated: 28-April-2014